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Translesion DNA synthesis (TLS) is a process whereby specialized DNA 
polymerases are recruited to bypass DNA lesions that would otherwise stall high-fidelity 
polymerases.  TLS may be a mechanism by which cancer cells resist the cytotoxic actions 
of chemotherapeutic agents that damage DNA.  Here, I addressed if the translesion 
polymerases eta, REV1 and zeta have a cellular role in protecting against cisplatin-
induced cytotoxicity.  HeLa cells depleted of polymerase eta, REV1 or polymerase zeta 
individually were found to display phenotypes suggestive of the inability to bypass 
cisplatin adducts.  In addition, the E3 ubiquitin ligase RAD18 and the Fanconi anemia 
core complex were found to be crucial for the localization of TLS polymerases to sites of 
DNA replication stalled by cisplatin adducts.  Together, the findings support a model 
where replicative bypass of cisplatin intrastrand cross-links requires cooperation of 
multiple translesion polymerases in human cells, and is regulated by both RAD18-
dependent PCNA monoubiquitination and the Fanconi anemia core complex. 
Recently, translesion DNA polymerases have been implicated in the repair of 
DNA damage induced by chemotherapeutic agents.  I addressed if the translesion 
polymerases eta, REV1 and zeta were essential for efficient repair of DNA interstrand 
cross-links induced by mitomycin C and DNA double strand breaks (DSBs) caused by 
exposure to ionizing radiation (IR).  Depletion of REV1 or polymerase zeta in HeLa 
cells, but not polymerase eta or the RAD18 ubiquitin ligase, resulted in a loss in 
clonogenic survival following exposure to both mitomycin C and IR.  I demonstrated that 
the loss in survival following mitomycin treatment is likely due to inefficient repair of 
interstrand cross-links in cells depleted of REV1 or polymerase zeta by measuring the 
resolution of DSBs, an intermediate of interstrand cross-link repair.  Furthermore, I 
showed that REV1 and polymerase zeta were required for the timely repair of DSBs 
induced by ionizing radiation.  REV1 and polymerase zeta depleted HeLa cells exhibited 
a relatively mild but significant defect in homologous recombination, an essential DNA 
 ix
repair pathway important for resolving DSBs.  However, the lack of translesion synthesis 
past damaged DNA bases in REV1 or polymerase zeta deficient cells exposed to ionizing 
radiation may also explain the loss in survival and apparent deficiency to resolve DSBs.  
Overall, the results suggest both REV1 and polymerase zeta play an active role in 
protection against mitomycin C or ionizing radiation-induced cytotoxicity,  most likely 















Efficient and accurate replication of the eukaryotic genome is necessary for exact 
transmission of genetic information from one generation to the next therefore preventing 
genomic instability.  Replicative polymerases are capable of copying DNA with high 
fidelity and speed due in part to their stringent active site enforcing correct Watson-Crick 
base pairing.  Any mismatching of nucleotides that does occur by replicative polymerases 
may be corrected by an intrinsic 3´-5´ exonuclease proofreading function, thus greatly 
increasing the fidelity of replicative polymerases 1-2.  Due to their low error rates, 
replicative polymerases are commonly referred to as high fidelity polymerases.  The 
more constrained active site of replicative polymerases is clearly advantageous during 
DNA replication, but there are certain situations where this property can be deleterious to 
a cell.  One such situation occurs when a replication fork encounters DNA damage.  
DNA is constantly undergoing endogenous and exogenous damage, which may lead to 
abasic sites, DNA cross-links, and large bulky adducts covalently attached to DNA bases.  
Sophisticated DNA repair mechanisms have evolved to correct the damage, however the 
process can be slow and incomplete 3-4.  If a high fidelity polymerase comes upon 
damaged DNA, such as bulky adducts or distorted DNA helical structures due to 
intrastrand cross-links, the stringent active site will not accommodate the damaged 
template.  The end result is a stalled replication fork with long regions of single stranded 
DNA generated due to the uncoupling of the helicase and polymerase 5-6.  Eventually the 
stalled replication fork will collapse producing a DNA double strand break, which is one 
of the most, if not the most, toxic DNA lesions 7-8.  In order to prevent replication stress 
due to stalled replication forks at sites of damaged DNA, translesion DNA polymerases 
are employed to synthesize past the sites of DNA damage 9-11.   
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Translesion DNA polymerases are specialized polymerases that are capable of 
replicating damaged template DNA, a process referred to as translesion DNA synthesis 
12.  Currently eight translesion DNA polymerases are known to exist in humans.  Based 
on homology, the eight human translesion polymerases have been placed into four 
different families of DNA polymerases.  Four of the human translesion polymerases, 
polymerase eta (pol η), polymerase ίota (pol ί), polymerase kappa (pol k) and REV1, 
belong to the Y-Family of DNA polymerases.  Polymerase zeta (pol ζ), which consists of 
the catalytic subunit REV3 and an accessory subunit REV7, is categorized in the B-
Family of DNA polymerases, while the translesion polymerase theta (pol θ) belongs to 
the A-Family of DNA polymerases.  The two remaining translesion polymerases, 
polymerase lamda (pol λ) and polymerase mu (pol µ), are grouped in the X-Family of 
DNA polymerases of which limited information is known about their cellular functions.  
There is another polymerase found in the A-Family of DNA polymerases, polymerase nu, 
which displays similar biological properties to translesion polymerases 13.  However, too 
little is currently known about polymerase nu to officially declare this polymerase a 
translesion polymerase.  Four homologues of the translesion polymerases known to exist 
in humans are also found in yeast including Rad30 (pol η), Rev1, Rev3 (pol ζ) and pol4 
(pol λ).  
Although nine human gene products are recognized to be translesion DNA 
polymerases, the vast majority of scientific data published thus far on eukaryotic 
translesion DNA synthesis has focused on the Y-Family polymerases eta and REV1 
along with the B-Family polymerase zeta.  One reason as to why we have a greater 
understanding of polymerase eta, REV1 and polymerase zeta is due to the fact homologs 
exist in Saccharomyces cerevisiae, one of the most extensively studied eukaryotes.  
Polymerase eta is the most widely studied translesion polymerase due to the fact 
mutations in this polymerase were found to be responsible for the genetic disease 
Xeroderma pigmentosum variant (XP-V) 6, 14-15.  In addition, many scientific studies have 
focused upon the translesion polymerases eta, REV1 and zeta because they are currently 
thought to be the dominate polymerases in terms of translesion synthesis past damaged 
DNA bases 6. 
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The other human translesion polymerases discovered to date are thought to have a 
limited role in translesion synthesis.  Polymerases ίota and kappa have been demonstrated 
to participate in translesion DNA synthesis, but their contributions are thought to be 
restricted and/or redundant 16-17.  Polymerase ίota is speculated to have a cellular role in 
response to oxidative stress, while polymerase kappa may be necessary for bypass of 
intrastrand cross-links formed between adjacent N2 linked guanine bases and possibly 
extension beyond mismatched primer termini 17-22.  A deficiency in either polymerase 
ίota or kappa, though, does not greatly effect spontaneous or damage induce mutagenesis 
18, 23.  One explanation for this observation is that both of these polymerases may function 
as partial replacements for polymerase eta and/or polymerase zeta 24-25.  The X-Family 
translesion polymerases along with the A-Family translesion polymerase theta are not 
thought to play a major role in preventing replication stress by synthesizing past damaged 
DNA bases, but rather may contribute to non-homologous end joining, base excision 
repair and interstrand cross-link repair 6, 26-28.  It should be emphasized, though, that their 
impact on non-homologous end joining, base excision repair and interstrand cross-link 
repair is still poorly understood.  As further research is performed in the area of 
translesion DNA synthesis, it is reasonable to assume more specific biological functions 
will be assigned to the translesion polymerases ίota, kappa, lamda, theta and mu.  
However, for the purposes of my dissertation I will be focusing on the translesion 
polymerases currently demonstrated to have the most significant biological roles in 
eukaryotic translesion synthesis, polymerases eta, REV1 and zeta.  Figure 1.1 
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Figure 1.1  Proposed functions of polymerase eta, REV1 and polymerase zeta 
Translesion DNA polymerases are capable of synthesizing damaged template 
DNA due to possessing a more spacious active site than replicative polymerases 29-30.  All 
known DNA polymerases contain a catalytic core comprising of subdomains referred to 
as the thumb, palm and finger 31.  The domains act essentially as a hand allowing the 
polymerase to grip both the template and the incoming nucleotide.  The finger domain of 
high fidelity polymerases plays a crucial role in ensuring correct Watson-Crick base 
pairing by tightly gripping the DNA 32-35.  Translesion polymerases, however, have key 
differences in their structure.  First, translesion polymerases have shorter thumb and 
finger domains resulting in fewer contacts with DNA 23, 36-37.  Second, all translesion 
polymerases belonging to the Y-Family have an additional subdomain called either the 
little finger or polymerase-association domain (PAD) 29, 38-40.  In the Y-Family of 
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translesion polymerases, the little finger and palm domains have a critical role in base 
pairing during synthesis.  Unlike replicative polymerases, the little figure and palm 
domains in Y-Family translesion polymerases preform a more open and solvent-exposed 
active site before substrate binding allowing for the accommodation of a damaged 
template 22, 30.  REV1 appears to be unique among the Y-Family of translesion 
polymerases in that the protein itself provides specificity for the template and incoming 
nucleotide and not the DNA 41-42.  The catalytic domain structure of REV3 has yet to be 
solved, so the exact mechanism of how this polymerase synthesizes damaged template 
DNA is unknown 43-44.  The general principle that translesion polymerases are able to 
accommodate damaged template DNA due to having a more open and solvent exposed 
active site than compared to high fidelity polymerases should still apply to REV3.   
There is a trade off, though, for the unique ability of translesion polymerases to 
accommodate damaged templates.  Due to their less stringent active site, translesion 
polymerases do not enforce correct Watson-Crick base pairing, thus leading to erroneous 
base pairing and mutagenesis 30, 45.  High fidelity polymerases make very few mistakes 
during replication, inserting one incorrect nucleotide for every 106-108 bases replicated, 
which is due to both their stringent active site and proofreading capability 23.  Translesion 
polymerases, on the other hand, have a much higher error rate when synthesizing 
undamaged DNA.  Error rates as high as 1 mismatch per 10 bases to 1 mismatch per 
10,000 bases replicated have been observed with translesion polymerases 23.  Conversely, 
translesion polymerases may have higher fidelity rates when replicating a damaged 
template 6, 46-47.  Any mistakes made by translesion polymerases cannot be corrected 
during synthesis since they lack an intrinsic 3΄-5΄ proofreading function 48-49.  Overall, the 
number of mismatched nucleotides produced by translesion polymerases is thought to be 
several orders of magnitude greater than high fidelity polymerases 11, 23, 47, 50-51.  The 
observed increase in mutagenesis, or the lack thereof, is often used as an experimental 
endpoint to determine if a translesion polymerase may be involved in a particular 
biological pathway.  Since translesion polymerases have such a high error rate when 
compared to replicative polymerases, they are often referred to as low fidelity 
polymerases.  Even though it may seem unwise to risk an increase of mutagenesis during 
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translesion synthesis, the alternative, enhanced cell death due to collapsed replication 
forks, is less desirable.  
The ability to synthesize damaged template DNA, thus preventing replication 
stress, enables a cell to cope with various types of DNA damage.  In most circumstances, 
prevention of collapsed replication forks and ensuing cell death is, evolutionarily 
speaking, advantageous and allows organisms to survive and reproduce in harsh 
environmental conditions.  Nonetheless, all DNA damage is not inherently bad and in 
particular situations, such as the treatment of cancer, the damage is purposely induced to 
cause cell death.  The bypassing of chemotherapy associated DNA damage may prevent 
individual cell death initially, but eventually could result in the demise of the organism.  
Many of the most successful anti-cancer agents currently used in clinic have a 
mechanism of action resulting in damaged DNA.  Examples of chemotherapeutic agents 
that induce DNA damage consist of the alkylating drugs such as cyclophosphamide and 
ifosfamide, the nitrosoureas including carmustine, and methylating anti-cancer 
compounds such as dacarbazine.   
Currently, the extent to which the translesion polymerases promote bypass of 
DNA damage caused by anti-cancer drugs in intact cancer cells is unknown.  To address 
this issue, I will focus on the platinum compound cisplatin (cis-diammineplatinum(II) 
dichloride) to determine if the translesion polymerases eta, REV1 and zeta allow for 
tolerance of platinum adducts. The major DNA lesion induced by cisplatin is an 
intrastrand cross-link between the N7 position of two adjacent guanines, accounting for 
approximately 60-65% of all cross-links produced by cisplatin 52.  Intrastrand cross-links 
can also be produced between neighboring adenine-guanine bases and guanine bases 
separated by a cytosine.  Overall the dominating lesions are intrastrand cross-links with 
only about 2% of the DNA damage representing monofunctional guanine adducts and 
another 2%  being interstrand cross-links between guanines on opposite DNA strands 52.  
In general, the interstrand cross-link is by far the most physiologically relevant lesion 
when considering the toxicity induced by anti-cancer agents that produce both intra and 
interstrand cross-links 53.  However, both DNA intrastrand and interstrand cross-links 
have been proposed to contribute to the cytotoxicity of cisplatin 54.  The most abundant 
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intrastrand cross-link induced by cisplatin, 1,2-d(GpG), is thought to be a major 
contributor to cisplatin cytotoxicity.  The toxic nature of 1,2-d(GpG) cross-links may be 
attributed to the DNA distortions caused by this particular intrastrand cross-link 55. 
Translesion polymerases were originally recognized for their ability to replicate 
past DNA lesions in an error prone manner leading to mutagenesis.  A point should be 
made that in this particular biological process the DNA damage is not corrected, rather 
the bypass of the lesion allows the cell to cope with the unrepaired lesion until the 
damage is removed at a later time.  Recently, published reports provided evidence to 
suggest the translesion polymerases eta, REV1 and zeta may also have an active role in 
repair of DNA damage, notably repair of DNA interstrand cross-links and double strand 
breaks 56-61.  Specifically, translesion polymerases may be necessary for gap filling during 
interstrand cross-link repair and extension of D-loops during homologous recombination.  
Translesion polymerases continue to function by synthesizing damaged or altered 
templates during repair of the DNA lesion, but the major difference is that their 
replicating ability is a necessary step during the correction of the DNA damage.  As part 
of my dissertation I will test the hypothesis that the translesion polymerases eta, REV1 
and zeta have a role in repair of both DNA interstrand cross-links and double strand 
breaks in intact human cancer cells, which theoretically could contribute to resistance of 
chemotherapeutic agents known to induce interstrand cross-links or double strand breaks.  
Multiple chemotherapeutic agents used to treat cancer have a mechanism of 
action that results in the formation of DNA interstrand cross-links.  Many of the 
intrastrand cross-link inducers such as mitomycin C, chlorambucil, carmustine, cisplatin 
and psoralen also form interstrand cross-links.  To address the role of polymerases eta, 
REV1 and zeta in interstrand cross-link repair I will use mitomycin C as the primary 
agent for inducing interstrand cross-links.  Exposure to Mitomycin C results in a 
significantly greater percentage of interstrand cross-links when compared to drugs such 
as cisplatin 52, 62-63.  Interstrand cross-links are formed at the N2 position of guanines at 
dCpG sequences in the minor groove following mitomycin C exposure 64-65.  The 
monoadducts formed by mitomycin C are also located in the minor groove, but they do 
not perturb the DNA structure and are thought to have little influence upon mitomycin C-
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induced cytotoxicity 65.  However, just one mitomycin C interstrand cross-link is capable 
of killing a bacterial cell if not repaired efficiently 66. 
DNA double strand breaks are generated by several anti-cancer agents including 
the topoisomerase I and II poisons such as camptothecin and etoposide respectively, 
bleomycin and ionizing radiation.  To test the hypothesis that the translesion polymerases 
eta, REV1 and zeta are necessary for repair of DNA double strand breaks I will use 
ionizing radiation as the principal inducer of DNA damage.  Following exposure to 
ionizing radiation multiple DNA lesions are formed including DNA adducts such as 7,8-
dihydro-8-oxoguanine, abasic sites, DNA single strand breaks and DNA double strand 
breaks 67.  The proportion of DNA double strand breaks are relativity small when 
compared to other types of damage induced by ionizing radiation.  The ratio of single 
strand DNA breaks formed by ionizing radiation to double strand breaks formed is 
approximately 1:0.04 68.  However, the formation of DNA double strand breaks are by far 
more toxic to the cell, and the other lesions formed such as DNA adducts and single 
strand breaks are thought to be repaired relatively quickly and have little if any influence 
on cell killing due to ionizing radiation 67-69.  
In summary, the overall goal of this dissertation is to test the hypothesis that the 
translesion polymerases eta, REV1 and zeta have a biological role in the bypass of 
chemotherapeutic associated DNA damage in intact human cancer cells.  I will also 
assess the contribution of the translesion polymerases eta, REV1 and zeta to the repair of 
interstrand cross-links and DNA double strand breaks induced by anti-cancer agents.  
 
Y-Family translesion DNA polymerases Eta and REV1 
In the early years of mutagenesis research there was no clear understanding as to 
why mutations arose in bacteria and yeast following exposure to DNA damaging agents 
such as ultraviolet (UV) radiation.  In fact, up until the mid to late 1960’s scientists were 
unsure if DNA damage-induced mutations observed in bacteria and yeast occurred 
naturally or if a gene product played an active role in creating mutations.  By the late 
1960’s a hypothesis was proposed suggesting that mutagenesis was an active process due 
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to errors in the repair of UV-induced DNA damage, with errors during post-replication 
repair responsible for the majority of mutagenic events 70-72.  Gene products in both 
Escherichia coli and Saccharomyces cerevisiae were found to contribute to the 
mutagenesis observed following DNA damage.  Mutations in either the Umu (UV-
induced mutability) locus in Escherichia coli or the Rev1 (UV- mutation reversion) locus 
in Saccharomyces cerevisiae resulted in decreased mutation rates following DNA 
damaging agents 73-76.  The Rev1 gene product in Saccharomyces cerevisiae was later 
found to have 25% homology with the UmuC gene product of Escherichia coli 
suggesting this active process of mutagenesis was conserved through evolution 77.  
Additional orthologs were discovered in Escherichia coli (DinB), the archeon Sulfolobus 
sulfatarirus (Dbh) and in Saccharomyces cerevisiae (Rad30) leading to the identity of a 
superfamily of proteins responsible for mutations following DNA damage referred to as 
the UmuC/DinB/Rev1/Rad30 superfamily 78-80.  However, the mechanistic actions of how 
the UmuC/DinB/Rev1/Rad30 superfamily of proteins induced mutations were still 
unknown.  At the time an hypothesis was formed that the UmuC/DinB/Rev1/Rad30 
superfamily of proteins functioned as accessory factors to replicative polymerases in an 
undefined cellular process allowing for low fidelity synthesis of damaged DNA templates 
and the emergence of mutagenesis 22. 
Two major events occurred in the mid to late 1990’s unlocking the mystery as to 
how the UmuC/DinB/Rev1/Rad30 superfamily of proteins are able to influence 
mutagenesis following DNA damage.  In 1995 it was discovered that purified 
Saccharomyces cerevisiae Rev1 protein had a deoxycytidyl transferase activity, which is 
the transfer of a dCMP to DNA from a dCTP, and that Rev1 may have a biological role 
in the bypassing of abasic sites 81-82.  The revelation that Rev1 had a catalytic function 
was exciting, but due to the observed limited catalytic activity it was still unclear as to 
exactly how the UmuC/DinB/Rev1/Rad30 superfamily contributed to mutagenesis.  Then 
in 1999 a major discovery was made that forever changed how the scientific community 
viewed the UmuC/DinB/Rev1/Rad30 superfamily.  Johnson et al. provided evidence that 
the yeast Rad30 protein was a DNA polymerase capable of using all four dNTPs and was 
demonstrated to bypass UV-induced thymine-thymine cyclobutane pyrimidine dimers 46.  
The human homolog of Rad30, polymerase eta, was discovered shortly thereafter 83.  The 
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Escherichia coli UmuD΄2C and DinB proteins were demonstrated to be DNA 
polymerases in 1999 as well and renamed DNA pol IV and pol V respectively 84-85.  By 
the end of 2000 two other human translesion polymerases were discovered, the DNA 
translesion polymerases ίota and kappa 86-91.  In fact, translesion polymerases were being 
described so quickly in the literature in such a short time frame that confusion arose 
about naming the newly discovered polymerases leading to polymerase kappa being 
referred to as both kappa and theta 92.  In order to effectively and efficiently communicate 
about the newly discovered superfamily of mutagenic proteins, the 
UmuC/DinB/Rev1/Rad30 superfamily of proteins were later grouped together into the Y-
Family of translesion polymerases 93.  In retrospect, the time from early 1999 to late 2000 
was a major turning point in both identifying human translesion polymerases and 
understanding the cellular functions of these polymerases.   
The translesion DNA polymerase eta (polη), encoded by the POLH gene located 
on chromosome 6p21.1, was the first translesion polymerase identified in humans 83, 94.  
The initial biological function described for polymerase eta was its ability to accurately 
bypass thymine-thymine cyclobutane pyrimidine dimers induced by UV radiation 46, 83, 95.  
In other words, polymerase eta always places two adenines across from thymine-thymine 
dimers caused by UV radiation.  Mutations in polymerase eta were found to be 
responsible for the genetic disease Xeroderma pigmentosum variant (XP-V), which is 
clinically described as extreme photosensitivity to UV light and the predisposition to 
develop cancers, especially of the skin, at an early onset 6, 14-15.  Unlike Xeroderma 
pigmentosum, cells from Xeroderma pigmentosum variant patients have normal 
nucleotide excision repair activity, but are unable to efficiently bypass UV-induced DNA 
damage.  Currently it is unclear as to why Xeroderma pigmentosum variant patients 
develop cancer at an early onset.  One theory is that another, more error prone translesion 
polymerase, such as polymerase ίota, replicates past UV-induced DNA damage in the 
absence of polymerase eta resulting in an increase of mutations 96.  Another hypothesis is 
that UV-induced DNA damage is not bypassed in the absence of polymerase eta leading 
to replication fork collapse and subsequent repair of the double strand breaks formed with 
a noted increase in sister chromatid exchanges 97-99.  The resulting escalation of genomic 
instability could significantly impact cancer development.   
  11
In addition to replicating past UV-induced cyclobutane pyrimidine dimers, 
polymerase eta is also capable of inserting nucleotides across from other types of 
damaged DNA bases.  Polymerase eta has been demonstrated to replicate past the 
oxidative lesion 7,8-dihydro-8-oxoguanine in a mostly error free manner via insertion of 
a cytosine opposite the DNA lesion 48, 100-102.  Similar to the oxidative lesion 7,8-dihydro-
8-oxoguanine, Yuan et al. found polymerase eta correctly incorporates a cytosine across 
from an acetylaminofluorene modified guanine 48.  Polymerase eta is capable of 
bypassing other spontaneous, oxidative, or metabolically induced DNA lesions, though 
with low fidelity, including O6-methylguanine, benzo[a]pyrene guanine adducts, 7,8-diol 
9,10-epoxide deoxyguanosine, thymine glycol, and the R diastereoisomer of 
cyclodeoxyadenosine 6, 25, 48, 103-105.  Accumulating data suggest polymerase eta is fairly 
promiscuous in terms of what lesions are bypassed; clearly demonstrating that 
polymerase eta may have an extremely important biological role in preventing replication 
stress due to numerous types of endogenous and exogenous DNA damage.  Nevertheless, 
polymerase eta is unable to effectively place nucleotides across from all types of DNA 
damage, such as abasic sites, suggesting polymerase eta alone is not sufficient for the 
prevention of all stalled replication forks. 
Since polymerase eta can facilitate the bypass of various DNA adducts, there is 
potential that this polymerase may be capable of synthesizing across chemotherapeutic 
drug-induced DNA lesions and thus contribute to resistance of anti-cancer drugs.  Both 
Vaisman et al. and Alt et al. have provided biochemical evidence that polymerase eta is 
capable of synthesizing past cisplatin induced N7-guanine-guanine intrastrand cross-links 
106-107.  Studies employing cell lines obtained from Xeroderma pigmentosum variant 
patients found that cells deficient in polymerase eta are sensitive to cisplatin and 
accumulate more mutations following cisplatin exposure than cells with functional 
polymerase eta, suggesting that polymerase eta is capable of synthesizing past cisplatin-
induced DNA intrastrand cross-links.  Furthermore, the observed phenotypes of cisplatin 
hypersensitivity and enhanced genomic instability in cells derived from Xeroderma 
pigmentosum variant patients can be rescued by transient expression of polymerase eta 
108-109.  Recently, using a quantitative translesion synthesis reporter assay, Schachar et al. 
found polymerase eta bypasses cisplatin guanine-guanine intrastrand cross-links in an 
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established human cancer cell line 25.  In this investigation, Schachar was able to measure 
polymerase eta gap filling a plasmid engineered to contain a single-stranded gap region 
with a cisplatin guanine-guanine intrastrand cross-link placed within the gapped region.  
 Polymerase eta may have additional biological functions beyond bypassing 
damaged template DNA such as stabilizing fragile sites during replication, diversification 
of antibodies and repair of DNA double strand breaks 110.  There is an emerging body of 
evidence that polymerase eta promotes somatic hypermutations at the Ig locus during 
immunoglobulin class switch recombination 111-114.  Somatic mutations may arise when 
activation-induced cytidine deaminase (AID) generates uracils in the DNA creating a 
uracil-guanine mismatch 112, 115-117.  Although poorly understood, correction of the uracil-
guanine mismatch through a process involving polymerase eta and the mismatch repair 
proteins MSH2 and MSH6 creates mutations at nearby adenine-thymine base pairs 118.  
Polymerase eta has also been proposed to function in the homologous recombination 
repair pathway.  Specifically, McIlwraith et al. proposed that polymerase eta interacts 
with the recombinase RAD51, which in turn stimulates polymerase eta-mediated D-loop 
extension 119.  However, the finding that polymerase eta is necessary for the extension of 
D-loops during homologous recombination has not been confirmed.  I will assess the 
participation of polymerase eta in homologous recombination. 
The cellular functions of polymerase eta are in part regulated by protein-protein 
interactions.  Along with a catalytic site, polymerase eta contains a REV1 interacting 
region, an ubiquitin-binding zinc finger domain, a PCNA interacting peptide region and a 
nucleus localization domain (Fig. 1.2) 22-23, 120.  Replication stress initiated by UV 
exposure results in polymerase eta foci formation presumably at sites of stalled 
replication forks 121-123.  The ability to form foci in response to DNA damage is critically 
important since polymerase eta mutants deficient in foci formation cannot complement 
Xeroderma pigmentosum variant cells 121.  Polymerase eta localizes to sites of replication 
by interactions with PCNA, proliferating cell nuclear antigen, via its PCNA interacting 
peptide (PIP) box motif 124-125.  In response to stalled replication forks PCNA is known to 
be monoubiquitinated by the E3 ubiquitin ligase RAD18.  The monoubiquitination of 
PCNA is thought to increase the affinity of polymerase eta to PCNA through its 
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ubiquitin-binding zinc finger domain 126.  There is some controversy as to how important 
the ubiquitin-binding zinc finger domain is for proper foci formation of polymerase eta.  
Published reports from Acharya et al. propose that PCNA monoubiquitination is not 
necessary for foci formation while reports from both Bienko et al. and Sabbioneda et al. 
suggest that the ubiquitin-binding zinc finger domain of polymerase eta is necessary for 
proper foci formation following DNA damage 125-127.  The REV1 interacting region of 
polymerase eta may also contribute to foci formation by encouraging localization with 
REV1, which might act as a scaffold at sites of replication stress 128-129.  This scenario is 
doubtful, though, since polymerase eta is speculated to localize to sites of replication 
stress independently of REV1 130-131.  The more likely role for the REV1 interaction 
region is to promote polymerase switching between polymerase eta and other translesion 
polymerases such as polymerase zeta.  The p53 and p21 pathway or phosphorylation 
following DNA damage may also regulate the cellular processes of polymerase eta 132-133.  
Figure 1.2  Structural domains of polymerase eta and REV1.  Sites common to both 
proteins include the catalytic site and PAD, polymerase association domain.  (A) 
Structural domains of polymerase eta (Polη), a 713 amino acid protein.  Polymerase eta 
contains an ubiquitin-binding zinc finger (UBZ) domain, REV1 interacting region, PCNA 
interacting domain (PIP) and a nucleus localization domain.  (B) Structural domains of 
REV1, a 1251 amino acid protein.  REV1 contains a BRCT domain, an ubiquitin-binding 
motif (UBM) and a polymerase interacting domain.  
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Yeast Rev1 was the first translesion polymerase described to have catalytic 
activity, functioning as a deoxycytidyl transferase 82.  Human REV1 was discovered in 
1999 and is encoded by the REV1L gene located between chromosome 2q11.1 and 
2q11.2 134.  Similar to the yeast homolog, human REV1 also functions as a deoxycytidyl 
transferase.  REV1 is capable of inserting cytosines across from uracil residues and 
undamaged guanine, adenine, thymine or cytosine bases, and is thought to have an 
important role in bypassing abasic sites 81, 134-137.  REV1 may also incorporate a single 
cytosine opposite various types of base adducts, especially guanines bearing a large 
adduct, and extend beyond mismatched bases by insertion of a cytosine at the primer 
terminus 6, 135-136, 138-139.    
A mechanistic role for REV1 in translesion DNA synthesis was originally 
difficult to envision due to its limited catalytic activity.  To add to the confusion, 
Haracska et al. found that yeast strains with double amino acid substitutions rendering 
Rev1 catalytically dead had no differences in observed mutagenesis induced by DNA 
damage when compared to strains with wild type Rev1, suggesting that Rev1 contributes 
to translesion DNA synthesis independently of its catalytic function 137.  Furthermore, 
cells deficient of REV1 were found to have an observable loss of mutagenesis and to be 
hypersensitive to agents that induce lesions REV1 is incapable of synthesizing across in 
vitro 137, 140-143.  An explanation of how REV1 contributes to translesion DNA synthesis 
was revealed when several reports were published describing that REV1 interacts with 
numerous translesion polymerases, including polymerases eta and zeta, through its C-
terminal domain 128-129, 144-146.  Based on these observations, REV1 is thought to 
participate in translesion DNA synthesis via two different mechanisms.  First, REV1 
might act as a scaffold that promotes localization of multiple translesion polymerases to 
sites of damaged DNA.  Second, REV1 may be essential for polymerase switching at 
sites of replication stress by facilitating interactions between different translesion 
polymerases via its C-terminal domain 12, 147. 
Along with a C-terminal domain that allows for interactions with other translesion 
polymerases, REV1 also contains a BRCA1 C-terminal (BRCT) domain at the N-
terminus, along with two ubiquitin-binding motifs near the C-terminus (Fig. 1.2) 22-23, 120.  
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REV1 is unique among the Y-Family of translesion polymerases in that it has a BRCT 
domain.  In general, BRCT domains are found in many cell cycle and DNA repair 
proteins and are thought to mediate protein-protein interactions.  Mutations in the BRCT 
domain can drastically alter the localization of DNA repair proteins to sites of DNA 
damage 148.  The BRCT domain of REV1 is thought to be required for participation in the 
bypass of damaged template DNA, specifically through promoting protein interactions 
with PCNA 149-151.  There are, though, some discrepancies in the literature as to whether 
or not the REV1 BRCT domain is necessary for translesion synthesis 152.  The ubiquitin-
binding motifs are necessary for localization of REV1 to stalled replication forks as well, 
presumably by interacting with monoubiquitinated PCNA 153-154.   
Due to REV1’s apparent involvement in translesion DNA synthesis, an extremely 
important question is whether or not REV1 has a cellular role in the bypassing of 
chemotherapy-induced DNA lesions.  REV1 knockout DT40 cells, a cell line derived 
from a chicken B-lymphocyte, are known to be hypersensitive to chemotherapeutic 
agents including cisplatin 61, 155.  Okuda et al. demonstrated that human ovarian 
carcinoma cells depleted of REV1 are hypersensitive to cisplatin, have a decrease in 
measurable mutagenesis and a lower rate of acquired resistance to cisplatin 156.  
Furthermore, over-expression of REV1 in human ovarian carcinoma cells results in 
decreased cisplatin sensitivity and enhanced development of cisplatin resistant variants 
157.  It should be noted that in the context of bypassing cisplatin DNA adducts, REV1’s 
catalytic activity may be dispensable.  The most likely role of REV1 in terms of 
translesion synthesis past cisplatin intrastrand cross-links is localization of polymerase 
zeta to sites of replication stress, and promotion of polymerase switching between 
polymerase eta and polymerase zeta in order for translesion synthesis to be completed.   
In addition to participating in translesion synthesis past damaged template DNA, 
REV1 may also have a biological role in antibody diversification and DNA repair.  REV1 
may insert a cytosine across from uracils or abasic sites that are created during somatic 
hypermutations 158-160.  Along with contributing to somatic hypermutations, REV1 may 
also have an important cellular role in the repair of DNA interstrand cross-links and 
double strand breaks 59.  REV1-/- DT40 cells are hypersensitive to interstrand cross-
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linking agents such as mitomycin C and genetic epistasis exist between REV1 and the 
interstrand cross-linking repair protein Fanconi anemia complementation group C 
(FANCC) 60-61.  Employing a luciferase reporter reactivation assay, Shen et al. 
demonstrated that REV1 is required for efficient repair of a mitomycin C interstrand 
cross-link 161.  Although currently unknown, REV1 may insert a cytosine across from the 
base containing an unhooked interstrand cross-link.  There is also speculation that REV1 
has a crucial role in response to ionizing radiation based on observations that REV1-/- 
DT40 cells are hypersensitive to ionizing radiation 155.  In response to ionizing radiation, 
REV1 may simply bypass abasic sites caused by ionizing radiation, or REV1 could 
contribute to D-loop extension during homologous recombination to repair DNA double 
strand breaks.  Unlike translesion synthesis across cisplatin cross-links, the catalytic 
activity of REV1 may be crucial for antibody diversification, and repair of DNA 
interstrand cross-links and double strand breaks. 
 
Polymerase Zeta (REV3 and REV7) 
 The Rev3 gene was originally discovered in Saccharomyces cerevisiae using the 
same screen for reversionless mutants that identified Rev1, and shortly thereafter a 
similar screen was employed to isolate Rev7 162-163.  Saccharomyces cerevisiae deficient 
of functional Rev3 or Rev7 are known to exhibit defects in both spontaneous and DNA 
damaged induced mutagenesis, but it was not initially appreciated that Rev3 and Rev7 
cooperate with each other to form a translesion polymerase.  Nelson et al. discovered 
Rev3 and Rev7 associate with each other to form the translesion polymerase zeta, with 
the Rev3 subunit consisting of the catalytic activity and the Rev7 subunit functioning as 
an accessory protein for catalytic enhancement 164.  In yeast, polymerase zeta is not 
essential, but this polymerase does contribute to viability following DNA damage noted 
by the decrease in survival of Rev3-/- Saccharomyces cerevisiae exposed to UV, 
hydroxyurea and methyl methanesulfonate 49, 165-166.  Polymerase zeta does have a crucial 
role in UV-induced mutagenesis in yeast, accounting for approximately 90% of 
frameshift mutations and base alterations 44.  Mutations are also diminished in Rev3-/- 
yeast following treatment by the chemotherapeutic agents hydroxyurea and methyl 
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methanesulfonate along with ionizing radiation, signifying that polymerase zeta 
participates in the translesion synthesis of templates containing DNA damage caused by 
these agents 43, 167.  Polymerase zeta contributes to spontaneous mutations as well, with a 
50% observed decrease of point mutations in Rev3-/- Saccharomyces cerevisiae 44, 168-169. 
 Mammalian REV3, located on chromosome 6q21 in humans, is unique among the 
translesion polymerases because it is absolutely required during embryonic development, 
as REV3-/- mice are not viable 144, 170-176.  Currently, the essential role REV3 plays during 
embryonic development is unknown, but a logical explanation is that REV3 is necessary 
for bypass, repair or both of endogenous DNA damage; such damage being most likely 
due to oxidative stress.  REV3-/- mouse embryos display a reduced size at 10.5 days into 
development and are usually aborted by roughly day 12.5 177.  Except for erythrocytes, no 
hematopoietic cells are developed and mesenchymal tissues including heart and blood 
vessels lack integrity.  As expected, the time when REV3 is most widely expressed in 
mouse embryos coincides with the time REV3-/- mouse embryos die.  Polymerase zeta is 
thought to participate in the bypass of chemotherapeutic drug-induced DNA damage, thus 
it is considered a possible drug target to sensitize cancers to anti-cancer agents 57, 161, 178-
180.  Therefore, knowing whether or not REV3 is absolutely indispensable beyond 
embryonic development is of extreme importance.  REV3-/- mouse embryonic fibroblast 
are capable of being rescued in a p53 null background and REV3 can be knocked out or 
depleted in other vertebrate cell lines including chicken DT40 cells, human fibroblast and 
human BL2 cells derived from Burkitt’s lymphoma, suggesting REV3 is dispensable 
beyond, but not during, embryonic development.   
Human REV7, described approximately two years after the discovery of human 
REV3, is located on chromosome 1p36 144.  REV7 has not been as intensely investigated 
as REV3 primarily due to the fact that REV7 contains no catalytic function, but rather 
supports the catalytic activity of REV3.  Recently published reports strongly suggest 
human REV7 is truly the homolog of yeast Rev7 178, 181-183, but there still remains some 
skepticism in the scientific community if the currently identified human REV7 is the true 
homolog of yeast Rev7 and if it has a crucial role in translesion synthesis.  Contributing 
to the confusion over REV7 is the fact this protein has 23% identity and 54% similarity to 
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the human mitotic checkpoint protein MAD2, therefore resulting in REV7 also being 
referred to as MAD2B or MAD2L2 184.  REV7/MAD2B is thought to interact with 
several cell cycle proteins and is proposed to have a role in cell cycle regulation 23, 183.  
Nonetheless, the role that REV7 may have in cell cycle control is still poorly understood.   
Biochemical studies demonstrated polymerase zeta has limited ability to replicate 
across from DNA lesions such as 6-4 thymine-thymine photoproducts, thymine glycol 
and acetylaminofluorene-adducted guanine, while insertion directly opposite cyclobutane 
pyrimidine dimers or abasic sites is basically non-existent 88, 137, 185-186.  Polymerase zeta, 
though, is an efficient extender beyond distorted base pairs resulting from an incorrect 
base insertion opposite a DNA lesion or a base containing a bulky DNA lesion 88, 137, 164, 
185.  Therefore, polymerase zeta is unlikely to directly insert a nucleotide opposite a DNA 
adduct, but rather functions in the translesion DNA synthesis pathway by extending 
beyond distorted primer termini.   
Polymerase zeta is crucial for efficient replication of damaged template DNA, 
including DNA damage due to chemotherapeutic agents.  Multiple published reports, 
using DT40 cells as a model for translesion synthesis in intact cells, have provided 
evidence that REV3 deficiency is extremely toxic to cells in the presence of 
chemotherapeutic agents such as cisplatin, melphalan, mitomycin C, transplatin and 
methyl methanesulfonate 56, 187.  REV7 depleted nasopharyngeal carcinoma cells are 
hypersensitive to cisplatin while REV3 protects colorectal cancer cells from cisplatin-
induced cytotoxicity 178, 180.  Wu et al. determined depletion of REV3 from human 
fibroblasts had no measurable effect on the removal of cisplatin adducts, but the down-
regulation of REV3 did result in greater sensitivity to cisplatin and a decrease in cisplatin 
resistant variants 179.  Employing a luciferase reactivation reporter plasmid, REV3 was 
found to be necessary for translesion synthesis across platinum adducts.  Taken together, 
the data suggest that polymerase zeta has no major role in repair of cisplatin adducts, but 
rather participates in the bypass of cisplatin-induced intrastrand cross-links and may 
contribute to cisplatin resistance.   
Very little is known about REV3 structurally, thus the exact mechanism of how 
REV3 extends beyond distorted primer termini or how REV3 even localizes to sites of 
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DNA damage is still a mystery.  Human REV3 is approximately twice as large as 
Saccharomyces cerevisiae Rev3, containing a large exon region not found in yeast 44.  
Even though human REV3 is a very large protein, it is currently known to have only two 
domains, a catalytic region and a REV7 interaction domain (Fig. 1.3) 23, 44.  There is 
speculation that REV3 is able to interact with REV1 as well.  REV7 is known to interact 
with REV1, and also contains a HORMA domain allowing for interactions with 
chromatin and other proteins (Fig. 1.3) 129, 188.  Hence, not only does REV7 enhance 
catalytic activity, but may also direct REV3 to sites of DNA damage by interacting with 
REV1 and other proteins via the HORMA domain 189. 
 
Figure 1.3  Structural domains of REV3 and REV7 
 
 In addition to translesion synthesis past DNA adducts, polymerase zeta is 
hypothesized to participate in interstrand cross-link repair and double strand break repair.  
REV3-/- DT40 cells are hypersensitive to interstrand cross-linking agents such as 
mitomycin C and genetic epistasis exists between REV3 and the interstrand cross-linking 
repair protein Fanconi anemia complementation group C (FANCC) 60, 187.  Via 
construction of a luciferase reaction reporter assay containing both a psoralen and 
mitomycin C interstrand cross-link, Shen et al. proposed that REV3 is necessary for 
efficient recombination-independent repair of interstrand cross-links 161.  Polymerase zeta 
is also thought to have a cellular role in recombination-dependent repair of interstrand 
cross-links as well 57.  Raschle et al., using a Xenopus egg extract model, elegantly 
demonstrated that polymerase zeta is necessary for extension beyond a cisplatin 
interstrand cross-link during recombination-dependent repair of the cross-link 59.  
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Polymerase zeta is also hypothesized to have a biological role in repair of DNA double 
strand breaks, possibly by participating in homologous recombination.  REV7 depleted 
nasopharyngeal carcinoma cells are hypersensitive to ionizing radiation, while REV3-/- 
DT40 cells are sensitive to ionizing radiation and have an increase of ionizing radiation-
induced chromosome aberrations 56, 178.  However, it is unclear if polymerase zeta extends 
beyond nucleotides placed opposite DNA adducts induced by ionizing radiation or if this 
polymerase has an active role in repair of ionizing radiation-induced DNA double strand 
breaks. 
 
Insertion and extension model of translesion DNA synthesis 
 Translesion DNA synthesis is the process whereby specialized translesion DNA 
polymerases replicate damaged template DNA that would otherwise stall high fidelity 
polymerases 12.  Translesion polymerases insert nucleotides opposite the DNA lesion and 
extend beyond the DNA damage to prevent prolonged replication stress and the eventual 
formation of DNA double strand breaks.  Translesion synthesis is drastically different in 
prokaryotes and lower eukaryotes when compared to lesion bypass in vertebrates.  Both 
prokaryotes and yeast have two different branches of translesion synthesis, an error free 
pathway and an error prone post-replication repair pathway 6.  Polymerase eta is thought 
to operate independently of REV1 or polymerase zeta during replication of DNA damage 
in the error free pathway, while the REV1/ polymerase zeta functional complex bypasses 
DNA damage in an error prone manner 190-192.  Based almost entirely on in vitro 
biochemical experiments and plasmid reactivation assays, polymerases eta, REV1 and 
zeta are all thought to cooperate with each other, referred to as an insertion and extension 
model, in higher eukaryotes to replicate past DNA lesions 6, 12, 22, 25.  A representative 
diagram depicting the insertion and extension model of translesion synthesis is shown in 
Figure 1.4.  Since I am addressing the bypass of chemotherapeutic drug-induced DNA 
damage in human cancer cells, I will focus only on the insertion and extension model of 
translesion synthesis.  
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Figure 1.4  Insertion and extension model of translesion synthesis.  In response to a 
cisplatin-induced stalled replication fork, the E3 ubiquitin ligase RAD18 
monoubiquitinates PCNA on lysine 164.  The monoubiquitination of PCNA is thought to 
act as a molecular switch from high fidelity replication to translesion synthesis.  
Polymerase eta (Polη), via interactions with PCNA, localizes to the site of the stalled fork 
and synthesizes directly across from the cisplatin intrastrand cross-link.  REV1 then 
promotes translesion polymerase switching between polymerase eta and polymerase zeta 
(REV3 and REV7).  Polymerase zeta extends beyond the distorted primer terminus. 
 
Once a replication fork encounters a DNA adduct that a high fidelity polymerase 
is incapable of replicating past, the fork stalls and the helicase and polymerase uncouple 
resulting in continued unwinding of the DNA and formation of long stretches of single 
stranded DNA 193-194.  A lesion located on the lagging strand would immediately result in 
a single stranded DNA gap.  A lesion located on the leading strand may also cause a 
single stranded DNA gap to form if the leading strand is reprimed to allow for 
continuation of replication (Fig. 1.5) 194.  RPA, replication protein antigen, coats and 
stabilizes the single stranded DNA protecting it from nucleases and hairpin loop 
formation.  RPA also acts as an indicator of replication stress and initiates the localization 
of proteins involved in the replication stress response to stalled replication forks 195.  
Chang et al. demonstrated, using a Xenopus egg extract model, that the formation of 
single stranded DNA coated with RPA is crucial for localizing the RAD6 (E2)-RAD18 
(E3) ubiquitin ligase to sites of stalled replication forks 196.  The RAD6 (E2)-RAD18 (E3) 
ubiquitin ligase complex specifically monoubiquitinates proliferating cell nuclear antigen 
(PCNA) on lysine 164 in response to replication fork stalling.  The monoubiquitination of 
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PCNA by RAD18 is thought to be a molecular switch between high fidelity synthesis and 
translesion DNA synthesis 121, 197-199.  Cells deficient in RAD18 are known to be 
hypersensitive to DNA damaging agents that induce replication fork stalling along with 
polymerase and helicase uncoupling signifying RAD18 is necessary for a proper response 
to this particular type of replication stress 6, 200-202. 
Figure 1.5  Single stranded DNA gap formation in response to stalled replication 
forks.  Depiction of a replication fork encountering a DNA lesion resulting in replication 
blockage.  (A) After blockage of the leading strand, the helicase and polymerase 
uncouple resulting in the formation of single stranded DNA.  The leading strand may 
eventually be reprimed leading to the formation of a single stranded gap.  (B) When a 
DNA lesion is located on the lagging strand a single stranded DNA gap will be formed 
due to incomplete replication of the Okazaki fragement 194. 
 
Y-Family translesion polymerases such as eta and REV1 are known to contain 
ubiquitin binding motifs (Fig. 1.2)  Following PCNA monoubiquitination by RAD18, the 
affinity of polymerase eta and REV1 to PCNA drastically increases 126, 153.  Therefore, 
RAD18-dependent PCNA monoubiquitination is thought to be the primary initiator of 
translesion synthesis by promoting localization of translesion polymerases to the site of 
replication stress.  Once localized to the stalled replication fork, polymerase eta is 
thought to incorporate a nucleotide opposite the adducted base(s).  However, polymerase 
eta is not very efficient extending beyond a terminus containing distorted base pairs 
resulting from either an incorrect base insertion opposite a DNA lesion or a base pair 
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containing a bulky DNA lesion 6, 12, 203.  In the insertion and extension model, polymerase 
eta replicates across from the damaged base(s), but another translesion polymerase is 
necessary to extend beyond the distorted primer terminus 25.  As discussed earlier, REV1 
is thought to promote localization of translesion polymerases to sites of stalled replication 
forks and facilitate polymerase switching through interactions with its C-terminal 
domain.  After polymerase eta inserts nucleotides opposite the DNA lesion, REV1 is 
thought to promote localization of polymerase zeta to the site of the stalled fork via 
interactions with REV7 and facilitate switching between polymerase eta and polymerase 
zeta 12.  Even though polymerase zeta is not very proficient at inserting bases opposite 
DNA lesions, this polymerase is efficient at extending beyond distorted primer termini.     
Taken together, the insertion and extension model proposes RAD18 initiates 
translesion synthesis by monoubiquitinating PCNA, and this promotes localization of 
translesion polymerases to the site of a stalled replication fork.  Once at the site of 
replication stress, polymerase eta inserts a nucleotide opposite the DNA lesion.  REV1 
promotes localization of polymerase zeta to the stalled replication fork and facilitates 
polymerase switching between polymerase eta and polymerase zeta.  Polymerase zeta 
extends beyond the inserted base until either the gap is filled or high fidelity polymerases 
take over replication responsibilities.  A point should be made that translesion synthesis 
in vertebrates is more complicated than previously stated and depends on the type of 
damage present.  In certain situations, such as the bypass of cylcobutane pyrimidine 
dimers, polymerase eta may be able to replicate past the DNA lesion error free 
independently of REV1 or polymerase zeta.  In other circumstances REV1 and 
polymerase zeta may be essential for extension beyond the damaged DNA template, 
while another translesion polymerase besides eta inserts opposite the lesion 25.  However, 
multiple scientific publications employing both biochemical assays and plasmid 
reactivation reporter assays suggest polymerases eta, REV1and zeta are all necessary for 




Translesion polymerases and interstrand cross-link repair 
DNA interstrand cross-links are formed when a bifunctional chemical covalently 
links both strands of a DNA duplex.  The linking of opposite strands of DNA prevents 
vital biological processes from proceeding, such as the unwinding of DNA by helicases, 
thereby halting both the replication and transcription machinery.  Interstrand cross-links 
are extremely toxic to cells, and in fact one interstrand cross-link is thought to be capable 
of killing a yeast cell if not repaired efficiently 204-206.  Nitric oxide, byproducts of 
metabolism such as malonic dialdehyde along with other naturally occurring 
environmental chemicals, including crontonaldehyde or acetaldehyde, induce interstrand 
cross-link formation 205.  Since endogenous and environmental chemicals are capable of 
interacting with DNA forming cross-linked duplexes, it would be reasonable to assume 
that organisms have evolved efficient cellular pathways to remove interstrand cross-links.  
The removal of these toxic lesions is advantageous for cell survival, but the evolution of 
sophisticated mechanisms for interstrand cross-link repair may result in chemotherapy 
resistance.  
The highly toxic nature of interstrand cross-links have been noted in the clinic 
setting and several chemotherapeutic agents that promote interstrand cross-link 
formation, including mitomycin C, are used for cancer treatment.  Unfortunately, 
cancerous cells can become resistant to interstrand cross-linking agents impairing the 
usefulness of these agents.  Furthermore, cross-resistance between interstrand cross-
linking agents is known to occur, that is, acquired resistance to one cross-linking agent 
results in the resistance to multiple interstrand cross-linking agents 207.  The exact 
mechanism of how resistance arises is unknown, but the occurrence of cross-resistance 
suggests the involvement of a biological pathway common to all interstrand cross-linking 
agents.  One possible cellular process ubiquitous to all interstrand cross-linking agents 
that may promote the development of resistance is alterations in repair of interstrand 
cross-links 207-209.  Currently, interstrand cross-link repair is poorly understood.  Due to 
acquired cross-resistance of chemotherapeutic agents that induce DNA interstrand cross-
links, determining how interstrand cross-links are repaired and if alterations in repair 
promote resistance is of uttermost importance.  Comprehending interstrand cross-link 
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repair may also reveal novel targets that can influence drug design of new 
chemotherapeutic agents.  
DNA interstrand cross-links can be repaired in a recombination-independent 
manner or a recombination-dependent manner (Fig. 1.6).  Recombination-independent 
repair does not take place at sites of DNA replication and is thought to be independent of 
homologous recombination.  However, recombination-independent repair may be 
dependent upon monoubiquitinated PCNA 161.  Recombination-dependent repair, on the 
other hand, is initiated when replication forks encounter interstrand cross-links.  The 
unhooking of the DNA interstrand cross-link results in a DNA double strand break, 
which in turn is repaired by homologous recombination.  The majority of interstrand 
cross-links are thought be repaired in a recombination-dependent pathway during S phase 
in human cells 59, 161, 210-211.  Translesion DNA polymerases are thought to play a role 
during interstrand cross-link repair by either gap filling across from the unhooked cross-
link or by extending the D-loop during homologous recombination. 
  26
 
Figure 1.6  A model of recombination-dependent and recombination-independent 
repair of DNA interstrand cross-links.  (A) During recombination-dependent repair, 
replication forks approach the interstrand cross-link from both sides. MUS81-EME1 
makes an incision on side of the cross-link resulting in the formation of a DNA double 
strand break.  XPF-ERCC1 makes an incision on the other side of the interstrand cross-
link allowing for unhooking of the cross-link.  The REV1/polymerase zeta functional 
complex may replicate DNA opposite the unhooked cross-link.  The interstrand cross-
link is excised followed by further gap filling, and repair of the DNA double strand break 
by homologous recombination.  (B) During recombination-independent repair, an 
incision is made on both sides of the interstrand cross-link on the same strand of DNA 
allowing for unhooking of the cross-link.  The REV1/polymerase zeta functional complex 
is thought to replicate DNA opposite the unhooked cross-link.  The cross-link is excised 
followed by gap filling of the excised interstrand cross-link.  
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Based on biochemical and genetic studies several DNA repair pathways appear to 
be required for repair of interstrand cross-links including nucleotide excision repair, 
translesion synthesis and homologous recombination 6, 60, 187, 205-206, 212.  The most widely 
accepted model of interstrand cross-link repair at present time is based upon work from 
multiple laboratories and is in described in Figure 1.6A 6, 206, 213.  Raschle et al. recently 
proposed a recombination-dependent model of interstrand cross-link repair where 
replication forks approach the interstrand cross-link from both sides and stall multiple 
base pairs away 59.  Eventually one of the two stalled replication forks will progress up to 
the site of the interstrand cross-link where structure-specific endonucleases will recognize 
the resulting branched DNA structure cleaving on both sides and unhooking the 
interstrand cross-link.  The endonuclease MUS81-EME1 is thought to make the first 
incision resulting in the formation of a DNA double strand break 214.  The endonuclease 
XPF-ERCC1 then makes an incision on the other side uncoupling the cross-linked DNA 
duplex and unhooking the interstrand cross-link 215.  Exactly how an interstrand cross-
link is repaired after the unhooking step occurs is unknown, but the currently accepted 
model proposes gap filling via translesion synthesis opposite from the unhooked cross-
link.  The unhooked cross-link is then removed by the nucleotide excision repair pathway 
followed by further gap filling of the excised cross-link, and lastly repair of the DNA 
double strand break via homologous recombination 206, 212.   
The Fanconi anemia pathway, via an undefined cellular process, is thought to 
recognize interstrand cross-links and initiate repair along with coordinating all of the 
DNA repair pathways involved in removal of interstrand cross-links 206, 213.  The genetic 
disease Fanconi anemia arises due to mutations in genes associated with 13 different 
complementation groups, and is characterized by chromosomal instability, bone marrow 
failure, congenital defects and early onset of cancer.  Fanconi anemia patients are known 
to be hypersensitive to interstrand cross-linking agents such as mitomycin-C and this 
observation was one of the first pieces of data linking the Fanconi anemia pathway with 
interstrand cross-link repair 216-218.  The Fanconi anemia complex of proteins consist of 8 
Fanconi anemia complementation group (FANC) proteins including A, B, C, E, F, G, L 
and M which form a core complex.  There are also 5 FANC proteins that operate outside 
the core complex including D2 and I (known as the I-D complex), D1, J and N.  Gene 
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products of FAAP24 and FAAP100 are associated with the Fanconi anemia core complex, 
but presently no mutations in FAAP24 or FAAP100 have been associated with disease 206. 
Fanconi anemia proteins are thought to initiate and coordinate interstrand cross-
link removal in the recombination-dependent repair pathway.  The FANCM -FAAP24 
heterodimer recognizes stalled replication forks located at interstrand cross-links, and via 
DNA translocase activity recruits the Fanconi anemia core complex to the site of DNA 
damage where the core complex is activated and functions as a large multisubunit 
ubiquitin ligase 219-220.  Upon localization to stalled replication forks the Fanconi anemia 
core complex, through the E3 ubiquitin ligase FANCL, monoubiquitinates both FANCD2 
and FANCI, which is required for activation of the Fanconi anemia pathway 221-223.  In 
the absence of FANCM the core complex is stable although binding to chromatin is 
reduced.  Under these conditions only a partial decrease in FANCD2 monoubiquitination 
is noted signifying FANCM is not absolutely required for activation of the Fanconi 
anemia pathway 222, 224-225.  FANCM may contribute to interstrand cross-link repair 
outside activation of the Fanconi anemia pathway.  FANCM is a helicase that, in vitro, is 
capable of regressing replication forks, which could be an important remodeling step for 
initiation of cross-link removal 219, 226.  Along with activating the Fanconi anemia 
pathway, the core complex also recruits translesion polymerases to sites of stalled 
replication forks 130. 
Ubiquitination of FANCD2 is indispensable for cross-link repair, whereas FANCI 
ubiquitination is non essential but may enhance repair 206.  FANCI is phosphorylated by 
ataxia telangiectasia-Rad3 related (ATR) in response to stalled replication forks located 
at sites of interstrand cross-links, and this phosphorylation is thought to promote 
localization of  the FANCD2-I complex to sites of DNA damage 227.  Inhibition of 
FANCI phosphorylation ablates FANCD2 ubiquitination, suggesting ATR dependent 
phosphorylation of FANCI is crucial for localization of the FANCD2-I complex to the 
site of DNA damage where FANCD2-I is monoubiquitinated by the Fanconi anemia core 
complex 227.  Ubiquitination of FANCD2 and FANCI by the core complex promotes 
localization of these proteins into chromatin bound foci presumably at sites of DNA 
repair since the foci contain other DNA repair proteins such as RAD51 and γ-H2AX 228-
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231.  The precise function of FANCD2 and FANCI at sites of DNA repair is unknown, but 
it is speculated that monoubiquitinated FANCD2 may promote localization of repair 
proteins to the site of interstrand cross-links such as the chromatin remodeling protein 
Tip60 206, 213.  Since translesion polymerase eta and REV1 have ubiquitin binding 
domains, ubiquitination of the FANCD2-I complex may promote localization of these 
translesion polymerases to certain types of DNA damage.   
The Fanconi anemia proteins FANCD1, FANCJ and FANCN are not required for 
FANCD2-I monoubiquitination, thus these proteins are thought to function downstream 
of both the core complex and FANCD2-I or possibly operate independently in a parallel 
pathway of interstrand cross-link repair 206.  In general FANCD1, FANCJ and FANCN 
are thought to be necessary for correction of the DNA double strand breaks formed 
during recombination-dependent repair of interstrand cross-links via regulation or 
participation in homologous recombination.  FANCJ, also known as BRIP1 or BACH1, 
is a helicase with unknown function in cross-link removal, but may contribute to both 
repair of the DNA double strand break and endonucleolytic cross-link unhooking 206, 213.  
One hypothesis is that FANCJ, via its 5΄ to 3΄ helicase activity, may facilitate cross-link 
repair by remodeling DNA at sites of interstrand cross-link unhooking 213, 232.  FANCJ 
may also contribute to homologous recombination repair of interstrand cross-links by 
unwinding D-loop structures and promoting RAD51 nucleofilament removal to allow for 
completion of homologous recombination 206, 233-234.  However, FANCJ knockout cells 
are not sensitive to ionizing radiation, thus bringing into question its role in homologous 
recombination 235.  FANCD1, more famously known as BRAC2, is necessary for 
homologous recombination and functions by promoting RAD51 loading onto DNA 236-
237.  FANCN, also known as PALB2, may participate in homologous recombination 
through interactions with FANCD1 206, 238.   
Translesion synthesis has been implicated in repair of DNA interstrand cross-links 
based on the fact cells deficient of REV1, REV3 or REV7 are known to be hypersensitive 
to interstrand cross-linking agents such as mitomycin-C.  Also, both REV1 and REV3 are 
epistatic with the Fanconi anemia core complex protein FANCC in terms of cisplatin 
cytotoxicity suggesting REV1 and REV3 have an active role in repair of interstrand 
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cross-links.  However, only recently was the contribution of polymerase zeta to repair of 
DNA interstrand cross-links revealed.  Raschle et al., via a Xenopus egg extract model, 
elegantly demonstrated polymerase zeta is necessary for extension beyond an unhooked 
cisplatin cross-link during gap filling 59.  The polymerase responsible for inserting 
directly opposite the base containing the covalently bound cross-link has not yet been 
identified, but REV1 is a lead candidate.  Mitomycin C and cisplatin-induced interstrand 
cross-links are formed between guanines on opposite strands of DNA.  Since REV1 is 
capable of inserting a cytosine opposite a guanine containing a covalently bound bulky 
group, REV1 is a logical choice for inserting opposite the unhooked cross-link.  
Currently it is unknown if translesion synthesis is necessary for gap filling following 
excision of the unhooked cross-link or if translesion polymerases have a role in 
homologous recombination during recombination-dependent repair of interstrand cross-
links.  Nonetheless, translesion synthesis has yet to be directly linked to recombination-
dependent interstrand cross-link repair in humans.     
One of the most intriguing questions is how the Fanconi anemia pathway 
regulates translesion synthesis.  Fanconi anemia patients lacking a functional core 
complex and FANCC-/- DT40 cells are known to have decreased mutation rates 
suggesting that the Fanconi anemia core complex somehow affects translesion synthesis 
130, 239-241.  Furthermore, FANCD2 or FANCI deficient cells display an increase of 
mutagenesis further supporting the hypothesis that the Fanconi anemia pathway 
influences translesion synthesis 130.  Mirchandani et al. provided direct evidence that the 
Fanconi anemia pathway regulates translesion synthesis by showing the Fanconi anemia 
core complex, independently of FANCD2-I, is necessary for REV1 foci formation after 
exposure to UV 130.  Therefore, the Fanconi anemia core complex appears to be necessary 
for localization of REV1 to sites of stalled replication forks due to adducted DNA.  
Although unproven, the core complex is assumed to promote localization of translesion 
polymerases to sites of stalled replication forks induced by interstrand cross-links in order 
for gap filling to occur opposite unhooked cross-links.  This assumption is made because 
PCNA is not thought to be monoubiquitinated to a great extent following mitomycin C 
exposure.  There is speculation that the Fanconi anemia pathway is forked, in which case 
the core complex and FANCD2-I may regulate translesion synthesis during gap filling 
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while Fanconi anemia proteins downstream of the core complex would regulate 
homologous recombination repair of DNA double strand breaks formed during 
recombination-dependent repair of interstrand cross-links 57, 206, 213.  Translesion 
polymerases may also be needed for homologous recombination repair of double strand 
breaks, which if true presents the possibility that translesion polymerases may also be 
regulated by Fanconi anemia proteins downstream of the core complex 57, 213. 
To further complicate the relationship between the Fanconi anemia pathway and 
translesion synthesis, Shen et al. recently proposed a drastically different view of how the 
Fanconi anemia pathway contributes to interstrand cross-link repair 211.  Shen et al. 
suggest the Fanconi anemia core complex along with FANCD2-I is necessary for 
recombination-independent cross-link repair while FANCD1/BRAC2, FANCN and 
FANCJ are necessary for recombination-dependent cross-link repair 211.  REV1 and 
REV3 are known to participate in recombination-independent repair of interstrand cross-
links, which is dependent upon PCNA monoubiquitination 161.  Presumably in the 
Fanconi anemia pathway proposed by Shen et al., the core complex would regulate 
translesion synthesis at sites of recombination-independent cross-link repair.  However, 
Raschle et al. provided evidence that polymerase zeta and possibly REV1 are essential 
for recombination-dependent repair of interstrand cross-links 59.  In the Fanconi anemia 
pathway model presented by Shen et al., the possibility exists for translesion synthesis to 
regulated by FANCD1/BRAC2, FANCN and/or FANCJ during recombination-dependent 
repair of interstrand cross-links.   
Nevertheless, much work is needed to understand the cellular process of 
interstrand cross-link repair in human cells and how translesion synthesis contributes to 
removal of cross-links.  I will address if the translesion DNA polymerases eta, REV1 and 





Translesion polymerases and DNA double strand break repair 
DNA double strand breaks are thought to be the most toxic form of DNA damage 
242.  If unrepaired in a timely manner, double strand breaks will lead to cell cycle arrest, 
apoptosis, and possible loss of genetic material which can lead to mitotic cell death 243.  
Several anti-cancer treatments have a mechanism of action that results in DNA double 
stand break formation including ionizing radiation, bleomycin, the topoisomerase I 
poisons such as camptothecin, and the topoisomerase II poisons including etoposide and 
doxorubicin.  Even though DNA double strand breaks are exceptionally lethal, cancer 
cells can become refractory to the damage 244.  The ability to repair DNA double strand 
breaks, thus lessening the cytotoxic effects, may contribute to resistance of double strand 
break-inducing agents 245-247.  Recently, the translesion polymerases eta, REV1 and zeta 
have been proposed to play a role in the repair of DNA double strand breaks 56, 119, 155, 178, 
248.  However, several questions remain unanswered as to how translesion polymerases 
protect against cytotoxicity caused by DNA double strand break-inducing agents, 
particularly if translesion polymerases are simply bypassing damaged DNA bases 
induced by these agents or if translesion polymerases have an active role in double strand 
break repair. 
Translesion polymerases have been linked to DNA double stand break repair 
mostly based on the observation that in the absence of REV1 or polymerase zeta cells are 
hypersensitive to double strand break-inducing agents.  Chen et al. demonstrated that 
Rev1, Rev3 or Rev7 knockout Saccharomyces cerevisiae are sensitive to ionizing 
radiation, a known inducer of DNA double strand breaks 249.  Also, Rev1-/-, Rev3-/- or 
Rev7-/- Saccharomyces cerevisiae display a decrease in ionizing radiation-associated 
mutagenesis implying these translesion polymerases have a cellular role in response to 
ionizing radiation 249.  REV7-depleted nasopharyngeal carcinoma cells are hypersensitive 
to ionizing radiation, while REV1-/- or REV3-/- DT40 cells are sensitive to ionizing 
radiation and exhibit an increase of ionizing radiation-induced chromosomal aberrations 
56, 178.  In addition, polymerase eta  has been proposed to be necessary for D-loop 
extension during homologous recombination 119.   
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Nonetheless, many types of DNA lesions are formed in addition to DNA double 
strand breaks by the aforementioned agents rendering results difficult to interpret.  In the 
case of ionizing radiation, DNA adducts such as 7,8-dihydro-8-oxoguanine, abasic sites, 
DNA single strand breaks and DNA double strand breaks are all formed following 
exposure 67.  The translesion polymerases eta, REV1 and zeta may be necessary to bypass 
DNA abasic sites or adducts formed by ionizing radiation 48, 81, 100, 102, 137.  On the other 
hand, translesion polymerases may also be necessary for repair of DNA double strand 
breaks by participating in either non-homologous end-joining or homologous 
recombination 6, 26-27, 119, 250.  A depiction of the different cellular pathways the translesion 
polymerases eta, REV1 and zeta may participate in following ionizing radiation is 
contained in Figure 1.7. 
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Figure 1.7  Different cellular pathways the translesion polymerases eta, REV1 and 
zeta may participate in following ionizing radiation.  (A)  In response to ionizing 
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radiation-induced abasic sites, the REV1/polymerase zeta function complex may be 
necessary for inserting a cytosine opposite the abasic site and extending beyond the 
damage.  Replicative bypass of abasic sites would be expected to dependent upon PCNA 
monoubiquitination since helicase and polymerase uncoupling should occur.  (B)  It is 
hypothesized that in certain situations translesion polymerases may be needed for 
completion of non-homologous end-joining 250.  Ionizing radiation may produce DNA 
double strand breaks with non-complementary overhangs containing DNA damage 
denoted by X.  In order to conserve DNA bases within the overhangs, the translesion 
polymerases eta, REV1 and zeta may be necessary for gap filling.  The blunt ends created 
by gap filling are ligated together by ligase IV-XRCC4.  (C) During homologous 
recombination, the termini of DNA double strand breaks are resected in a 5΄ to 3΄ manner 
in order to reveal 3΄ overhangs.  The single stranded overhangs are first coated by RPA, 
then FANCD1 along with RAD51 paralogues displaces RPA and loads RAD51 onto the 
single stranded DNA.  RAD51 searches for a homologous repair template, and once 
found promotes strand invasion forming a D-loop structure.  The translesion polymerases 
eta, REV1 and zeta may be essential for D-loop extension, especially if the repair 
template contains DNA damage. 
 
Non-homologous end-joining can occur during any phase of the cell cycle, and is 
the only operational DNA double strand break repair mechanism during the cell cycle 
phases G0, G1 and early S since a homologous repair template is not present in these 
phases of the cell cycle 251-252.  Non-homologous end-joining is thought to be a fast 
process, capable of being completed within 30 minutes, and is the dominate repair 
pathway of double strand breaks in eukaryotic cells 253-254.  Upon the formation of a DNA 
double strand break, the Ku heterodimer complex, which consists of the Ku70 and Ku80 
subunits, binds to the DNA termini 255-256.  The Ku heterodimer complex allows for 
alignment of the broken ends and promotes localization of other proteins involved in non-
homologous end-joining to the site of the DNA break including the DNA-dependent 
protein kinase catalytic subunit (DNA-PKcs) and the XRCC4-DNA ligase IV complex 256-
258.  The Ku heterodimer complex translocates into the DNA leaving DNA-PKcs at the 
DNA terminus on each of the aligned broken ends 259.  Upon binding the DNA ends, 
DNA-PKcs is activated and functions as a synapse between the two DNA termini 257, 260.  
The broken DNA ends are rejoined by the actions of DNA ligase IV stimulated by 
XRCC4 and XLF 261-263.  It should be pointed out this is a simplistic over view of non-
homologous end-joining, and this repair pathway is not as sequentially ordered as 
depicted here. 
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When DNA double strand breaks are formed due to exposure of ionizing 
radiation, the ends of the DNA can be damaged or contain single strand overhangs that 
are non-complimentary resulting in DNA termini that cannot be ligated.  In order to join 
the broken ends together, end-processing enzymes such as Artemis transform the termini 
into 5΄-phosphorylated ends capable of being ligated together 264.  If non-complimentary 
single strand DNA overhangs are present, gap filling may occur before ligation in order 
to conserve the overhang sequence 265.  The presence of modified bases in the vicinity of 
the processed ends, though, may interfere with gap filling and repair of the DNA double 
strand break.  Covo et al. developed a plasmid-based assay containing an abasic site on a 
short 5΄overhang located at the terminus of a DNA strand break to determine what effect 
altered bases have upon non-homologous end-joining  250.  The presence of the abasic site 
reduced the overall repair of the DNA double strand break, while translesion synthesis 
across from the abasic site allowed non-homologous end-joining to proceed with out loss 
of DNA bases 250.  Therefore, in certain situations translesion synthesis may be necessary 
for non-homologous end-joining to proceed, such as gap filling of DNA overhangs where 
the overhang contains an altered base.  Translesion polymerases contained within the X-
Family of polymerases may contribute to gap filling during non-homologous end-joining, 
therefore it is unclear if the translesion polymerases eta, REV1 and zeta are also 
necessary for non-homologous end-joining.  Furthermore, McElhinny et al. pointed out 
that in the absence of polymerases, non-homologous end-joining should still occur via the 
actions of a nuclease 265.  In this situation a nuclease would cleave off any non-
complimentary overhangs allowing for non-homologous end-joining to proceed. 
Consequently, translesion synthesis across altered bases contained within DNA 
overhangs may allow for conservation of DNA bases, but should not influence the 
efficiency of non-homologous end-joining. 
Even though non-homologous end-joining is the major repair pathway for DNA 
double strand breaks in mammalian cells, homologous recombination repair may occur if 
a homologous repair template is present.  Homologous recombination is a slow repair 
process taking seven hours or longer to complete and utilizes a homologous sister 
chromatid as a template for DNA repair 253.  In the homologous recombination repair 
pathway DNA is resected at the site of the DNA double strand break, perhaps by the 
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MRN complex, revealing a single stranded 3΄ overhang 266-268.  RPA binds the single 
stranded DNA overhang in order to stabilize it and prevent formation of secondary 
structures 268-271.  For the homology search to take place, RPA must be displaced to allow 
for the recombinase RAD51 to form a nucleofilament on the single stranded 3΄ overhang.  
RAD51 mediators including FANCD1 and the RAD51 paralogues, such as RAD51B and 
RAD51C, are responsible for RPA dissociation, and RAD51 loading onto the single 
stranded DNA 3΄ overhang 272-278.  Once formed, the RAD51 nucleofilament searches for 
a homologous repair template and promotes strand invasion at the site of the homologous 
template resulting in the formation of a D-loop structure 279-280.  DNA synthesis occurs at 
the site of the D-loop structure utilizing the homologous repair template, and once 
synthesis is complete the invading structure is resolved resulting in a repaired double 
strand break 268. 
Translesion polymerases may contribute to homologous recombination by 
participating in DNA synthesis at the D-loop structure.  Polymerase eta is proposed to 
associate with RAD51 and extend the 3΄ overhang repair substrate 119.  Sonoda et al. 
suggested that ionizing radiation-induced DNA double strand breaks may contain 
unsuitable 3΄ ends for initiation of D-loop extension and the translesion polymerase zeta 
may be critical for commencement of synthesis during homologous recombination repair 
56.  This scenario is unlikely due to the end-processing that takes place to ready the DNA 
termini for repair.  However, if altered bases are contained within the repair template, 
such as ionizing radiation-induced abasic sites, then translesion polymerases may be 
required for extension of the D-loop.   
 
Hypothesis 
The overall goals of my dissertation are as follows: 
1. To determine if the translesion DNA polymerases eta, REV1, and zeta are all 
necessary to bypass cisplatin-induced DNA adducts in a human cancer cell line, and 
gain an understanding of how these translesion polymerases are regulated during 
replicative bypass. 
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Several lines of evidence suggest that in vertebrates multiple translesion polymerases 
are necessary for translesion synthesis past damaged DNA bases.  However, few studies 
have addressed if multiple translesion polymerases are essential for replicative bypass in 
intact human cells.  Furthermore, biochemical assays have suggested that translesion 
polymerases are capable of replicating past chemotherapeutic-induced DNA damage, 
including cisplatin intrastrand cross-links.  Based upon these studies, I hypothesize that 
the translesion polymerases eta, REV1 and zeta are crucial for translesion synthesis past 
cisplatin-induced intrastrand cross-links in human cancer cells, thus reducing the 
cytotoxicity of this anti-cancer agent.  Monoubiquitination of PCNA by RAD18 at sites 
of stalled replication forks is thought to be an important event in terms of initiating 
translesion synthesis.  Recently, the Fanconi anemia core complex has been suggested to 
regulate translesion synthesis by promoting localization of REV1 to sites of ultraviolet 
radiation-induced replication stress.  I hypothesize that both RAD18 and the Fanconi 
anemia complex have important regulatory roles during translesion synthesis past 
cisplatin adducts.  
 
2. To determine if the translesion DNA polymerases eta, REV1 and zeta 
participate in the repair of chemotherapeutic drug-induced DNA interstrand cross-
links in a human cancer cell line. 
    Published studies have suggested the translesion polymerases REV1 and zeta have a 
cellular role in repairing interstrand cross-links in Xenopus egg extracts, DT40 cells and 
Saccharomyces cerevisiae.  Experiments utilizing plasmid reaction assays, where the 
plasmid contains a cisplatin or mitomycin C interstrand cross-link, have further implied 
that REV1 and polymerase zeta are essential for interstrand cross-link repair.  Multiple 
DNA repair pathways are thought be involved in the repair of interstrand cross-links 
including homologous recombination.  Polymerase eta has been proposed to extend D-
loops during homologous recombination.  Founded upon the data published in the 
aforementioned studies, I hypothesize that the translesion DNA polymerases eta, REV1, 
and zeta are required for efficient repair of DNA interstrand cross-links induced by the 
chemotherapeutic agents cisplatin and mitomycin C in a human cancer cell line.  
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3. To address if the translesion DNA polymerases eta, REV1 and zeta have a 
cellular role in bypass or repair of DNA damage induced by ionizing radiation. 
 DT40 cells and Saccharomyces cerevisiae deficient in REV1, REV3 or REV7 are 
known to be sensitive to ionizing radiation, suggesting REV1 and polymerase zeta have a 
biological role in response to ionizing radiation.  In addition, REV3-/- DT40 cells display 
enhanced chromosomal aberrations following ionizing radiation exposure.  Polymerase 
eta may be necessary for repair of ionizing radiation-induced DNA double strand breaks 
by extending D-loops during homologous recombination.  I hypothesize that the 
translesion polymerases eta, REV1 and zeta are necessary for protection against ionizing-
radiation induced cytotoxicity by either replicative bypass of damaged DNA bases or 
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Translesion DNA Polymerases Eta, REV1 and Zeta in lesion bypass of  





Translesion DNA synthesis (TLS) is a process whereby specialized DNA 
polymerases are recruited to bypass DNA lesions that would otherwise stall high-fidelity 
polymerases.  Currently, the process by which translesion polymerases bypass damaged 
template DNA in intact human cells is poorly understood.  In this chapter I provide 
evidence that multiple translesion polymerases are necessary to synthesize across 
cisplatin intrastrand cross-links in human cancer cells, supporting the insertion and 
extension model of translesion DNA synthesis. Furthermore, I demonstrated that PCNA 
monoubiquitination by RAD18 is necessary for efficient bypass of cisplatin adducts by 
the translesion synthesis polymerases eta (Polη), REV1, and zeta (Polζ) based on the 
observations that depletion of these proteins individually leads to decreased cell survival, 
cell cycle arrest in S phase, and activation of the DNA damage response.  In addition to 
PCNA monoubiquitination by RAD18, the Fanconi anemia core complex is also crucial 
for recruitment of REV1 to stalled replication forks in cisplatin treated cells.  Together 
the findings support a model where replicative bypass of cisplatin intrastrand cross-links 
requires cooperation of multiple TLS polymerases in mammalian cells and is regulated 




 Efficient and accurate replication of the eukaryotic genome is necessary for exact 
transmission of genetic information from generation to generation therefore preventing 
genomic instability.  In the presence of DNA damage, maintenance of genomic integrity 
involves the activation of cell cycle checkpoints coupled with DNA repair to remove any 
damaged bases before synthesis occurs.  Despite these sophisticated mechanisms to 
remove DNA lesions prior to DNA replication or cell division, DNA replication forks 
inevitably encounter lesions that block high fidelity polymerases potentially leading to 
replication fork instability, gaps in replicated DNA, and generation of DNA double strand 
breaks (DSBs).  In order to preserve replication fork stability by allowing completion of 
DNA replication, template DNA containing a damaged base or abasic site can be 
bypassed through the actions of specialized translesion DNA synthesis (TLS) 
polymerases 1.  A key event in the regulation of TLS is the monoubiquitination of PCNA, 
a homotrimeric protein that functions as an auxiliary factor for DNA polymerases 2-5.   
The RAD6 (E2)-RAD18 (E3) complex specifically monoubiquitinates PCNA 
(proliferating cell nuclear antigen) on Lysine-164 in response to replication fork stalling.  
This event is thought to operate as a molecular switch from normal DNA replication to 
the TLS pathway based on the observations that association of Y-Family TLS 
polymerases with monoubiquitinated PCNA is strengthened through the cooperative 
binding of one or more ubiquitin binding domains (UBM or UBZ) plus a PCNA-
interacting domain 6-7.   
In yeast and higher eukaryotes, the Y-Family polymerase eta (Polη) plays a key 
role in the efficient bypass of cyclobutane pyrimidine (TT) dimers, one of the major 
lesions resulting from exposure to ultraviolet (UV) radiation 8.  Inactivation of 
polymerase eta in humans results in the variant form of xeroderma pigmentosum (XP-V), 
an inherited disease associated with an increased incidence of skin cancers and sensitivity 
to sunlight, thus highlighting the importance of polymerase eta in performing error-free 
bypass of UV-induced DNA damage 9-10.  In yeast, most mutagenesis induced by various 
DNA damaging agents is thought to arise from the activity of a non-Y-Family TLS 
polymerase, polymerase zeta (Polζ) 11.  Polymerase zeta is a B-Family polymerase 
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composed of the Rev3 catalytic subunit and its accessory subunit, Rev7.  The Rev (for 
“defective mutation reversion”) genes were originally identified from genetic screens 
searching for mutants that are defective in UV-induced mutagenesis and include the Rev1 
gene encoding the Y-Family TLS polymerase rev1.  Biochemically, Rev1 is 
characterized as having limited polymerase activity restricted to inserting dCMP opposite 
guanine, adducted guanine, or abasic sites in DNA 8.  Rev1 is essential for polymerase 
zeta-dependent mutagenesis in yeast and in this role, rev1 appears to perform a regulatory 
function independent of catalytic activity 12.  With regards to DNA damage-induced 
mutagenesis, the genetic epistasis observed in yeast between Rev1, Rev3, and Rev7 
contributed to the prevailing model that Rev1 and polymerase zeta function together 
during lesion bypass 11.  Recent evidence suggests that Rev1 is necessary to target 
polymerase zeta to stalled replication forks 13. 
Although the genetic studies performed in yeast suggest that polymerase eta and 
the Rev1/polymerase zeta functional complex operate independently of one another in an 
error-free and error-prone mode of lesion bypass, recent studies in vitro implicate 
multiple translesion synthesis polymerases working in concert to bypass a single DNA 
adduct.  For example, polymerase eta efficiently replicates templates containing 
cyclobutane pyrimidine dimers but not other lesions (e.g. 6-4 pyrimidine-pyrimidone 
photoproducts induced by UV radiation).  In the latter case, polymerase eta can only 
insert a nucleotide directly opposite the adducted base and requires an additional 
translesion polymerase, such as polymerase zeta, to extend beyond the insertion 8.  
Polymerase zeta is unique among translesion polymerases in that its primary role appears 
to be extending mispaired primer termini and nucleotides already inserted opposite a 
variety of DNA lesions 8.  These observations brought forth a two polymerase insertion 
and extension model for translesion synthesis in higher eukaryotes and implicates 
polymerase zeta as being essential for completing lesion bypass across multiple DNA 
lesions and adducts, a concept recently supported through mutagenesis reporter studies 
conducted in REV3-depleted mammalian cells 14-15. 
 Rather than directly participating in nucleotide insertion opposite DNA lesions, 
vertebrate REV1 is thought to serve as a molecular scaffold during translesion synthesis 
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polymerase switching events.  In addition to a UBM domain that directly interacts with 
monoubiquitinated PCNA, REV1 is unique among the Y-Family polymerases in that it 
possesses an N-terminal BRCT motif that directly interacts with PCNA 7, 16.  In addition, 
REV1 possesses a unique protein interaction domain in its carboxy-terminus which 
makes mutually exclusive contact with the polymerase zeta accessory subunit, REV7, 
and other translesion polymerases including polymerase eta and the catalytic subunit of 
polymerase zeta, REV3 13, 17-20.   
  Agents which introduce intrastrand cross-links are widely used in cancer 
chemotherapy and thus understanding the means by which cells cope with these lesions 
will be instrumental in identifying novel mechanisms leading to drug resistance and 
designing new agents refractory to DNA damage tolerance mechanisms.  Polymerase eta, 
REV1, and polymerase zeta have all been implicated in mediating translesion synthesis 
past cisplatin intrastrand cross-links based on the findings that inhibiting their expression 
increases sensitivity and reduces cisplatin-induced mutagenesis in human cancer cells 21-
25.  Furthermore, biochemical and structural analyses of polymerase eta demonstrate that 
this translesion polymerase is capable of efficiently inserting dCTP opposite the 3’dG of 
a 1,2-d(GpG) cisplatin intrastrand cross-link 26.  Here, RAD18, polymerase eta, and 
REV1 are all demonstrated to localize to sites of replication stress marked by PCNA and 
γ-H2AX foci following treatment of cells with cisplatin; however, REV1 focus formation 
is specifically dependent upon a functional Fanconi anemia (FA) core complex 
suggesting FA core proteins play an important role in directing REV1 to cisplatin-
induced stalled replication forks.  In addition, depletion of RAD18, polymerase eta, 
REV1, or polymerase zeta proteins lead to the induction of cellular responses indicative 
of inefficient lesion bypass of cisplatin adducts. 
Together the findings support a model where replicative bypass of cisplatin 
intrastrand cross-links requires cooperation of multiple translesion polymerases in 
mammalian cells.  This is one of the first reports directly supporting an insertion and 
extension model in a human cell line.  Evidence is also provided that translesion 
synthesis is triggered by PCNA monoubiquitination and REV1 dependent bypass of 
cisplatin adducts is specifically regulated by the Fanconi anemia core complex. 
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Materials and Methods  
Cell lines and culture conditions.  HeLa, U2OS, and 293T/17 cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine 
serum. The BL2 human Burkitt’s lymphoma cell lines were cultured in RPMI-1640 
medium supplemented with 10% fetal bovine serum.  Construction of POLI, POLH, and 
REV3L -/- BL2 lines have been described 27-28.  Cisplatin (cis-
diammineplatinum(II)dichloride) was purchased from Sigma-Aldrich and dissolved in 
0.9% NaCl as a 3.3 mM stock solution.   
RNA interference.  HeLa cells were seeded at a density of 1x105 per well of a 6 well 
plate.  Introduction of siRNA into HeLa cells was carried out with X-tremeGENE 
(Roche).  Each well was exposed to 50 nM siRNA plus 5µl X-tremeGENE overnight in 
the presence of serum followed by a change in medium the next morning.  For FANCA 
and FANCD2 knockdown, U2OS cells were plated at a density of 2x105 per well of a 6 
well plate and transfected with 50 nM siRNA plus 5µl X-tremeGENE for 8 hours on 
sequential days.  When delivering siRNA into cells cultured in 12 well plates, the 
conditions for transfection was reduced by one half.  For most experiments, cells were 
treated with cisplatin or mitomycin C approximately 40 hours after the addition of 
siRNA.    siRNAs directed against RAD18, Polη, REV1, REV3, REV7, FANCA, or 
FANCD2 were obtained from Qiagen.  The gene-specific target sequences are as follows: 
RAD18-3 (GAG CAT GGA TTA TCT ATT CAA), Polη-1 (CTG GTT GTG AGC ATT 
CGT GTA), REV1-4 (ATC GGT GGA ATC GGT TTG GAA), REV3-2 (CCC ACT 
GGA ATT AAT GCA CAA), REV7-1 (GTG GAA GAG CGC GCT CAT AAA), 
FANCA-6 (AGG CCT ATG CTA ATC ATT CTA), FANCA-7 (CAG GGC CAT GCT 
TTC TGA TTT), FANCD2-2 (CAG AGT TTG CTT CAC TCT CTA), and FANCD2-5 
(AAG CAG CTC TCT AGC ACC GTA).  The negative control Non-si sequence (AAT 
TCT CCG AAC GTG TCA CGT) was purchased from Qiagen.  To create stable RAD18 
knockdowns, U2OS cells were infected with pLKO.1 lentivirus (Sigma-Aldrich) that 
encodes no shRNA (control) or shRNA targeting the following sequences: RAD18-2 
(TGC TTC GAG TAT TTC AAC ATT) or RAD18-6 (ATG GTT GTT GCC CGA GGT 
TAA). Cells were selected in puromycin and used within one week after drug selection. 
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Assessment of cell viability.  For clonogenic survival assays, HeLa cells were 
transfected overnight with siRNA as described above. When assessing survival following 
cisplatin treatment, cells were seeded at known densities the next day, allowed to attach 
to culture plates overnight, and then treated with cisplatin for two hours.  Cells were 
washed and allowed to form colonies for approximately 12 days.  Twelve days later, 
colonies were simultaneously stained and fixed in a solution containing 3:1 methanol and 
glacial acetic acid plus 1% trypan blue (Sigma).  Colonies of 50 cells or greater were 
counted and the surviving fractions for each siRNA treatment group represent the plating 
efficiency for each treatment divided by the plating efficiency of the corresponding 
untreated control.  The BL2 lymphoma lines were treated with cisplatin for 2 hrs and then 
harvested 48 hours later.  Cells were then washed with PBS and assessed as to their 
ability to exclude the trypan blue as a measure of viability.  
Antibodies.  Rabbit polyclonal anti-Polη (H-300), anti-GAPDH (FL-335), and anti-
REV1 (H-300) antibodies were purchased from Santa Cruz Biotechnology.  Rabbit 
polyclonal anti-phospho-CHK1 (ser345) and anti-phospho-Ser139 Histone H2AX were 
purchased from Cell Signaling and Active Motif respectively.  The following mouse 
monoclonal antibodies were used in these studies:  anti-PCNA PC10 (Ab-1, Oncogene 
Research Products), anti-RAD18 (3H7, Abnova), anti-phospho-histone H2A.X (Ser139, 
clone JBW301, Millipore), and anti-MAD2B/REV7 (BD Biosciences).  The anti-β-
tubulin (TUB 2.1) and anti-Flag M2 monoclonal antibodies were purchased from Sigma-
Aldrich Inc.   
Immunoblotting and rtPCR.  Cells were lysed in a sodium dodecyl sulfate (SDS) 
sample buffer (10 mM Tris pH 8.0, 2% SDS, 1 × protease inhibitor cocktail (Roche) and 
1 × phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich)), sonicated, heated at 95°C, 
and equal amounts of protein were separated on SDS-PAGE gels.  Proteins were 
transferred onto a nitrocellulose membrane and probed with the appropriate primary 
antibodies described above followed by secondary horseradish peroxidase (HRP)-
conjugated goat anti-rabbit or mouse antibody (Thermo Scientific).  Proteins were 
visualized using SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific).  To detect REV3L mRNA, total cellular RNA was extracted with TRIzol 
 58
reagent (Invitrogen), and 1µg of RNA was reverse transcribed with the High Capacity 
Reverse Transcription Kit (Applied Biosystems) according to manufacturer’s protocol. 
REV3L cDNA were PCR amplified using primers flanking either side of the REV3L 
siRNA targeting sequence.  GAPDH cDNA primers were included in each rtPCR 
reaction as an internal control.  The following PCR primers were used in these studies: 
REV3L forward 5΄-CTT TCT CAG ATG GCA TTC AG -3΄, REV3L reverse 5΄- TTT 
CGG AAC TTG ACA GCA GC-3΄; GAPDH forward 5΄- AAG GTC GGA GTC AAC 
GGA TTT GGT -3΄, GAPDH reverse 5΄- AGT GAT GGC ATG GAC TGT GGT CAT -
3΄.  The PCR protocol was as follows: 94°C for 5 min, 25 cycles of 94°C for 30 sec, 59°C 
for 30 sec, and 72°C for 2 min.  The RT-PCR products were separated on 1% agarose 
gels and visualized by ethidium bromide staining.   
Immunofluorescence.  For γ-H2AX, cells cultured on glass coverslips were washed in 
phosphate buffered saline (PBS) and then fixed in ice cold 100% methanol for 10 
minutes.  Samples were blocked with 5% fetal bovine serum, 0.05% Triton X-100, and 
1% goat serum, and then incubated with primary antibodies for 45 minutes.  Coverslips 
were washed three times with PBS and then incubated with the appropriate secondary 
goat anti-rabbit or goat anti-mouse Alexa Fluor dye conjugated secondary antibody 
(Molecular Probes) for 45 minutes, washed with PBS, counterstained with DAPI to 
visualize nuclear DNA, and then mounted onto slides with ProLong Gold antifade 
reagent (Invitrogen).  For experiments assessing PCNA colocalization with EGFP-tagged 
proteins, soluble proteins were first extracted with a Triton X-100 containing buffer 
(0.5% triton X-100, 20 mM HEPES pH 7.4, 3 mM MgCl2, 50 mM NaCl and 300 mM 
sucrose) for 5 minutes at 4°C in order to reveal detergent extraction-resistant proteins in 
the nucleus.  Cells were then fixed with a 3.7% para-formaldehyde solution for 20 
minutes at 4°C, washed once with PBS, and then fixed again in ice cold 100% methanol 
to expose the PCNA (PC-10) epitope.  Immunofluorescence staining for PCNA was the 
same as described above.  To visualize EGFP-tagged proteins and FANCD2 in siRNA 
transfected U2OS cells, the cells were washed in PBS and then fixed in a 3.7% para-
formaldehyde solution containing 0.5% Triton-X-100 for 20 minutes, stained for 
FANCD2 along with counterstaining with DAPI, and then mounted onto slides with 
Prolong Gold antifade reagent.  Staining for FANCD2 protein was as described above.  
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Imaging was performed on either an Olympus BX-51 fluorescence microscope or 
Olympus FV-500 confocal microscope.  Images were further processed and merged using 
Adobe Photoshop CS. 
Flow cytometry.  For single parameter flow cytometry, cells were fixed with ice cold 
70% ethanol and then resuspended in PBS containing RNAse A and propidium iodide to 
determine DNA content.  For two parameter flow cytometry, cells were fixed with 70% 
ice cold ethanol, blocked with 5% fetal bovine serum, 1% goat serum plus 0.05% Tween 
20, and then stained with anti-γ-H2AX monoclonal antibody.  Cells were washed, 
incubated with goat anti-mouse FITC-conjugated secondary antibody, and then 
counterstained with propidium iodide in PBS containing RNAse A.  Cells were acquired 
on a BD FACSCaliber system using CellQuest software. 
Lentiviral vectors and virus production.  The cDNA for human POLH (Polη) and 
REV1L were purchased from Enzymax.  Human RAD18 cDNA was PCR amplified from 
I.M.A.G.E. clone No. 3451960 (American Tissue Culture Collection).  POLH, REV1, and 
RAD18 cDNAs were subloned into pEGFP-C1 (Clontech) such that EGFP was fused in 
frame at the amino terminal end of each protein.  The entire cDNA encoding EGFP fused 
with the open reading frame of Polη, REV1, or RAD18 was excised and then subcloned 
into pLenti EV (University of Michigan Vector core facility) to generate pLLEV-EGFP-
Polη, pLLEV-EGFP-REV1, and pLLEV-EGFP-RAD18.  To generate lentivirus, 293T/17 
cells were cotransfected with individual lentiviral vectors plus the following packaging 
plasmids at a 1:1:1:1 ratio (pLP1, pLP2, and pLP/VSVG, Invitrogen) using the calcium 
phosphate method to deliver plasmid DNA into cells.  U2OS cells were seeded onto 
coverslips in twelve well plates and then infected with 293T/17 supernatent in the 
presence of 4 µg/ml polybrene overnight.  The following morning, the medium was 







Replicative bypass of cisplatin intrastrand cross-links requires PCNA 
monoubiquitination, Polη, and the REV1/ Polζ functional complex.   
 Upon entering a cell, the major adduct cisplatin forms is covalent bonds with the 
N7 position of adjacent guanines within the same DNA strand 29.  Intrastrand cross-links 
are also formed between neighboring adenine-guanine bases and guanine-guanine bases 
separated by a cytosine.  Approximately 2% of the DNA damage represents interstrand 
cross-links between guanines on opposite DNA strands.  Both DNA intrastrand and 
interstrand cross-links have been proposed to contribute to the cytotoxicity of cisplatin 29-
30.  To assess the importance of each component of the translesion synthesis pathway 
hypothesized as being necessary for replicative bypass of cisplatin DNA adducts (a 
simplistic model is shown in Fig. 2.1A), HeLa cells were transiently depleted of RAD18, 
polymerase eta (Polη), REV1, or polymerase zeta (REV3, and REV7) individually via 
siRNA and then analyzed for their ability to progress through the cell cycle following 
cisplatin-treatment along with their cellular response to DNA damage.  The ability to 
specifically deplete endogenous proteins with siRNA in HeLa cells was determined by 
immunoblot analysis (RAD18, Polη, REV1, or REV7) (Fig. 2.1C and supplemental data 
Fig. S2.2).  Since antibodies are not available to detect endogenous REV3, rtPCR was 
used to confirm reduction of REV3 mRNA following transfection with REV3-specific 
siRNA (Fig. 2.1B).  Further validation of the specificity and potency of the siRNAs used 
in this study were examined by demonstrating the ability of different siRNA sequences 
targeting REV1 or REV3 to deplete ectopically expressed proteins in 293T cells 
(supplemental data Fig. S2.1).  In addition, depletion of RAD18 via siRNA prevented 
efficient monoubiquitination of PCNA in response to UV-C or cisplatin demonstrating 




Figure 2.1  Model for lesion bypass of cisplatin intrastrand cross-links and 
validation of siRNAs used to deplete individual components of the TLS pathway.  
(A) RAD18 responds to stalled replication forks by monoubiquitinating PCNA at K164.  
This event serves as a molecular switch by increasing the affinity of Y-Family TLS 
polymerases for PCNA via their ubiquitin binding domains.  Evidence suggests that Polη 
performs the initial nucleotide insertion step opposite the cisplatin intrastrand cross-link 
while Polζ (composed of the catalytic REV3 domain and the REV7 accessory subunit) 
performs the extension step beyond the initial insertion.  Polζ activity requires REV1, a 
Y-Family polymerase thought to promote TLS polymerase switching events.  See 
introduction for details.  (B and C) HeLa cells were transfected with the indicated 
siRNAs as described in Materials and Methods.  Forty-eight hours later, total cellular 
RNA was subjected to rtPCR using primers specific for either REV3 or GAPDH (B) or 
whole cell lysates were separated by SDS-PAGE and subjected to immunoblot analysis 
using the indicated primary antibodies (C).  Non-si indicates a nonspecific control 
siRNA. (D) Depletion of RAD18 prevents monoubiquitination of PCNA.  Control or 
RAD18-depleted HeLa cells were exposed to 40 J/m2 UV-C or 150 µM cisplatin for 2 
hours and then harvested 8 hrs later to measure the ubiquitination of PCNA.  Whole cell 
lysates were subjected to immunoblot analysis with anti-PCNA antibody.   
 
  Phosphorylation of the histone variant H2AX at serine 139 occurs in response to 
DNA damage such as double strand breaks or replication fork stalling, which are 
primarily mediated by ATM and ATR, respectively 31, and is an extremely sensitive 
marker for the presence of DNA damage or perturbation of DNA replication.  To 
determine if depletion of RAD18, Polη, REV1, or REV3 in HeLa cells leads to enhanced 
DNA damage following cisplatin treatment, these proteins were down-regulated in HeLa 
cells, exposed to cisplatin, and stained for γ-H2AX (Fig. 2.2A).  Rather than seeing 
individual foci in cisplatin-treated cells, the nuclei of RAD18, Polη, REV1 or REV3 
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siRNA-transfected cells exhibited indistinguishable, intense, and almost diffuse staining 
patterns 24 hours after drug exposure.  In comparison, non-specific (Non-si) siRNA-
transfected cells displayed little staining suggesting these cells were capable of 
replicating DNA containing cisplatin intrastrand cross-links in the presence of an intact 
translesion synthesis pathway.  Similar results were found when HeLa cells were 
transfected with several different siRNAs targeting RAD18, Polη, REV1, REV3 or REV7 
thus demonstrating that the enhanced γ-H2AX response induced by cisplatin treatment is 
not due to siRNA off-target effects (supplemental data Fig. S2.3 and S2.4).  In response 
to ionizing radiation, γ-H2AX staining patterns present as individual foci directly 
correlating with the number of DNA double strand breaks expected for a given dose 32.  
Since it is unlikely that the intense γ-H2AX staining observed in RAD18, Polη, REV1, or 
REV3 knock-down cells represents mass accumulations of double strand breaks, this 
staining pattern is interpreted as an indication of extensive DNA replication stalling due 
to the inability to perform lesion bypass, and this in turn results in the induction of a 
sustained checkpoint response mediated by ATR 33-34.   
 To determine whether the increased γ-H2AX staining detected by 
immunofluorescence was specifically associated with cells residing in S phase, HeLa 
cells were co-stained with propidium iodide for DNA content along with γ-H2AX and 
analyzed individually by flow cytometry.  REV7 knockdown was also examined to 
determine whether depletion gives rise to the same phenotype as observed with 
knockdown of RAD18, Polη, REV1, or REV3.  Transfection of siRNA specific for each 
component of the translesion synthesis pathway, including REV7, was associated with 
essentially identical γ-H2AX responses in that the majority of cells arrested primarily in 
S and G2 phases of the cell cycle and stained positive for γ-H2AX after cisplatin 
treatment (Fig. 2.2B and C).  This result also demonstrates that the gene identified as 
human REV7 (MAD2L2 or MAD2B) is likely to be the true homologue of yeast Rev7 
based on the observation that essentially an identical phenotype was exhibited in REV7-
depleted cells as compared to REV3-depleted cells challenged with cisplatin.  Depletion 
of translesion synthesis proteins using several different siRNA sequences targeting 
RAD18, Polη, REV1, REV3 or REV7 lead to similar cell cycle arrest profiles following 
cisplatin treatment demonstrating that the effects observed here are gene-specific 
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(supplemental data Fig. S2.5).  Time course studies analyzing γ-H2AX formation by 
immunoblot analysis indicate that the γ-H2AX response developed slowly over time and 
became prominent by 16 hours after cisplatin treatment as cells accumulated in S phase 
(supplemental data Fig. S2.6).  Consistent with enhanced ATR-dependent checkpoint 
activation in response to replication fork stalling, depletion of RAD18, Polη, REV1, 
REV3, or REV7 lead to increased phosphorylation of the CHK1 cell cycle checkpoint 
kinase, a direct and specific target of the ATR kinase (Fig. 2.2D) 13.   
 
Figure 2.2  Lesion bypass of cisplatin adducts in Hela cells requires PCNA 
monoubiquitination by RAD18, Polη, and the REV1/Polζ functional complex.  HeLa 
cells transfected with the indicated siRNAs were treated with 10 µM cisplatin for 1 hr.  
Twenty-four hours later the cells were fixed, stained for γ-H2AX (green), and then 
imaged by fluorescent microscopy (A) or analyzed by flow cytometry (B and C).  Dot 
plots showing the level of γ-H2AX staining versus DNA content are shown in (B) and 
corresponding histograms from the same experiment showing DNA content per event are 
shown in (C).  (D) RAD18, Polη, REV1, REV3 or REV7-depleted HeLa cells were 
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treated with 10 µM cisplatin as above.  Whole cell lysates were subjected to immunoblot 
analysis for CHK1 specifically phosphorylated at Ser 345 and GAPDH as a loading 
control.  Depletion of RAD18, Polη, REV1, REV3, or REV7 leads to an enhanced DNA 
damage response indicative of incomplete DNA replication in cisplatin treated cells. 
 
The γ-H2AX staining patterns compared to cisplatin treatment were essentially 
identical both in intensity and pattern when RAD18, Polη, REV1, REV3, or REV7 
siRNA-transfected HeLa cells were exposed to a relatively low dose of UV-C light (4 
J/m2) (Fig. 2.3).  Depletion of translesion synthesis proteins using several different 
siRNA sequences targeting RAD18, Polη, REV1, REV3 or REV7 lead to similar γ-
H2AX staining patterns via immunofluorescence following UV-C exposure 
demonstrating that the effects observed are gene-specific (supplemental data Fig. S2.7 
and S2.8).  The staining pattern observed in Figures 2.2A and 2.3 is very similar to other 
published reports where replication fork stalling activates ATR leading to pan-nuclear 
like γ-H2AX staining patterns 35.  Taken together, the data supports an insertion and 
extension model of translesion synthesis in a human cancer cell line where RAD18 along 
with translesion polymerases eta, REV1 and zeta are all necessary to bypass cisplatin and 
UV-C induced DNA intrastrand cross-links. 
 
 
Figure 2.3  RAD18, Polη, 
and the REV1/Polζ 
functional complex are 
necessary for lesion bypass 
of UV-C adducts.  HeLa cells 
depleted of RAD18, Polη, 
REV1, REV3 or REV7 
individually were exposed to 4 
J/m2 UV-C radiation. Twenty-
four hours later the cells were 
fixed, stained for γ-H2AX 
(green), and then imaged by 
fluorescent microscopy.  
 65
RAD18, polymerase eta, and REV1 colocalize with PCNA at sites of cisplatin-
induced replication stress 
To gain additional evidence that RAD18, polymerase eta, and REV1 are involved 
in replicative bypass of cisplatin intrastrand cross-links, the proteins were assessed as to 
whether they colocalize with PCNA foci in a cisplatin-dependent manner.  To determine 
sites of cisplatin-induced stalled replication forks, PCNA foci were utilized as a surrogate 
marker of replication stress.  To distinguish whether cisplatin-induced PCNA foci 
represent sites of replication stress (e.g. stalled replication forks) as opposed to 
unperturbed DNA replication, a determination was made as to whether cisplatin-induced 
PCNA foci co-localize with γ-H2AX.  As expected, untreated U2OS cells exhibited both 
PCNA and γ-H2AX foci; however, these foci rarely colocalized (Fig. 2.4A).  In response 
to agents known to cause replicative fork stalling, helicase-polymerase uncoupling and 
monoubiquitination of PCNA, such as UV-C, hydroxyurea, aphidicolin or cisplatin, 
PCNA focus formation greatly increased and exhibited significant colocalization with γ-
H2AX (Fig. 2.4A and B).  Even though replication forks may stall due to DNA double 
strand breaks or interstrand cross-links, these lesions are unlikely to promote or cause 
helicase-polymerase uncoupling thus prohibiting formation of long stretches of single 
stranded DNA.  Chang et al. demonstrated that the single stranded DNA formed due to 
helicase-polymerase uncoupling at sites of stalled replication forks is coated with RPA 
and is crucial for localizing the RAD6 (E2)-RAD18 (E3) ubiquitin ligase to sites of 
replication stress 36.  As expected, monoubiquitination of PCNA was not detected after 
exposure to ionizing radiation (DNA double strand break inducer), mitomycin C 
(interstrand cross-linker), or camptothecin (topoisomerase I poison that induces formation 
of replication-associated DNA double strand breaks) and extensive colocalization was not 
observed between PCNA and γ-H2AX (Fig. 2.4A and B).  Taken together, PCNA foci 
mark sites of replication stress induced by lesions that promote induction of RAD18-





Figure 2.4  Agents that induce replication fork stalling and helicase/replicase 
uncoupling promote extensive colocalization between PCNA and γ-H2AX foci along 
with PCNA monoubiquitination.  (A) U2OS cells grown on coverslips or 6 well dishes 
were left untreated or treated with 8 J/m2 UV-C, 33 µM cisplatin for 2 hours, 100 ng/ml 
mitomycin C (MMC) for 2 hours, or 10 Gy ionizing radiation (IR).  Six hours later, 
Triton-X-100 detergent soluble proteins were extracted from the nuclei prior to fixation 
with para-formaldehyde followed by additional fixation with 100% methanol to reveal 
the PCNA epitope.  Cells were stained with anti-γH2AX (green) and anti-PCNA (red) 
and then imaged on an Olympus BX-51 fluorescence microscope.  (B) HeLa cells were 
exposed to 5 µM aphidicolin, 40 J/m2 UV-C, 150 µM cisplatin for 2 hours, 300 ng/ml 
mitomycin C (MMC) for 2 hours, 100nM camptothecin (CPT), or 10 Gy ionizing 
radiation (IR).  Cells were harvested 24 hours after the initiation of treatment, lysed, and 
subjected to SDS-PAGE.  Shown is a representative immmunoblot probing for PCNA.  
MMC, CPT and IR did not induce detectable PCNA monoubiquitination even when cells 
were treated with or exposed to relatively high doses of drug or radiation.  
 
To determine if RAD18, polymerase eta, and REV1 localize to sites of cisplatin-
induced replication stress, replication-deficient lentivirus was engineered to deliver 
EGFP-tagged RAD18, POLH, or REV1 genes into mammalian cells in a highly efficient 
manner such that nearly 100% of cells express EGFP-tagged protein after lentiviral 
transduction.  Since HeLa cells expressed extremely low levels of EGFP-REV1 protein, 
U2OS osteosarcoma cells were used for these studies.  In agreement with previous 
studies, untreated or cisplatin exposed cells exhibited EGFP-Polη foci that colocalize 
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nearly 1 to 1 with PCNA foci (Fig. 2.5A and D) 21, 37.  Following cisplatin treatment, the 
number of EGFP-Polη foci within a given cell increased dramatically (Fig. 2.5A and 
supplement data Fig. S2.9).  In contrast, a significant number of untreated cells exhibited 
EGFP-REV1 or RAD18 foci that failed to show co-localization with PCNA suggesting 
these two proteins do not strictly localize to replication factories.  In response to cisplatin 
treatment, the majority of cisplatin-induced EGFP-REV1 or RAD18 foci colocalized with 
PCNA, similar to EGFP-Polη (Fig. 2.5A and D).  While the majority of EGFP-RAD18 
expressing cells contained 10 or greater foci in the presence or absence of cisplatin 
treatment, EGFP-REV1 expressing cells exhibited cisplatin-induced foci formation (Fig. 
2.5A and supplemental data Fig. S2.9).  Cisplatin-induced EGFP-Polη, REV1 and 
RAD18 foci also displayed extensive colocalization with γ-H2AX (Fig. 2.5B).  
Consistent with the model that Polη and REV1 cooperate to perform lesion bypass of 
cisplatin-DNA adducts, cisplatin induced the formation of foci consisting of EGFP-Polη 










Figure 2.5  RAD18, Polη and REV1 localize to sites of cisplatin-induced replication 
stress marked by PCNA and γ-H2AX.  (A and B) Cisplatin induces RAD18, Polη, and 
REV1 foci that extensively colocalize with PCNA and γ-H2AX.  U2OS cells grown on 
cover slips were infected with lentivirus designed to express EGFP-tagged RAD18, Polη, 
or REV1 as described in Materials and Methods.  Cells were treated with 33 µM cisplatin 
for 2 hrs, allowed to recover for 8 hours and then fixed.  Prior to fixation, Triton-X-100 
soluble proteins were extracted from nuclei in order to enhance visualization of focus 
formation.  Samples were stained with anti-PCNA antibody (red) and imaged using 
confocal microscopy (A) or stained with anti-γ-H2AX antibody (red) and imaged using 
an Olympus BX-51 fluorescence microscope (B).  (C) Cisplatin induces the formation of 
Polη and REV1 foci that colocalize.  U2OS cells were first infected with lentivirus 
encoding EGFP-tagged Polη.  Thirty hours later, the same cells were infected with 
lentivirus encoding Flag-tagged REV1.  Cells were treated with cisplatin, fixed as 
described above, and then stained with anti-Flag antibody (red).  Cells were imaged using 
confocal microscopy.  (D) Graphs represent the average percentage of cells exhibiting 
greater than 10 foci per cell of either EGFP-tagged RAD18, Polη or REV1 foci 
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colocalizing with PCNA foci.  Data represent the mean ± S.E.M of three independent 
experiments where >100 cells were counted in each experiment.    
 
RAD18 is essential for localization of polymerase eta and REV1 to cisplatin-induced 
stalled replication forks 
As described in Figure 2.5 the translesion polymerases eta and REV1 form 
cisplatin-induced foci at sites of stalled replication forks.  To access how foci formation 
is regulated in response to replication stress, RAD18 depleted U2OS were examined to 
determine whether polymerase eta and REV1 foci form in response to cisplatin treatment.  
The RAD6 (E2)-RAD18 (E3) ubiquitin ligase complex specifically monoubiquitinates 
PCNA in response to replication fork stalling and is thought to be a molecular switch 
between high fidelity synthesis and translesion DNA synthesis 38-41.  Cells deficient of 
RAD18 are known to be hypersensitive to DNA damaging agents that induce replication 
fork stalling signifying RAD18 is necessary for a proper response to replication stress 42-
45.  Furthermore, the affinity of translesion polymerases such as eta and REV1 to PCNA 
drastically increases following monoubiquitination due to interactions via UBZ and UBM 
domains respectively 7, 46.  Therefore, RAD18 is thought to be the primary initiator of 
translesion synthesis promoting localization of translesion polymerases to the site of 
replication stress.  However, discrepancies in the literature exist over whether the 
monoubiquitination of PCNA is truly a regulator of translesion synthesis 47. 
 U2OS cells with stable knockdown of RAD18 were developed as described in 
Materials in Methods.  RAD18 was depleted from U2OS cells via two different shRNA 
sequences independently of each other.  Exposure of the RAD18-depleted cells to 
cisplatin did not result in monoubiquitination of PCNA demonstrating efficient stable 
knockdown of RAD18 (Fig. 2.6A).  After stable knockdown of RAD18 was established, 
both EGFP-Polη and EGFP-REV1 were introduced into U2OS cells as in Figure 2.5.  In 
the cells deficient of RAD18, EGFP-Polη or EGFP-REV1 foci formation was abrogated 
in response to cisplatin treatment (Fig. 2.6B, C, and D).  The reduction in both EGFP-
Polη or EGFP-REV1 foci formation in the RAD18-depleted cells suggests RAD18 is an 
important initiator of translesion synthesis.  Taking into consideration the data presented 
here and in Figure 2.5C, both polymerase eta and REV1, via RAD18 regulation, appear 
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to operate together in the same translesion synthesis pathway to bypass cisplatin adducts 
consistent with previously published reports 15. 
 
Figure 2.6  RAD18 is necessary for efficient Polη and REV1 focus formation in 
U2OS cells following cisplatin treatment.  U2OS cells were infected with lentivirus 
designed to deliver shRNA targeting RAD18 as detailed in Material and Methods.  (A) 
Control or RAD18-depleted HeLa cells were exposed to 150 µM cisplatin for 2 hours and 
then harvested 24 hrs later to measure the ubiquitination of PCNA.  Whole cell lysates 
were subjected to immunoblot analysis with anti-PCNA antibody.  (B) U2OS cells stably 
depleted of RAD18 via two different shRAD18 sequences independently of each other 
were grown on cover slips and infected with lentivirus designed to express EGFP-tagged 
Polη or REV1. Cells were treated with 33 µM cisplatin for 2 hrs, allowed to recover for 6 
hours and then fixed with para-formaldehyde and imaged using an Olympus BX-51 
fluorescence microscope.  (C and D) Graphs represent the average percentage of cells 
exhibiting greater than 10 foci of either EGFP-tagged Polη or REV1. Data represent the 
mean ± S.E.M of three independent experiments where >100 cells were counted in each 
experiment.    
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The Fanconi anemia (FA) core complex recruits REV1, but not Polη, to sites of 
cisplatin-induced replication stress   
Given that RAD18 appears to initiate translesion synthesis at sites of cisplatin-
induced replication stress, it was of interest to determine if any other proteins may 
contribute to the regulation of translesion synthesis.  Several lines of evidence implicate 
the Fanconi anemia pathway in regulating REV1 and polymerase zeta-dependent 
translesion synthesis.  First, cells deficient in components of the Fanconi anemia pathway 
have been characterized as being hypomutagenic at the HPRT locus 48-50.   In addition to 
the genetic epistasis observed between FANCC and REV1 or REV3 for cisplatin 
sensitivity in DT40 cells, FANCC-deleted cells are also deficient for somatic 
hypermutation of abasic sites at the IgM locus, a process dependent upon the TLS 
pathway 51.  Mirchandani et al. have recently shown that the Fanconi anemia core 
complex is necessary for both spontaneous and UV-C induced mutagenesis, as well as 
proper recruitment of ectopically expressed REV1 protein to nuclear foci upon exposure 
to UV-C irradiation 52.  Interestingly, regulation of REV1 localization into UV-C induced 
foci does not require the Fanconi anemia complementation group I (FANCI) or Fanconi 
anemia complementation group D2 (FANCD2) proteins, which are believed to act 
downstream of the FA core complex to direct DNA repair.  Regulation of REV1 focus 
formation by the FA core complex also appears to be a parallel pathway to RAD18-
dependent PCNA monoubiquitination since localization of RAD18 and its activity are 
unperturbed in UV-C irradiated cells deficient in FANCA or FANCG protein, 
components of the Fanconi anemia core complex 52.  Based on these observations, the 
influence of the FA-pathway on recruitment of REV1 or Polη into foci after cisplatin 
treatment was investigated. 
 U2OS cells were transfected twice with two different siRNAs specific for either 
the FANCA or FANCD2 mRNA, and then infected with lentivirus encoding EGFP-
RAD18, EGFP-Polη, or EGFP-REV1. Cells were exposed to cisplatin, fixed, and then 
analyzed for foci formation.  Eliminating FANCA or FANCD2 expression had little 
impact on cisplatin-induced RAD18 or Polη foci formation (Fig. 2.7A and B). However, 
cells depleted of FANCA protein failed to exhibit cisplatin-induced EGFP-REV1 foci 
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demonstrating that the Fanconi anemia core complex specifically regulates REV1 
localization at stalled replication forks. The efficiency of FANCA knockdown was 
confirmed by assessing disruption of cisplatin-induced FANCD2 foci formation (Fig. 
2.7C) and also by demonstrating that FANCD2 monoubiquitination was abrogated in 
FANCA siRNA transfected cells (Fig. 2.7D). Both FANCD2 foci formation and 
monoubiquitination are known to require a functional Fanconi anemia core complex 53.   
Figure 2.7  The Fanconi anemia core complex is necessary for cisplatin-induced 
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REV1 focus formation.  U2OS cells were transfected twice with Non-si siRNA or 
siRNA specific for FANCA or FANCD2 mRNA. After the second transfection, cells 
were infected with lentivirus encoding EGFP-RAD18, Polη, or REV1 as described in 
Materials and Methods. Forty hours after infection, cells were treated with 33 µM 
cisplatin for 2 hrs and 6 hrs later samples were fixed in para-formaldehyde plus 0.5% 
Triton-X-100, and then stained for FANCD2 protein.  Cells were imaged using an 
Olympus BX-51 fluorescence microscope. (A) FANCA-deficient cells are defective in 
REV1 focus formation in response to cisplatin treatment. (B) The percentage of EGFP- 
RAD18, Polη or REV1 positive cells exhibiting 10 or more foci per cell was determined. 
Results represent the mean ± S.E.M. of two independent experiments.  Effective 
knockdown of FANCA or FANCD2 protein was assessed by analyzing FANCD2 foci 
formation by immunofluorescence (C) and FANCD2 monoubiquitination by 
immunoblotting (D).  Depletion of FANCA protein abrogates both cisplatin-induced 
FANCD2 foci formation and mitomycin C-induced FANCD2 monoubiquitination. 
 
REV1, REV3 and REV7 protect against cisplatin-induced cytotoxicity  
Since depletion of RAD18, Polη, REV1, REV3, or REV7 lead to 
indistinguishable responses with regards to phosphorylation of H2AX and cell cycle 
redistribution (Fig. 2.2), the expectation was that knock-down of these proteins in HeLa 
cells would result in equivalent hypersensitivity to cisplatin as measured by a standard 
colony formation assay.  RAD18 or the translesion synthesis polymerases were noted to 
promote tolerance of cisplatin.  However, REV1, REV3, or REV7 siRNA-transfected 
HeLa cells were found to exhibit greater sensitivity to cisplatin-induced loss in 
clonogenicity at lower drug concentrations (e.g. 1 and 3 µM) suggesting that REV1 and 
polymerase zeta may perform additional roles in promoting tolerance to cisplatin (Fig. 
2.8A).  To confirm this observation, human Burkitt’s lymphoma BL2 cells deleted of 
POLH (eta), POLI (ίota) or REV3L (332 and 504) were treated with various 
concentrations of cisplatin for 2 hours and viability measured 48 hours later by trypan 
blue dye exclusion (Fig. 2.8B).  Consistent with the results observed in HeLa cells 
transfected with REV3 siRNA, REV3 knockout BL2 cells were significantly more 





Figure 2.8  Depletion of REV1, REV3 or REV7 renders HeLa or BL2 cells 
hypersensitive to cisplatin-induced cytotoxicity.  (A) HeLa cells were transfected with 
control (Non-si) siRNA or siRNA targeting RAD18, Polη, REV1, REV3 or REV7.  Cells 
were seeded at known densities, treated with cisplatin for 2 hrs the following day, and 
then allowed to form colonies for approximately 12 days.  Data is expressed as the 
average surviving fraction ± S.E.M. for each dose of cisplatin.  (B) Wild type BL2 cells 
or BL2 cells lacking expression of polymerase ίota (Polι), Polη, or REV3 (clones 332 and 
504) were treated with various doses of cisplatin for 2 hrs.  Two days later, the cells were 
harvested and subjected to the trypan blue exclusion assay to assess viability.  Data is 
expressed as the average percentage of cells stained negative for trypan blue, normalized 
to untreated control.  At least three independent experiments were performed.  Error bars 




 Here the demonstration is made that elimination of translesion synthesis activity 
can significantly alter the ability of cells to progress through the cell cycle when treated 
with the anti-cancer drug cisplatin.  In order to fully comprehend the complete molecular 
apparatus that performs translesion synthesis across cisplatin DNA adducts in intact cells,  
RAD18, polymerase eta (Polη), REV1, and polymerase zeta (REV3 and REV7) protein 
were individually depleted via siRNA in HeLa cells and their individual responses to 
cisplatin were measured.  The data demonstrate that PCNA monoubiquitination by 
RAD18 is necessary to promote translesion synthesis across these lesions.  Eliminating 
this essential first step in the translesion synthesis pathway resulted in the accumulation 
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of cells in S and G2 phases of the cell cycle and this block of cell cycle progression was 
associated with a markedly enhanced cell cycle checkpoint response as measured by the 
phosphorylation of H2AX and the CHK1 kinase.  The results indicate that RAD18-
depleted cells experienced profound replication stalling due to the inability to bypass 
cisplatin adducts during DNA replication.   
Furthermore, depletion of RAD18 inhibited cisplatin-induced polymerase eta and 
REV1 focus formation.  The fact that Polη, REV1, REV3, or REV7-depleted cells 
exhibited essentially identical responses to cisplatin as RAD18-depleted cells, 
demonstrates that polymerase eta, REV1, and polymerase zeta cooperate in order to 
achieve efficient bypass of cisplatin intrastrand cross-links, the major cisplatin adduct 
formed on DNA.  Consistent with the model that polymerase eta and REV1 cooperate to 
perform lesion bypass of cisplatin-DNA adducts, cisplatin induced the formation of foci 
consisting of EGFP-Polη and Flag-REV1 colocalized together (Fig. 5C).  
 The Y-Family polymerase kappa has also been implicated in performing the 
insertion step during error prone replicative bypass of cisplatin adducts 15.   The data 
presented here indicates that polymerase eta is the primary translesion synthesis 
polymerase that performs the insertion step opposite these lesions during replication of 
genomic DNA, at least in HeLa cells.  This is based on the observation that eliminating 
polymerase eta expression is just as effective as eliminating REV1, REV3 or REV7 with 
regards to the ability of cisplatin-treated cells to progress through S phase.  Also, 
phenotypes associated with the phosphorylation of H2AX (Fig. 2.2) is basically identical 
in RAD18, polymerase eta, REV1 or polymerase zeta depleted HeLa cells exposed to 
cisplatin.  Overall, the findings agree with those of Shachar et al. 15, and provide evidence 
supporting the multiple polymerase insertion and extension model for translesion 
synthesis across cisplatin intrastrand cross-links in mammalian cells.  Together, these 
observations are consistent with a model where polymerase eta performs the insertion 
step across a 1,2-d(GpG) cisplatin adduct and polymerase zeta completes translesion 
synthesis by extending beyond the initial insertion, with the latter polymerase zeta step 
facilitated through REV1 interactions (Fig. 2.1A).   
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 Consistent with this model, polymerase eta and REV1 form distinct foci in 
response to cisplatin treatment which colocalize with PCNA.   Whether or not translesion 
polymerase focus formation truly represents an increase in actual translesion synthesis 
activity at stalled replication forks is not known; however, these visible foci likely 
represent increased residency times of Y-Family translesion polymerases associated with 
monoubiquitinated PCNA 54.  The fact that cisplatin-induced PCNA foci also colocalized 
with γ-H2AX strongly suggests that these sites coincide with a replication stress response 
that effectively results in the localized phosphorylation of H2AX.  It is interesting to note 
that translesion polymerase focus formation appears to occur only in response to DNA 
damaging agents that are thought to cause uncoupling of replicative helicase and 
polymerase activities as an indirect consequence of replication fork stalling 34.  The 
generation of RPA-primed single stranded DNA, an end result of extensive DNA 
unwinding at a stalled replication fork, is essential for triggering RAD18-dependent 
monoubiquitination of PCNA 55-56.  Consistent with this model, DNA damage-induced 
polymerase eta and REV1 focus formation occurs in response to agents that strongly 
induce PCNA monoubiquitination, such as UV-C irradiation, hydroxyurea, aphidicolin, 
and cisplatin 57-60.  Treatments which predominantly introduce interstrand cross-links 
(e.g. mitomycin C) or alternatively, DSBs (e.g. ionizing radiation and camptothecin, a 
topoisomerase I poison), do not effectively induce PCNA monoubiquitination or 
translesion polymerase focus formation (Fig. 2.4) 37, 57, 61.   
 In addition to RAD18, the Fanconi anemia core complex was found to have a 
regulatory role in translesion synthesis.  In the absence of the Fanconi anemia core 
complex protein FANCA, REV1 focus formation following cisplatin treatment was 
defective.  Interestingly, RAD18 and polymerase eta foci formation in response to 
cisplatin exposure was unaffected in FANCA deficient cells, suggesting the regulatory 
function of the Fanconi anemia core complex during translesion synthesis is specific to 
REV1.  Furthermore, the depletion of FANCD2 appeared to have no effect upon RAD18, 
polymerase eta or REV1 focus formation.  This result was somewhat surprising since 
FANCD2 is monoubiquitinated by the core complex and the Y-Family translesion 
polymerases have a high affinity for monoubiquitinated proteins.  The observation that 
localization of REV1 into foci following cisplatin treatment is deficient in cells lacking 
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FANCA, but not FANCD2 protein, is consistent with previously published models that 
Fanconi anemia core proteins facilitate REV1-dependent translesion synthesis 52. 
Taken together, a model can be proposed highlighting the stepwise approach to 
translesion synthesis past cisplatin adducts (Fig. 2.9).  In response to cisplatin intrastrand 
cross-links, the helicase and polymerase uncouple at the site of stalled forks leading to 
regions of single stranded DNA.  RPA coats the single stranded DNA and promotes 
localization of RAD18 in an ATR-independent manner to sites of replication stress 55, 62.  
As discussed in Figure 2.4, agents which do not allow helicase and polymerase 
uncoupling also do not promote monoubiquitination of PCNA, implying that single 
strand DNA formation is essential for recruitment of RAD18 to sites of stalled replication 
forks.  Once localized to the stalled forks, RAD18 monoubiquitinates PCNA on lysine 
164.  The monoubiquitination of PCNA is thought to act as a molecular switch between 
high fidelity synthesis and translesion synthesis by promoting the localization of 
translesion polymerases to the site of stalled forks.  In agreement with this model, 
depletion of RAD18 suppresses polymerase eta and REV1 foci formation suggesting 
PCNA monoubiquitination is indeed vital for localization of the Y-Family polymerases to 
sites of replication stress (Fig. 2.6).  Polymerase eta inserts a cytosine opposite the 3’dG 
of a 1,2-d(GpG) cisplatin adduct, and is thought to perform this function independently of 
the REV1/polymerase zeta functional complex 26.  Data presented in Figure 2.7 
demonstrated that the Fanconi anemia core complex has a regulatory role in REV1 but 
not polymerase eta focus formation following cisplatin exposure, thus polymerase eta can 
localize to the sites of replication stress independently of both REV1 and the Fanconi 
anemia core complex.  In this stepwise approach to translesion synthesis, PCNA 
monoubiquitination, the Fanconi anemia core complex and possibly polymerase eta 63 are 
all necessary for REV1 focus formation at sites of stalled forks.  REV1 is thought to 
promote localization of polymerase zeta to sites of replication stress and facilitate a 
translesion polymerase switch between polymerase eta and polymerase zeta.  Polymerase 





Figure 2.9  A stepwise approach to translesion synthesis past cisplatin adducts.  (A) 
A replication fork encounters a cisplatin intrastrand cross-link and stalls, thus leading to 
helicase and polymerase uncoupling and the formation of single stranded DNA (ssDNA).  
Replication may be reinitiated downstream of the stalled fork creating a ssDNA gap.  
RPA coats the single stranded DNA, and in an ATR-independent manner RAD18 
localizes to the site of the stalled fork and monoubiquitinates PCNA on lysine 164.  (B) 
Polymerase eta (Polη) localizes to the site of the stalled replication fork and synthesizes 
directly across from the cisplatin adduct.  (C) REV1/Polζ complex localizes to the stalled 
replication fork in a monoubiquitinated PCNA, Polη, Fanconi anemia core complex 
dependent manner.  The Fanconi anemia core complex likely translocates to the site of 
replication stress via FANCM-FAAP24 interactions.  Once located at the stalled fork 
polymerase zeta (Polζ) synthesizes beyond the cisplatin intrastrand cross-link filling the 
ssDNA gap.  (D)  The completed bypass of a cisplatin intrastrand-cross link.  The 
cisplatin adduct is not removed, but translesion synthesis across the lesion allows the cell 
more time to cope with the DNA damage, thus promoting resistance to cisplatin 
intrastrand cross-links.   
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Lastly, RAD18 along with the translesion polymerases eta, REV1 and zeta were 
all found to promote cisplatin tolerance noted by the loss of survival in cisplatin treated 
HeLa cells depleted of these proteins.  Unexpectedly, depletion of REV1, REV3 or REV7 
resulted in a significantly greater sensitivity to cisplatin when compared to RAD18 or 
polymerase eta knockdown.  The hypersensitivity of REV3-depleted HeLa cells to 
cisplatin was confirmed in REV3L-/- BL2 cells.  The results suggest that REV1 and 
polymerase zeta may have additional biological roles beyond lesion bypass in HeLa cells 
exposed to cisplatin.  Chapters 3 and 4 will address if the REV1/polymerase zeta 
functional complex participates in other biological pathways besides lesion bypass of 
DNA adducts.   
Here, evidence was provided to support an insertion and extension model in 
human cells where RAD18 along with the translesion polymerases eta, REV1 and zeta 
are all required for bypass of cisplatin intrastrand cross-links.  Furthermore, RAD18 
along with the Fanconi anemia core complex had an important regulatory role over 













Figure S2.1 Validation of REV1 and REV3 siRNA specificity.  Multiple siRNAs were 
individually tested as to their ability to downregulate ectopically expressed epitope-
tagged REV1 (A) or REV3 (B) proteins.  cDNA encoding REV1 (Enzymax) was 
subcloned into the pSG5 vector (Stratagene) such that the Flag epitope was placed at the 
amino terminus of the REV1 open reading frame.  cDNA encoding human REV3L was 
amplified through rtPCR from HeLa total RNA using Pfu DNA polymerase (Stratagene).  
Primers for cDNA amplification were designed such that the entire coding frame for 
REV3L was subcloned in frame with the carboxy-terminal V5-His epitope tag of 
pEF6/V5-HisA (Invitrogen) and the insert was verified by DNA sequence analysis.  For 
the data shown in A and B, 293T/17 cells were cotransfected with either Flag-REV1 or 
V5-REV3 expression plasmids plus the indicated siRNAs using X-tremeGENE (Roche) 
according to manufacturer’s suggestions.  REV1-1,2 and REV3-1,2 indicate that a 
combination of REV1-1 and REV1-2 or REV3-1 and REV3-2 siRNAs were used 
together at a 1:1 ratio.  Total cell lysates were separated by SDSPAGE, transferred to 
nitrocellulose membrane and probed with either anti-Flag (M2) antibody (Sigma) or anti-
V5 monoclonal antibody (Invitrogen).  Membranes were immunoblotted for 
Topoisomerase 1 as a loading control.  All siRNAs were purchased from Qiagen with the 
exception of REV1-B, REV1-C, and REV3-C which were obtained from Ambion.  This 
work was performed by Christine Canman. 
 
The gene specific target sequences for each individual siRNA used here and throughout the 
supplemental data section are as follows: 
 
Non-si 1  AATTCTCCGAACGTGTCACGT REV3-4 ATGAGTATGGATCATATACAA 
Non-si 2 Qiagen AllStars Neg. Control (proprietary) REV3-C AAGCAATTTTGAACCTTATGG 
REV1-1 AGGAGATATGTCAGTATTGAA REV7-1 GTGGAAGAGCGCGCTCATAAA 
REV1-2 CAGCGCATCTGTGCCAAAGAA REV7-3 AAGATGCAGCTTTACGTGGAA 
REV1-3 CTGCCAGGTCCAAGCAATATA REV7-4 CACCCGGAGCTGAATCAGTAT 
REV1-4 ATCGGTGGAATCGGTTTGGAA Polη-1 CTGGTTGTGAGCATTCGTGTA 
REV1-B AAGCATCAAAGCTGGACGACT Polη-3 CAGCCAAATGCCCATTCGCAA 
REV1-C AACCAGTAAATGGCTGTAATA Polη-6 CCCGCTATGATGCTCACAAGA 
REV3-1 CGGGATGTAGTCAAACTGCAA RAD18-3 GAGCATGGATTATCTATTCAA 
REV3-2 CCCACTGGAATTAATGCACAA RAD18-4 TGCGATGCTTTGCATCCTAAA  
REV3-3 CCCATTATCAACAGAACCAAA RAD18-6 ATGGTTGTTGCCCGAGGTTAA  
 














Figure S2.2 Validation of RAD18, Polη and REV7 siRNA specificity.  HeLa cells 
were transfected with Non-si or three different siRNA sequences targeting either RAD18 
(A), REV7 (B) or Polη (C). Whole cell lysates were collected forty-eight hours after 
transfection and separated via SDS-PAGE as described in Materials in Methods.  
Immunoblot analysis was performed using the indicated primary antibodies to 
demonstrate depletion of RAD18, REV7 or Polη by each individual siRNA.  Membranes 





A: Validation of RAD18 siRNA B: Validation of REV7 siRNA 
C: Validation of Polη siRNA 
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Figure S2.3  Depletion of RAD18 or Polη with siRNA targeting different mRNA 
sequences results in enhanced H2AX phosphorylation (γ-H2AX) following cisplatin 
treatment.  HeLa cells were transfected with one of three different siRNAs targeting 
either RAD18 or Polη.  Mock transfected or cells transfected with non-specific siRNA 
(Non-si 1) were included as controls.  Forty hours after transfection, cells were treated 
with 10 µM cisplatin for 1 hour. Twenty-four hours later the cells were fixed, stained for 
γ-H2AX (green), and then imaged by fluorescent microscopy as detailed in Materials in 
Methods. Depletion of RAD18 or Polη by each individual siRNA sequence lead to 
identical γ-H2AX staining patterns and intensities following cisplatin treatment 
confirming gene specificity of siRNA-mediated protein knock down. The same exposure 




Figure S2.4  Depletion of REV1, REV3 or REV7 with siRNA targeting different 
mRNA sequences leads to enhanced H2AX phosphorylation (γ-H2AX) following 
cisplatin treatment. HeLa cells were independently transfected with one of at least three 
different siRNA sequences targeting REV1, REV3 or REV7.  Qiagen AllStar Negative 
Control siRNA (Non-si 2) was included as a control.  Forty hours after transfection, cells 
were treated with 10 µM cisplatin for 1 hour. Twenty-four hours later the cells were 
fixed, stained for γ-H2AX (green), and then imaged by fluorescent microscopy as 
detailed in Materials in Methods.  Depletion of REV1, REV3 or REV7 by each individual 
siRNA sequence lead to identical γ-H2AX staining patterns and intensities following 
cisplatin treatment confirming gene specificity of siRNA-mediated protein knockdown.  


























































Figure S2.5  Depletion of RAD18, Polη, REV1, REV3 or REV7 leads to cell cycle 
arrest in S and G2 phases of the cell cycle following cisplatin treatment.  HeLa cells 
were independently transfected with one of at least three different siRNA sequences 
targeting RAD18, Polη, REV1, REV3 or REV7.  Forty hours after transfection the cells 
were exposed to 10 µM cisplatin for 1 hour.  Twenty-four hours later cells were fixed, 
resuspended in PBS containing RNAse A and propidium iodide, and then acquired on a 
BD FACSCaliber system using CellQuest software.  The y-axis represents number of 
events.  The x-axis reflects DNA content.  Depletion of RAD18, Polη, REV1, REV3 or 
REV7 by each individual siRNA sequence resulted in similar cell cycle profiles 
following cisplatin treatment.  Mock transfected or Non-si 1 siRNA-transfected cells 


























Figure S2.6  Time course analysis of γ-H2AX induction by cisplatin in siRNA-
transfected HeLa cells.  HeLa cells were transfected with RAD18-3, Polη-1, REV1-4, 
REV3-2, REV7-1 or Non-si 1 siRNA overnight. Forty hours later, cells were treated with 
10 µM cisplatin for 1 hour and then lysed in SDS-sample buffer at 0, 4, 8, 16, and 24 
hours after cisplatin treatment.  Total cell lysates were separated by SDS-PAGE, 
transferred to nitrocellulose membrane, and then probed with anti-S139P-H2AX 













Figure S2.7  Depletion of RAD18 or polymerase eta (Polη) with siRNA targeting 
different mRNA sequences results in enhanced H2AX phosphorylation (γ-H2AX) 
following UV-C exposure.  HeLa cells were transfected with one of two different 
siRNAs targeting RAD18 or Polη.  Forty hours after transfection, cells were exposed to 4 
J/m2 UV-C radiation. Twenty-four hours later the cells were fixed, stained for γ-H2AX 
(green), and then imaged by fluorescent microscopy. Depletion of RAD18 or Polη by 
each individual siRNA sequence lead to identical γ-H2AX staining patterns and 
intensities following cisplatin treatment confirming gene specificity of siRNA-mediated 










Figure S2.8  Depletion of REV1 or polymerase zeta (REV3 and REV7) with siRNA 
targeting different mRNA sequences results in enhanced H2AX phosphorylation (γ-
H2AX) following UV-C exposure.  HeLa cells were transfected with one of two 
different siRNAs targeting REV1, REV3 or REV7.  Mock transfected cells were included 
as a control.  Forty hours after transfection, cells were exposed to 4 J/m2 UV-C radiation. 
Twenty-four hours later the cells were fixed, stained for γ-H2AX (green), and then 
imaged by fluorescent microscopy.  Depletion of REV1, REV3 or REV7 by each 
individual siRNA sequence lead to identical γ-H2AX staining patterns and intensities 
following cisplatin treatment confirming gene specificity of siRNA-mediated protein 











































Figure S2.9  Cisplatin-induced polymerase eta (Polη) and REV1 focus formation.  
U2OS cells transduced with EGFP-Polη or EGFP-REV1 were untreated or exposed to 
33µM cisplatin for 2 hours then fixed 8 hours later.  Soluble proteins were first extracted 
with a Triton X-100 containing buffer (0.5% triton X-100, 20 mM HEPES pH 7.4, 3 mM 
MgCl2, 50 mM NaCl and 300 mM sucrose) for 5 minutes at 4°C in order to reveal 
detergent extraction-resistant proteins in the nucleus.  Cells were then fixed with a 3.7% 
para-formaldehyde solution for 20 minutes at 4°C.  Graphs represent the average 
percentage of cells exhibiting greater than 10 foci of either EGFP-tagged Polη or REV1 
foci. Data represent the mean ± S.E.M of three independent experiments where >100 
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The Translesion Polymerases REV1 and Zeta, but not Eta, are Required for 
Interstrand cross-link Repair in a Human Cancer Cell Line 
 
Summary  
 DNA interstrand cross-links are extremely cytotoxic lesions that halt both the 
replication and transcription machinery.  Multiple chemotherapeutic agents that promote 
interstrand cross-link formation, including mitomycin C, are successfully used for the 
treatment of cancer.  Unfortunately, cancer cells can become resistant to interstrand 
cross-linking agents impairing the usefulness of these agents.  Removal of interstrand 
cross-links has been implicated in resistance development, thus determining how 
interstrand cross-links are repaired in human cells is of uttermost importance.  Multiple 
DNA repair pathways including nucleotide excision repair, homologous recombination 
and translesion synthesis are thought to participate in interstrand cross-link removal.  
Here, evidence is presented strongly suggesting translesion synthesis is required for 
interstrand cross-link repair in human cells.  Depletion of the translesion polymerases 
REV1 and zeta are uniquely associated with protection against cisplatin and mitomycin 
C-induced chromosomal aberrations when compared to polymerase eta depleted HeLa 
cells.  Furthermore, knockdown of REV1 and polymerase zeta, but not polymerase eta, 
leads to extraordinary mitomycin C hypersensitive along with cell cycle arrest in late S 
and G2 phases of the cell cycle, a phenotype characteristically displayed by cells 
deficient in interstrand cross-link repair.  REV1 and polymerase zeta were also found to 
be necessary for the timely resolution of DNA double strand breaks associated with 
repair of DNA interstrand cross-links.  Together, the findings indicate that REV1 and 
polymerase zeta facilitate repair of DNA interstrand cross-links independently of PCNA 
monoubiquitination and polymerase eta. 
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Introduction 
  DNA interstrand cross-links are formed when a bifunctional chemical covalently 
links both strands of a DNA duplex.  The linking of opposite strands of DNA prevents 
vital biological processes from proceeding, such as the unwinding of DNA by helicases, 
thereby halting both the replication and transcription machinery.  DNA interstrand cross-
links are extremely toxic, with one interstrand cross-link capable of killing a yeast cell if 
not repaired efficiently 1-3.  The highly toxic nature of interstrand cross-links have been 
noted in the clinic setting, and several chemotherapeutic agents that promote interstrand 
cross-link formation, including mitomycin C, are successfully used for cancer treatment.  
Unfortunately, cancer cells can become resistant to interstrand cross-linking agents 
impairing the usefulness of these agents.  Furthermore, cross-resistance between 
interstrand cross-linking agents is known to occur, that is developed resistance to one 
cross-linking agent results in the resistance to multiple interstrand cross-linking agents 4.  
The observance of cross-resistance suggests a biological pathway common to all 
interstrand cross-linking agents is involved in development of resistance.  Although 
acquired resistance is not completely understood, one possible cellular process that is 
ubiquitous to all cross-linking agents that may promote resistance is alterations in repair 
of interstrand cross-links 4-6.  Currently, interstrand cross-link repair is poorly understood, 
thus determining how interstrand cross-links are repaired and if alterations in repair 
promote resistance is of uttermost importance.  Comprehending interstrand cross-link 
repair may also reveal novel targets influencing drug design of chemotherapeutic agents.  
Based on biochemical and genetic studies, multiple DNA repair pathways appear 
to be required for removal of interstrand cross-links including nucleotide excision repair, 
homologous recombination and translesion synthesis 2-3, 7-10.  As discussed in Chapter 2, 
translesion polymerases are capable of synthesizing past DNA adducts induced by both 
ultraviolet radiation and the chemotherapeutic agent cisplatin.  In addition to facilitating 
direct lesion bypass and filling in postreplicative gaps in DNA, REV1 and polymerase 
zeta may also play an important role in the repair of interstrand cross-links 11-12.  Deletion 
of REV1, REV3 or REV7 in chicken DT40 cells leads to remarkable hypersensitivity to a 
wide variety of genotoxic stresses, most notably cisplatin and other DNA cross-linking 
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agents such as mitomycin C 9, 13-15.  Both Shen et al. and Zhang et al., via a plasmid 
reactivation assay, demonstrated that the translesion polymerases REV1 and zeta are 
essential for both recombination-dependent and recombination-independent repair of 
interstrand cross-links 16-17.  Polymerase zeta was recently demonstrated to be required 
for extension beyond an unhooked cisplatin interstrand cross-link during gap filling via a 
Xenopus egg extract model, while REV1 may be capable of inserting directly opposite 
the base containing the unhooked cross-link 7, 11, 18.   
The Fanconi anemia pathway is known to be essential for repair of DNA 
interstrand cross-links, possibly by coordinating the different DNA repair mechanisms 
involved in cross-link removal 3, 19.  Therefore, DNA repair pathways regulated by the 
Fanconi anemia complex of proteins have a high probability of participating in 
interstrand cross-link repair.  Fanconi anemia patients lacking a functional Fanconi 
anemia core complex and FANCC-/- DT40 cells are known to have decreased mutation 
rates suggesting that the Fanconi anemia core complex somehow regulates translesion 
synthesis 20-23.  The genetic epistasis observed between REV1, REV3 and the Fanconi 
anemia complementation group C (FANCC) gene for cisplatin sensitivity further 
implicates translesion synthesis in the interstrand cross-link repair pathway 9.  
Mirchandani et al. demonstrated the Fanconi anemia core complex is crucial for REV1 
foci formation following exposure to UV 23.  Data provided in Figure 2.7 confirms that 
the Fanconi anemia core complex regulates translesion synthesis by promoting the 
formation of REV1 foci at sites of cisplatin-induced replication stress.  Taken together, 
the data strongly suggest the translesion polymerases REV1 and zeta have an essential 
biological role in repair of interstrand cross-links.  However, direct evidence of 
translesion polymerases participating in repair of DNA cross-links in human cells is 
lacking. 
Based on evidence that interstrand cross-links are repaired primarily during S-
phase of the cell cycle 11, 17, 24-25, the most widely accepted models of interstrand cross-
link repair at present time suggest that two replication forks converge upon an interstrand 
cross-link where the MUS81-EME1 endonuclease recognizes and cleaves the resulting 
branched DNA structure.  The incision by MUS81-EME1 occurs on one side of the 
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cross-link creating a replication-associated DNA double strand break 26.  The XPF-
ERCC1 endonuclease uncouples the cross-linked complementary DNA strands by 
making an incision on the other side of the  interstrand cross-link 27.  Recent biochemical 
evidence suggests that polymerase zeta performs DNA synthesis opposite the DNA 
strand containing the residual cross-link (e.g. an uncoupled cisplatin interstrand cross-
link) and this process may be necessary to prepare the daughter strand for subsequent 
homologous recombination repair of the replication-associated DNA double strand break 
11.  Although unknown, translesion synthesis may also be necessary for gap filling 
following excision of the unhooked cross-link.  Currently there is some confusion in the 
literature as to whether or not polymerase eta contributes to recombination-dependent 
interstrand cross-link repair by directly participating in homologous recombination 19, 28-
29.   
In Chapter 2, I provided substantial evidence to support the hypothesis that the E3 
ubiquitin ligase RAD18 along with the translesion polymerases eta, REV1 and zeta are 
all necessary for bypass of DNA adducts induced by the chemotherapeutic agent 
cisplatin.  Depletion of RAD18 or the translesion polymerases eta, REV1 or zeta 
individually caused increased sensitivity to cisplatin implying these proteins may protect 
cells from the cytotoxic effects of anti-cancer agents whose main mechanism of action is 
adduct formation.  Unexpectedly, depletion of REV1, REV3 or REV7 resulted in a 
significantly greater sensitivity to cisplatin when compared to RAD18 or polymerase eta 
knockdown, suggesting that REV1 and polymerase zeta may have additional biological 
roles beyond lesion bypass.  In this chapter, I will determine if the increased sensitivity to 
cisplatin is due to lack of interstrand cross-link repair in HeLa cells depleted of the 
translesion polymerases REV1 and zeta.  I will also investigate if RAD18 and polymerase 
eta contribute to DNA interstrand cross-link removal in human cells.  Several 
publications have proved strong evidence that REV1 and polymerase zeta are crucial for 
repair of interstrand cross-links induced by chemotherapeutic agents.  However, little 
data is currently available directly connecting REV1 and polymerase zeta to interstrand 
cross-link repair in human cells.  Furthermore it is unclear if RAD18 regulates translesion 
synthesis during interstrand cross-link repair and if polymerase eta is vital for cross-link 
removal.  
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Chemotherapeutic agents which induce DNA interstrand cross-links are widely 
used in cancer treatment, thus understanding the means by which cells repair or cope with 
these lesions will be instrumental in identifying novel mechanisms leading to drug 
resistance.  Determining how interstrand cross-links are repaired may lead to the 
designing of new agents refractory to DNA damage tolerance mechanisms.  Here 
evidence is provided to demonstrate REV1 or polymerase zeta knockdown cells 
accumulated chromosome aberrations, and failed to resolve DNA double strand breaks in 
a timely manner after cisplatin treatment as compared to RAD18 or polymerase eta-
depleted cells.  These results suggest that REV1 and polymerase zeta may be essential for 
the repair of cisplatin interstrand cross-links in addition to performing lesion bypass of 
cisplatin intrastrand cross-links.  In agreement with this concept, REV1 and polymerase 
zeta-depleted cells were uniquely hypersensitive to mitomycin C, accumulated greater 
numbers of chromosome aberrations, and failed to resolve replication-associated double 
strand breaks induced by mitomycin C treatment.  
 Data presented in this chapter contributes to the understanding of how interstrand 
cross-links are repaired and directly implicates translesion synthesis in cross-link removal 
in human cells.  Together the findings support a model where REV1 and polymerase zeta 
facilitate repair of interstrand cross-links in intact cells and this process is likely 
independent of PCNA monoubiquitination and polymerase eta. 
 
Materials and Methods  
Cell lines and culture conditions.  HeLa and H1299 cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum. BL2 
human Burkitt’s lymphoma cell lines were cultured in RPMI-1640 medium supplemented 
with 10% fetal bovine serum.  Construction of POLI, POLH, and REV3L -/- BL2 lines 
have been described 20,22.  Cisplatin (cis-diammineplatinum(II)dichloride) was purchased 
from Sigma-Aldrich and dissolved in 0.9% NaCl as a 3.3 mM stock solution.  Mitomycin 
C (MMC) was purchased from Roche, dissolved in 95% ethanol at a concentration of 0.2 
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mg/ml, and stored at -20°C.  PD0332991, a gift from Pfizer, was dissolved in DMSO at a 
concentration of 10 mM and stored at -20°C.    
RNA interference.  HeLa cells were seeded at a density of 1x105 per well of a 6 well 
plate.  Introduction of siRNA into HeLa cells was carried out with X-tremeGENE 
(Roche).  Each well was exposed to 50 nM siRNA plus 5µl X-tremeGENE overnight in 
the presence of serum followed by a change in medium the next morning.  For most 
experiments, cells were treated with cisplatin or mitomycin C approximately 40 hours 
after the addition of siRNA.  When delivering siRNA into cells cultured in 12 well plates, 
the conditions for transfection was reduced by one half.  siRNAs directed against 
RAD18-3, Polη-1, REV1-4, REV3-2, REV7-1, and RAD51 were obtained from Qiagen.  
The gene-specific target sequences are as follows: RAD18-3 (GAG CAT GGA TTA TCT 
ATT CAA), Polη-1 (CTG GTT GTG AGC ATT CGT GTA), REV1-4 (ATC GGT GGA 
ATC GGT TTG GAA), REV3-2 (CCC ACT GGA ATT AAT GCA CAA), REV7-1 
(GTG GAA GAG CGC GCT CAT AAA) and RAD51 (AAG CTG AAG CTA TGT TCG 
CCA).  The negative control Non-si sequence (AAT TCT CCG AAC GTG TCA CGT) 
was purchased from Qiagen.  Refer to supplemental data Figure S2.1 for additional 
siRNA sequences used in this chapter. 
Assessment of cell viability.  For clonogenic survival assays, HeLa cells were 
transfected overnight with siRNA as described above.  The following afternoon cells 
were treated with mitomycin C for 24 hours and then seeded at known cell densities for 
colony formation.  Twelve days later, colonies were simultaneously stained and fixed in a 
solution containing 3:1 methanol and glacial acetic acid plus 1% trypan blue (Sigma).  
Colonies of 50 cells or greater were counted and the surviving fractions for each siRNA 
treatment group represent the plating efficiency for each  treatment divided by the plating 
efficiency of the corresponding untreated control.  The BL2 lymphoma lines were treated 
with mitomycin C continuously for 48 hours. Cells were then washed with PBS and 
assessed as to their ability to exclude the trypan blue as a measure of viability.  
Antibodies.  The rabbit polyclonal antibodies anti-53BP1 (H-300) and anti-RAD51 
(H92) were purchased from Santa Cruz Biotechnology.  Mouse monoclonal anti-
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phospho-ATM (Ser 1981) antibody was obtained from Rockland.  The anti-β-tubulin 
(TUB 2.1) antibody was purchased from Sigma-Aldrich Inc.   
Immunoblotting.  Cells were lysed in a sodium dodecyl sulfate (SDS) sample buffer (10 
mM Tris pH 8.0, 2% SDS, 1 × protease inhibitor cocktail (Roche) and 1 × phosphatase 
inhibitor cocktails 1 and 2 (Sigma-Aldrich)), sonicated, heated at 95°C, and equal 
amounts of protein were separated on SDS-PAGE gels.  Proteins were transferred onto a 
nitrocellulose membrane and probed with the appropriate primary antibodies described 
above followed by secondary horseradish peroxidase (HRP)-conjugated goat anti-rabbit 
or mouse antibody (Thermo Scientific).  Proteins were visualized using SuperSignal West 
Pico Chemiluminescent Substrate (Thermo Scientific).  
Immunofluorescence.  For S1981P-ATM and 53BP1 immunofluorescence, cells 
cultured on glass coverslips were washed in phosphate buffered saline (PBS) and then 
fixed in ice cold 100% methanol for 10 minutes.  Samples were blocked with 5% fetal 
bovine serum, 0.05% Triton X-100, and 1% goat serum, and then incubated with primary 
antibodies for 45 minutes.  Coverslips were washed three times with PBS and then 
incubated with the appropriate secondary goat anti-rabbit or goat anti-mouse Alexa Fluor 
dye conjugated secondary antibody (Molecular Probes) for 45 minutes, washed with 
PBS, counterstained with DAPI to visualize nuclear DNA, and then mounted onto slides 
with ProLong Gold antifade reagent (Invitrogen).  
Cyclin-dependent kinase inhibition.  H1299 cells were exposed to either 200 or 500 nM 
PD0332991 24 hours prior to cell cycle analysis or addition of mitomycin C.  The 
inhibitor was present during and after treatment with mitomycin C.  
Analysis of chromosomal aberrations.  HeLa or BL2 cells were treated with either 
cisplatin for 1 hr or mitomycin C continuously.  Twenty-four hours later, mitotic cells 
were enriched through the addition of 50 ng/mL colcemid (Gibco) for 45 minutes prior to 
cell harvesting.  Cells were treated for 18 minute at 37°C with a hypotonic solution 
consisting of 0.075 M KCl and then fixed in Carnoy’s fixative (3:1 methanol:glacial 
acetic acid).  Cells were dropped onto slides, allowed to dry for a day, and then 
chromosomes were stained with Giemsa prior to analysis as described 30.  50 mitotic 
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spreads were analyzed for each treatment.  For comparisons of the average number of 
gaps and breaks per metaphase between control and drug-treated treatment groups, the 
student’s T-test was employed. 
Flow cytometry.  For single parameter flow cytometry, cells were washed once with 
PBS then fixed with ice cold 70% ethanol.  The cells were resuspended in PBS 
containing RNAse A and propidium iodide to determine DNA content.  Cells were 
acquired on a BD FACSCaliber system using CellQuest software. 
 
Results 
REV1, REV3 and REV7 protect against cisplatin-induced chromosomal 
aberrations.  
As discussed in Chapter 2 (Fig. 2.8A), depletion of REV1 or polymerase zeta 
(REV3 and REV7) enhanced cisplatin-induced cytotoxicity as measured by clonogenic 
survival when compared to RAD18 or polymerase eta (Polη) depleted cells.  The results 
were confirmed by treating human Burkitt’s lymphoma BL2 cells deleted of POLH (eta), 
POLI (ίota) or REV3L with various concentrations of cisplatin for 2 hours and measuring 
viability 48 hours later by trypan blue dye exclusion.  Consistent with the results obtained 
from the clonogenic survival assay, REV3L knockout BL2 cells were significantly more 
sensitive to cisplatin cytotoxicity as compared with polymerase eta or polymerase ίota 
knockout cells (Fig. 2.8B).  Since knockdown of RAD18, polymerase eta, REV1 or 
polymerase zeta lead to indistinguishable phenotypes in response to cisplatin treatment 
with regards to phosphorylation of H2AX and cell cycle redistribution (Fig. 2.2), the 
survival and viability results were unexpected and suggested REV1 and polymerase zeta 
may perform additional roles in promoting tolerance to cisplatin.   
Cisplatin is known to create a small percentage of interstrand DNA cross-links (1-
3%) in addition to intrastrand cross-links 31.  Given the proposed role of REV1 and 
polymerase zeta in interstrand DNA cross-link repair and the genetic epistasis observed 
between the FANCC gene and REV1 and REV3 in cisplatin resistance in DT40 cells,  
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REV1 or polymerase zeta-deficient cells were investigated to determine if they are more 
prone to developing cisplatin-induced chromosome aberrations, a hallmark of interstrand 
DNA cross-link repair deficiency  32.  Depletion of RAD18 or polymerase eta in HeLa 
cells did not result in a significant increase in cisplatin-induced chromatid gaps and 
breaks per metaphase compared to controls, suggesting disruption of translesion synthesis 
alone does not cause an increase in chromosomal aberrations (Fig. 3.1A).  In contrast, 
depletion of REV1, REV3, or REV7 resulted in a 3 to 4 fold increase in chromatid gaps 
and breaks per metaphase in cisplatin-treated cells, consistent with the hypothesis that 
REV1 and polymerase zeta play an important role in interstrand DNA cross-link repair.  
Similar results were observed in BL2 cells where REV3L knockout cells accumulated 
twice as many chromosomal aberrations as compared to POLH knockout cells treated 
with cisplatin (Fig. 3.1B).  Representative images of chromosomal aberrations observed 
in RAD18, Polη, REV1, REV3 or REV7 depleted HeLa cells are displayed in Figure 
3.1C and supplemental data Figure S3.1.  For knockdown of RAD18, polymerase eta, 
REV1, REV3 or REV7 in HeLa cells refer to Figures 2.1B and C along with 
supplemental data Figures S2.1 and S2.2. 
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Figure 3.1  Depletion of REV1, REV3 or REV7 leads to genomic instability in HeLa 
or BL2 cells.  (A) siRNA transfected HeLa cells were treated with 10 µM cisplatin for 1 
hour and metaphase cells were assessed for chromosomal gaps and breaks 24 hours later 
as described in Materials and Methods.  Data is expressed as the average gaps and breaks 
per metaphase ± S.E.M. (n=50).  (B) Wild type BL2 or BL2 knockout cells were treated 
with 30 µM cisplatin for 1 hour and then analyzed for chromosomal aberrations 24 hours 
later.  Data is expressed as the average gaps and breaks per metaphase ± S.E.M. (n=50).  
p values were calculated by the Students t test, where ** represents p values <0.001.  (C) 
Representative images of chromosomal aberrations observed in siRNA-transfected HeLa 




REV1, REV3 and REV7 are necessary for resolution of DNA double strand breaks 
induced by repair of cisplatin interstrand cross-links  
Although interstrand cross-links can be repaired in a recombination-independent 
manner, the majority of interstrand cross-links are thought to be repaired in a 
recombination-dependent pathway during DNA replication resulting in the formation of 
DNA double strand breaks 11, 17, 24-25.  During recombination-dependent interstrand cross-
link repair a DNA double strand break is formed when structure specific endonucleases 
unhook the interstrand cross-link by cleaving on both sides of the cross-link.  As a way to 
measure repair of interstrand cross-links, the formation and resolution of protein foci 
marking sites of DNA double strand breaks were observed and quantitated.  Since γ-
H2AX is not a reliable surrogate marker for the presence of DNA double strand breaks 
under conditions of pronounced replication stalling (Fig. 2.2), foci formation was marked 
by activated ATM co-localized with 53BP1.  ATM is a central cell cycle checkpoint 
kinase that is specifically activated in response to DNA doubles strand breaks.  
Activation of ATM is associated with rapid transphosphorylation on S1981 and 
localization to sites of double strand breaks 33-34.  53BP1 is a cell cycle checkpoint 
mediator protein involved in DNA damage signaling and repair and is well characterized 
for its ability to localize to DNA double strand breaks in cells exposed to DNA damaging 
agents 35-36.  By examining colocalization of S1981P-ATM and 53BP1, this should be a 
more specific surrogate marker of double strand breaks under conditions of DNA 
replication arrest. 
To provide evidence that DNA double strand break formation is due to 
recombination-dependent repair, H1299 cells were arrested in the G1 phase of the cell 
cycle using a cyclin-dependent kinase (CDK) inhibitor, then treated with mitomycin C to 
determine if double strand break formation is dependent upon cells entering S phase.  
PD0332991, a CDK4 and CDK6 specific inhibitor, was utilized to arrest H1299 cells in 
G1 phase of the cell cycle 37-39.  Transition from G1 into the synthesis phase of the cell 
cycle requires the phosphorylation of retinoblastoma, a repressor of gene transcription.  
Both CDK4 and CDK6 phosphorylates retinoblastoma, which in turn prevents 
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retinoblastoma from inhibiting the E2 family of transcription factors thus allowing for 
progression into S phase 40-44.   
H1299 cells exposed to either 200 or 500 nM PD0332991 for 24 hours resulted in 
cell cycle arrest in the G1 phase (Fig. 3.2A).  To determine if cells must progress through 
S phase for mitomycin C induced DNA double strand breaks to form, H1299 cells were 
treated with 500 nM PD0332991 for 24 hours then pulsed with either 30 or 60 ng/ml 
mitomycin C for 2 hours in the presence of the CDK inhibitor.  Eight hours later the cells 
were collected and stained for S1981P ATM and 53BP1.  H1299 cells exposed to 
PD0332991 displayed a decrease of S1981P-ATM and 53BP1 containing foci, even when 
treated with mitomycin C, implying the induction of DNA double strand breaks can be 
attributed to recombination-dependent repair of interstrand cross-links (Fig. 3.2B).  
Approximately 75% of the cells pulsed with 30 ng/ml mitomycin C exhibited greater than 
ten S1981P-ATM and 53BP1 containing foci per cell while only 46% of the cells 
exposed to both the CDK inhibitor and mitomycin C displayed greater than ten S1981P-
ATM and 53BP1 containing foci per cell, a reduction of roughly 40% (Fig. 3.2C).  
Similarly, exposure to both the CDK4/CDK6 inhibitor and 60 ng/ml mitomycin C 
resulted in a 55% reduction in the number of cells demonstrating greater than ten 
S1981P-ATM and 53BP1 containing foci per cell when compared to H1299 cells only 
treated with 60 ng/ml mitomycin C (Fig. 3.2C).   
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Figure 3.2  DNA double strand break formation following mitomycin treatment may 
be contributed to recombination-dependent interstrand cross-link repair.  (A) 
H1299 cells were treated with either 200 or 500 nM PD0332991 for 24 hrs, then fixed, 
stained for DNA content with propidium iodide, and analyzed by flow cytometry.  (B) 
H1299 cells were either untreated or exposed to 500 nM PD0332991 for 24 hrs then 
pulsed with either 30 or 60 ng/ml mitomycin C for 2 hrs.  Eight hours later the cells were 
fixed in 100% ice cold methanol then stained for S1981P-ATM (green), and 53BP1 (red) 
as surrogate markers of DNA double stranded DNA breaks.  (C) The graph represents the 
average percentage of cells exhibiting greater than 10 colocalized foci containing both 
phospho-ATM and 53BP1 per cell.  Data represent the mean ± S.E.M of two independent 
experiments where >100 cells were counted in each experiment.  Treatment with the 
CDK4/CDK6 inhibitor PD0332991 diminishes DNA double strand break formation 
following mitomycin C treatment.    
 
To further test the hypothesis that REV1, REV3, and REV7 contribute to 
interstrand DNA cross-link repair in human cells, the formation and resolution of DNA 
double strand breaks in cisplatin-treated cells were examined as an indirect measurement 
of interstrand DNA cross-link repair 26-27, 45-46.   HeLa cells were transfected with 
individual siRNAs, treated with 3 µM cisplatin for 1 hour, and then allowed to recover 
for 24 or 48 hours before fixation and imaging of S1981P-ATM and 53BP1 by indirect 
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immunofluorescence.  The 3 µM dose was chosen since it produces the greatest 
difference in loss in clonogenic survival when cells are depleted of Rad18 or polymerase 
eta versus REV1 or REV3.  At 24 hours, all cisplatin-treated cells appeared to accumulate 
similar numbers of foci containing S1981P-ATM and 53BP1 regardless of which gene 
the siRNA was targeting (including the non-specific Non-si siRNA) (supplementary date 
Fig. S2.2).  However, at 48 hours, approximately 60% of HeLa cells depleted of REV1, 
REV3, or REV7 still exhibited greater than ten foci per cell (Fig. 3A and B).  In contrast, 
the majority of Non-si, RAD18 or polymerase eta siRNA-transfected cells contained 5 or 
fewer foci per cell 48 hours after cisplatin treatment suggesting that interstrand cross-link 
repair was not impacted to a significant degree.  These results were confirmed using two 
additional siRNA sequences targeting Rad18, Polη, REV1, REV3 or REV7 
(supplemental data Fig. S3.3 and S3.4).   
Figure 3.3  REV1 and polymerase zeta (REV3 and REV7) are necessary for repair 
of cisplatin-induced interstrand cross-links.  (A) RAD18, Polη, REV1, REV3 or 
REV7-depleted HeLa cells were treated with 3 µM cisplatin for 1 hr and fixed 48 hours 
later.  Cells were then stained for S1981P-ATM (green), and 53BP1 (red) as surrogate 
markers of DNA double strand breaks (DSBs).  Nuclear DNA was stained with DAPI 
(blue).  (B) The graph represents the average percentage of cells exhibiting greater than 
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10 colocalized foci containing both phospho-ATM and 53BP1 per cell.  Data represent 
the mean ± S.E.M of three independent experiments where >300 cells were counted in 
each experiment.  REV1, REV3, or REV7 depleted cells fail to resolve cisplatin-induced 
DSBs in a timely manner. 
 
To confirm the validity of the foci retention assay, I also analyzed the effect of 
depletion of RAD51 on foci resolution after cisplatin exposure. Similar to REV1, REV3, 
or REV7 depleted cells, RAD51-deficient cells (i.e. homologous recombination repair 
deficient cells) failed to resolve S1981P-ATM and 53BP1 foci in a timely manner (Fig. 
3.4A).  As in supplemental data Figure S3.2, the non-specific siRNA transfected HeLa 
cells displayed pATM-53BP1 foci formation 24 hours after cisplatin treatment, but by 48 
hours the majority of cisplatin-induced foci had resolved implicating repair of the DNA 
double strand breaks (Fig. 3.4A and B).  However, greater than 65% of the RAD51 
depleted HeLa cells still exhibited greater than ten pATM-53BP1 foci per cell 48 hours 
following cisplatin treatment suggesting the replication-associated DNA double strand 
breaks were not repaired efficiently (Fig. 3.4B).  The ability to deplete endogenous 
RAD51 was demonstrated by immunoblot analysis (Fig. 3.4C).  Together, these results 
are in agreement with the hypothesis that REV1, REV3, and REV7 play an important role 
in repair of cisplatin interstrand DNA cross-links. 
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Figure 3.4  RAD51-deficient HeLa cells fail to resolve cisplatin-induced DNA double 
strand breaks in a timely manner.  (A) RAD51 depleted HeLa cells were treated with 3 
µM cisplatin for 1 hour and then fixed 24 or 48 hours later.  Cells were then stained for 
S1981P-ATM (green), and 53BP1 (red) as surrogate markers of DNA double strand 
breaks (DSBs).  (B) The graph represents the average percentage of cells exhibiting 
greater than 10 colocalized foci containing both phospho-ATM and 53BP1 per cell at 24 
and 48 hours after cisplatin exposure.  Data represent the mean ± S.E.M of three 
independent experiments where >100 cells were counted in each experiment.  (C) HeLa 
cells were transfected with siRNA targeting the RAD51 gene product as described in 
Materials and Methods.  Forty-eight hours later whole cell lysates were collected, 
separated by SDS-PAGE and subjected to immunoblot analysis using a primary antibody 
against RAD51 and tubulin as a loading control.  Rad51 depleted HeLa cells did not 
resolve cisplatin-induced DSBs in a timely manner, consistent the with model that 
homologous recombination plays an important role in repair of replication-associated 




The REV1-polymerase zeta functional complex is necessary for protection against 
mitomycin C induced cytotoxicity and chromosomal aberrations 
The observation that REV1, REV3, or REV7-depleted HeLa cells accumulated or 
failed to resolve greater numbers of cisplatin-induced double strand breaks could be 
explained by increased replication fork instability and collapse due to the inability to 
complete replicative bypass of cisplatin intrastrand cross-links rather than deficient 
interstrand DNA cross-link repair.  Therefore REV1 or polymerase zeta depleted cells 
were tested to determine whether they are uniquely sensitive to mitomycin C, a clinically 
relevant anticancer agent that produces monoadducts, intrastrand cross-links, and a far 
greater percentage of interstrand DNA cross-links (20%) as compared to cisplatin 47.  As 
shown in Figure 3.5A, REV1, REV3, or REV7 siRNA-transfected HeLa cells are 
significantly more sensitive to loss in clonogenic cell survival as compared to RAD18 or 
polymerase eta siRNA transfected cells.  Similarly, REV3L knockout BL2 cells were also 
more sensitive to loss in viability after exposure to relatively low doses of mitomycin C 
when compared with polymerase eta or polymerase ίota knockout cells (Fig. 3.5B).  
Consistent with a deficiency in the repair of interstrand DNA cross-links, REV1, REV3, 
or REV7-depleted HeLa cells displayed greater numbers of mitomycin C-induced 
chromosomal aberrations per metaphase that primarily consisted of chromatid gaps and 
breaks, as compared to polymerase eta-depleted cells (Fig. 3.5C).  Representative images 
of chromosomal aberrations observed in mitotic spreads isolated from siRNA-transfected 
HeLa cells treated with mitomycin C are displayed in Figure 3.4E and supplemental data 
Figure S3.5.   
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Figure 3.5  The REV1/polymerase zeta functional complex protects cells from 
mitomycin C-induced cytotoxicity and genomic instability.  (A) HeLa cells depleted 
of RAD18, Polη, REV1, REV3 or REV7 were treated with mitomycin C (MMC) for 24 
hrs at the indicated doses, and then subjected to the clonogenic survival assay.  The 
average surviving fraction of at least three independent experiments are shown.  Error 
bars represent S.E.M.  (B) Wild type BL2 or BL2 cells deficient in polymerase ιota 
(Polι), polymerase eta (Polη), or REV3 (clones 332 and 504) were treated with MMC for 
48 hours and then subjected to the trypan blue exlusion assay.  The average percentage of 
cells excluding trypan blue is shown (n≥3).  Error bars represent S.E.M.  (C) Control 
(Non-si) or Polη, REV1, REV3, REV7 or RAD51-depleted HeLa cells were treated with 
10 or 20 ng/ml MMC for 24 hrs, fixed, and then analyzed for chromosomal aberrations.  
(D) BL2 or BL2 knockout cells were treated with 40 ng/ml MMC for 24 hrs and then 
analyzed for chromosomal aberrations.  Data is expressed as the average gaps and breaks 
per metaphase ± S.E.M. (n=50).  p values were calculated by the Students t test, where ** 
represents p values <0.001.  (E) Representative images of chromosomal aberrations 
observed in HeLa cells treated with 10 ng/ml MMC.  Red arrows point to chromatid gaps 
and breaks.    
 
For comparative purposes, HeLa cells were depleted of RAD51 via siRNA, a 
protein essential for homologous recombination repair (Fig. 3.4C).  As expected, Rad51-
depleted cells exhibited similar numbers of chromatid gaps and breaks per metaphase as 
compared to REV1, REV3, or REV7-depleted cells (Fig. 3.5C) consistent with the model 
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that these proteins are necessary for efficient recombination-dependent repair of 
interstrand DNA cross-links.  The requirement of REV3 was also confirmed for 
protection against mitomycin C-induced chromosome instability in the BL2 model 
system where greater numbers of chromosomal aberrations in REV3L knockout cells 
were consistently observed as compared to wild type or POLH knockout cells (Fig. 
3.5D).   
The REV1-polymerase zeta functional complex is necessary for efficient repair of 
mitomycin C interstrand cross-links.   
To further test the hypothesis that REV1 and polymerase zeta are necessary for 
efficient interstrand DNA cross-link repair, I assessed whether siRNA-transfected HeLa 
cells exhibit residual double strand breaks after a brief exposure to mitomycin C.  At 24 
hours, all mitomycin C-treated cells accumulated similar numbers of foci containing 
S1981P-ATM and 53BP1 regardless of which gene the siRNA was targeting (including 
the non-specific Non-si siRNA) (supplementary data Fig. S3.6).  Consistent with the 
results shown in Figure 3.3 examining the resolution of DNA double strand breaks 
marked by S1981P-ATM and 53BP1 in response to cisplatin treatment, REV1, REV3 or 
REV7-depleted HeLa cells, but not RAD18 or polymerase eta-depleted cells, were 
deficient in resolving DNA double strand breaks marked by foci containing S1981P-
ATM colocalized with 53BP1 48 hours after mitomycin C treatment (Fig. 3.6A and B).  
Similar results were found using two additional siRNA sequences to deplete Rad18, 
polymerase eta, REV1, REV3 or REV7 protein confirming that deficiencies in resolving 
mitomycin C-induced DSBs in REV1, REV3, or REV7-depleted HeLa cells are not due 
to off-target effects of the siRNA (supplemental data Fig. S3.7 and S3.8).  Again, I 
validated this assay by demonstrating that foci retention following mitomycin C 
treatment is also a major phenotype in RAD51-depleted cells (Fig. 3.6C and 
supplemental data Fig. S3.9).  
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Figure 3.6  The REV1/polymerase zeta functional complex is necessary for efficient 
repair of interstrand DNA cross-links induced by mitomycin C.  (A) RAD18, 
polymerase eta (Polη), REV1, REV3 or REV7-depleted HeLa cells grown on coverslips 
were treated with 30 ng/ml mitomycin C (MMC) for 1 hr and then allowed to recover for 
48 hrs.  Cells were fixed in 100% methanol and then stained for S1981P-ATM (green) 
and 53BP1 (red) as surrogate markers of DNA double strand breaks (DSBs).  Nuclear 
DNA was stained with DAPI (blue).  (B) The graph represents the average percentage of 
cells exhibiting 10 or more foci per cell containing both phospho-ATM and 53BP1.  
Error bars represent S.E.M. (n=3).  (C) Inhibition of homologous recombination repair 
leads to phospho-ATM and 53BP1 foci retention in mitomycin C treated cells.  Control 
or RAD51-depleted HeLa cells were treated with 30 ng/ml MMC for 1 hour and then 
fixed 24 or 48 hours later.  The percentage of cells exhibiting 10 or more phospho-ATM 
and 53BP1 colocalized foci per cell are shown.  Data represent the mean ± S.E.M of three 
independent experiments.  (D) siRNA-transfected HeLa cells were treated with 3 ng/ml 
MMC for 48 hrs.  Cells were fixed, stained for DNA content with propidium iodide, and 
then analyzed by flow cytometry.  REV1, REV3, or REV7-depleted cells exhibit a 
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prolonged G2 cell cycle checkpoint suggestive of a defect in interstrand DNA cross-link 
repair. 
 
Furthermore, HeLa cells deficient in REV1, REV3, or REV7, but not RAD18 or 
polymerase eta, displayed prominent cell cycle arrests in late S and G2 phases of the cell 
cycle (Fig. 3.6D).  The result is indicative of prolonged cell cycle checkpoint induction 
after treatment with a relatively low dose of mitomycin C (3 ng/ml), a phenotype 
characteristically displayed by cells deficient in components of the FA pathway.  
Together, these results suggest that REV1 and polymerase zeta are necessary for 
resistance to agents that introduce DNA interstrand cross-links and their activities are 
important for efficient resolution of DNA double strand breaks, an intermediate formed 
during DNA replication-dependent interstrand DNA cross-link repair. 
 
Discussion 
  In Chapter 2 data were presented to support the hypothesis that the E3 ubiquitin 
ligase RAD18 along with the translesion polymerases eta, REV1 and zeta are all 
necessary for synthesis past intrastrand cross-links induced by the chemotherapeutic 
agent cisplatin.  However, as noted in Figure 2.8 HeLa cells depleted of REV1, REV3 or 
REV7 were uniquely more sensitive to cisplatin treatment than HeLa cells down-
regulated for RAD18 or polymerase eta.  The hypersensitivity observed in REV1, REV3 
or REV7 knockdown cells suggest that REV1 and polymerase zeta may have additional 
biological roles beyond lesion bypass in HeLa cells exposed to cisplatin.  Since 
translesion polymerases are implicated in the repair of DNA interstrand cross-links 9, 13-15, 
I investigated if the hypersensitivity observed in REV1, REV3 or REV7 depleted HeLa 
cells is due to failure to repair chemotherapeutic induced DNA interstrand cross-links.  I 
also explored the possibility of polymerase eta contributing to interstrand cross-link 
repair and if RAD18 regulates translesion synthesis during interstrand cross-link repair.   
 Resistance to mitomycin C-induced chromosomal aberrations and cytotoxicity 
does not appear to require RAD18 in the experimental system suggesting that PCNA 
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monoubiquitination is not an important regulatory element in directing translesion 
synthesis during interstrand cross-link repair in S phase.  This conclusion is consistent 
with the observation that mitomycin C is a relatively weak inducer of PCNA 
monoubiquitination (Fig. 2.4B).  Though RAD18-mediated PCNA monoubiquitination 
may be necessary for translesion synthesis across cisplatin intrastrand cross-links or other 
distorting DNA adducts, depletion of RAD18 does not appear to have a significant 
impact on the resolution of replication-associated double strand breaks presumably 
associated with recombination-dependent interstrand DNA cross-link repair (Fig. 3.3 and 
3.6).  
  The results highlight major differences between how interstrand DNA cross-link 
repair is proposed to be regulated in G1 versus DNA cross-link repair operational during 
S phase and reliant upon homologous recombination.  In yeast and mammals, 
recombination-independent interstrand DNA cross-link repair involving polymerase zeta-
dependent translesion synthesis is dependent upon RAD18-mediated PCNA 
monoubiquitination 17, 48.  Therefore, the moderate sensitivity observed in RAD18 
depleted HeLa cells to mitomycin C (Fig. 3.5) may be contributed to disruption of 
recombination-independent repair of interstrand cross-links.  The exact percentage of 
interstrand cross-links repaired in a recombination-independent manner versus a 
recombination-dependent manner is unknown.  However, if recombination-independent 
repair of interstrand cross-links represented a major pathway of cross-link removal, the 
expectation would be a similar toxicity profile between RAD18 and polymerase zeta 
knockdown cells following mitomycin C exposure.  The chromosomal instability and 
significantly greater hypersensitivity observed in REV1, REV3 or REV7 knockdown 
cells compared to RAD18 depleted cells following cisplatin or mitomycin C treatment 
demonstrates the predominance of recombination-dependent interstrand cross-link repair 
in human cells.   
 Depletion of the translesion polymerases REV1 and zeta are uniquely associated 
with protection against cisplatin and mitomycin C-induced chromosomal aberrations 
when compared to polymerase eta depleted HeLa cells.  In addition, down-regulation of 
REV1 and polymerase zeta, but not polymerase eta, results in extraordinary mitomycin C 
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hypersensitive along with cell cycle arrest in late S and G2 phases of the cell cycle.  
REV1 and polymerase zeta were also found to be necessary for the timely resolution of 
DNA double strand breaks associated with repair of DNA interstrand cross-links.  
Polymerase eta is proposed to be necessary for extension of D-loops during homologous 
recombination 29.  Since cisplatin and mitomycin C-induced replication-associated DNA 
double strand breaks are resolved in a timely manner in polymerase eta deficient cells,  
polymerase eta is most likely not critical for recombination-dependent repair of 
interstrand cross-links (Fig 3.3 and Fig 3.6).   
  Treatments which predominantly introduce interstrand cross-links (e.g. 
mitomycin C) do not effectively induce PCNA monoubiquitination or translesion 
synthesis polymerase focus formation (Fig. 2.4B) 49-51.  Therefore a major question is 
how the REV1/polymerase zeta functional complex is regulated with respect to its 
recruitment to an active replication fork blocked by an interstrand DNA cross-link and 
the subsequent bypass across an unhooked interstrand DNA cross-link adduct.  
Mirchandani et al. demonstrated the Fanconi anemia core complex, independent of 
FANCD2, is crucial for REV1 foci formation following exposure to UV 23.  Data 
provided in chapter 2 confirms that the Fanconi anemia core complex regulates 
translesion synthesis by promoting the formation of REV1 foci at sites of replication 
stress in cisplatin treated cells, and the recruitment is independent of FANCD2 (Fig. 2.7). 
In contrast to translesion synthesis located at stalled replication forks due to adducted 
DNA, recent evidence suggests that recombination-dependent interstrand DNA cross-link 
repair, as measured by a sophisticated reporter system in mammalian cells, requires both 
the Fanconi anemia core complex and FANCD2, as well as polymerase zeta 12.   
  Therefore it is speculated that the Fanconi anemia core complex performs at least 
two distinct functions when responding to replication stress:  1) Fanconi anemia core 
proteins regulate REV1-dependent translesion synthesis in response to replication fork 
stalling via a FANCD2-independent process that is parallel to Rad18-mediated 
monoubiquitination of PCNA, and 2) Fanconi anemia core proteins promote REV1 and 
polymerase zeta-dependent translesion synthesis during replication-associated interstrand 
cross-link repair in a FANCD2-dependent manner.  Since FANCD2 is ubiquitinated via 
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the Fanconi anemia core complex in response to replication-associated interstrand cross-
links, and PCNA is not, this may be an important signal for the REV1/polymerase zeta 
functional complex to localize to the site of interstrand cross-links.   
  To further complicate the relationship between the Fanconi anemia pathway and 
translesion synthesis, a recently proposed model offers a drastically different view of how 
the Fanconi anemia pathway coordinates interstrand cross-link repair.  Shen et al. suggest 
the Fanconi anemia core complex along with the FANCD2-I complex is necessary for 
recombination-independent cross-link repair while FANCD1/BRAC2, FANCN and 
FANCJ are necessary for recombination-dependent cross-link repair 25.  Incorporating 
this model with previously published reports, the Fanconi anemia core complex, in a 
FANCD2-dependent manner, along with RAD18 via monoubiquitination of PCNA 
would regulate translesion synthesis at sites of recombination-independent repair of 
interstrand cross-links. The possibility would then exist for translesion synthesis to be 
regulated by FANCD1/BRAC2, FANCN and/or FANCJ during recombination-dependent 
repair of interstrand cross-links.  Nonetheless, much work is needed to determine how 
translesion synthesis is regulated at sites of recombination-independent and 
recombination-dependent interstrand DNA cross-link repair. 
 Together, the findings indicate that REV1 and polymerase zeta facilitate 
recombination-dependent repair of DNA interstrand cross-links independently of PCNA 
monoubiquitination and polymerase eta.  The observations reported here and elsewhere 
11, 52 provide novel insight into the crucial role REV1 and polymerase zeta play in 
providing tolerance to a variety of DNA lesions during replication of genomic DNA and 
in facilitating repair of interstrand DNA cross-links.  Understanding how REV1 and 
polymerase zeta contribute to bypass and repair of DNA damaged induced by 
chemotherapeutic agents may lead to the discovery of new drug targets to treat cancers 
resistant to DNA cross-linking agents.  Taking into account the data presented in Chapter
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2, the results clearly demonstrate differential roles of translesion polymerase in terms of 





Figure S3.1  Representative images showing cisplatin-induced chromosomal 
aberrations in siRNA-transfected HeLa cells. 
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Figure S3.2 Time course demonstrating the appearance and resolution of 53BP1 foci 
over 48 hours after a one hour treatment with 3 µM cisplatin.  HeLa cells exhibited 
cisplatin-induced 53BP1 foci, a surrogate marker of DSBs, between 8 and 24 hours.  
These foci resolve by 48 hours.  Cells depleted of REV1, REV3 or REV7 retain 53BP1 






Figure S3.3  Depletion of RAD18 or polymerase eta (Polη) has little impact on the 
ability of HeLa cells to resolve DNA double-stranded breaks (DSBs) associated with 
interstrand DNA cross-link repair.  HeLa cells were independently transfected with 
one of three different siRNA sequences targeting RAD18 or Polη.  Cells were then 
treated with 3 µM cisplatin for 1 hr, fixed 48 hours later, and then stained with antibodies 
specific for S1981P-ATM (green) and 53BP1 (red).  Colocalized foci indicate the 
presence of DSBs thought to be an intermediate of interstrand cross-link repair.  The data 







Figure S3.4  REV1, REV3 and REV7 are required for efficient resolution of 
cisplatin interstrand cross-link associated DNA double strand breaks.  HeLa cells 
were independently transfected with one of at least three different siRNAs targeting 
REV1, REV3, or REV7 mRNA.  Cells were treated with 3 µM cisplatin for 1 hr, fixed 48 
hours later, and then stained with antibodies specific for S1981P-ATM (green) and 
53BP1 (red).  Colocalized foci indicate the presence of DNA double-stranded DNA 
breaks (DSBs).  Depleting REV1, REV3 or REV7 with each individual siRNA sequence 
resulted in a significant increase of S1981P-ATM foci which colocalize with 53BP1 foci 
48 hours after cisplatin treatment when compared to controls as well as Polη or RAD18 
depleted cells). The data support the conclusion that REV1, REV3 and REV7 are 
necessary to efficiently resolve cisplatin-induced DNA DSBs, which are thought to arise 





Figure S3.5  Representative images showing MMC-induced chromosomal 





Figure S3.6 Time course showing the appearance and resolution of 53BP1 foci over 
48 hours after a one hour treatment with 30 ng/ml mitomycin C.  HeLa cells 
exhibited mitomycin C-induced 53BP1 foci, a surrogate marker of DNA double strand 
breaks, between 8 and 24 hours.  These foci typically resolve by 48 hours.  Cells depleted 




Figure S3.7  Depletion of RAD18 or polymerase eta (Polη) has little impact on the 
ability of HeLa cells to resolve DNA double strand breaks (DSBs) associated with 
interstrand DNA cross-link repair.  HeLa cells were independently transfected with 
one of three different siRNA sequences targeting RAD18 or Polη.  Cells were then 
treated with 30 ng/ml mitomycin C (MMC) for 1 hr, fixed 48 hours later, and then stained 
with antibodies specific for S1981P-ATM (green) and 53BP1 (red).  Colocalized foci 
indicate the presence of DSBs thought to be intermediates of interstrand cross-link repair.  






Figure S3.8  REV1, REV3 and REV7 are required for efficient resolution of DNA 
double strand breaks associated with repair of interstrand cross-links induced by 
mitomycin C.  HeLa cells were transfected with one of at least three different siRNAs 
targeting REV1, REV3, or REV7 mRNA.  Cells were treated with 30 ng/ml mitomycin C 
(MMC) for 1 hr, fixed 48 hours later, and then stained with antibodies specific for 
S1981P-ATM (green) and 53BP1 (red).  Colocalized foci indicate the presence of DNA 
double-strand breaks (DSBs). Depleting REV1, REV3 or REV7 with each individual 
siRNA sequence resulted in a significant increase of S1981P-ATM foci which colocalize 
with 53BP1 foci 48 hours after MMC treatment when compared to controls as well as 
Polη or RAD18 depleted cells. The data support the conclusion that REV1, REV3 and 
REV7 are necessary to efficiently resolve MMC-induced DSBs, which are thought to 






Figure S3.9  RAD51-deficient HeLa cells fail to resolve mitomycin C-induced DSBs 
in a timely manner.  siRNA transfected HeLa cells were treated with 30 ng/ml 
mitomycin C for 1 hour and then fixed 24 or 48 hours later.  RAD51-deficient cells failed 
to resolve mitomycin C-induced DSBs; consistent with the model that homologous 
recombination plays an important role in the repair of replication-associated DSBs during 
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A Role for the Translesion Polymerases REV1 and Zeta in Protection against 





 Translesion polymerases have the capacity to replicate past DNA adducts, thus 
preventing replication stress and allowing the cell more time to cope with the damaged 
DNA until it can repaired.  Recently, translesion polymerases have been implicated in the 
repair of DNA damage as well.  Here I addressed if the translesion polymerases eta, 
REV1 and zeta have a biological role in response to ionizing radiation, specifically if 
these translesion polymerases are necessary for DNA double strand break repair.  
Depletion of REV1 or polymerase zeta in HeLa cells resulted in a prolonged G2 cell 
cycle arrest following exposure to ionizing radiation suggestive of a defect in repair of 
double strand breaks. In addition, enhanced radiosensitivity and chromosomal aberration 
formation was observed in REV1 and polymerase zeta depleted cells.  REV1 and 
polymerase zeta were also found to be necessary to either prevent formation of DNA 
double strand breaks or repair DNA double strand breaks in response to ionizing 
radiation-induced DNA damage.  However, polymerase eta appeared to have no cellular 
role in protection against cytotoxicity induced by ionizing radiation.  Furthermore, 
RAD18 was found to have no major role in protecting cells against ionizing radiation-
induced cytotoxicity.  Lastly, REV1 and polymerase zeta depleted HeLa cells were 
demonstrated to have a mild defect in homologous recombination as measured by a 
homologous recombination reporter assay.
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Introduction 
 Translesion DNA polymerases are capable of preventing prolonged replication 
stress by replicating past DNA adducts capable of stalling high fidelity polymerases 1.  In 
mammalian cells, the translesion polymerases eta, REV1 and zeta are thought to 
cooperate, in an insertion and extension model, to bypass multiple types of DNA damage 
including chemotherapeutic drug-induced DNA damage 2-5.  In addition to facilitating 
direct lesion bypass, polymerase eta, REV1 and polymerase zeta (REV3 and REV7) may 
also play an important role in repair of DNA damage 6-11.  The translesion polymerases 
eta, REV1 and zeta have been proposed to be necessary for either translesion synthesis 
across ionizing radiation-induced DNA damage or repair of DNA damage caused by 
ionizing radiation.  Rev1, Rev3 or Rev7 knockout Saccharomyces cerevisiae are sensitive 
to ionizing radiation, and display a decrease in ionizing radiation-associated mutagenesis 
implying these translesion polymerases have a cellular role in response to ionizing 
radiation 12.  In addition, REV7 depleted nasopharyngeal carcinoma cells are 
hypersensitive to ionizing radiation, while REV1-/- and REV3-/- chicken DT40 cells are 
radiosensitive and display an increase of ionizing radiation-induced chromosomal 
aberrations 10-11, 13.  Furthermore, polymerase eta has been proposed to directly interact 
with RAD51 and to be necessary for D-loop extension during homologous recombination 
14.   
Currently, the biological role translesion polymerases have in response to ionizing 
radiation is poorly understood.  Following exposure to ionizing radiation several different 
DNA lesions are formed including DNA adducts such as 7,8-dihydro-8-oxoguanine, 
abasic sites, DNA single strand breaks and DNA double strand breaks 15.  The translesion 
polymerases eta, REV1 and zeta may be necessary to bypass DNA abasic sites or DNA 
adducts formed by ionizing radiation.  Polymerase eta is known to synthesize across from 
7,8-dihydro-8-oxoguanine in a error free manner, while REV1 is thought to be capable of 
inserting a cytosine across from abasic sites 16-20.  Translesion polymerases may also be 
necessary for repair of DNA double strand breaks by participating in either non-
homologous end-joining or homologous recombination 1, 14, 21-23.  Here, I tested the 
hypothesis that the translesion polymerases eta, REV1 and zeta have a biological role in 
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response to ionizing radiation in a human cancer cell line.  I also investigated what 
cellular pathways these polymerases may participate in. 
Depletion of REV1 or polymerase zeta in HeLa cells resulted in a prolonged G2 
cell cycle arrest following exposure to ionizing radiation, suggestive of a repair defect.  
The REV1/polymerase zeta functional complex also protected the cells against ionizing-
radiation induced cytotoxicity, noted by enhanced radiosensitivity and chromosomal 
aberration formation in REV1 or polymerase zeta down-regulated cells.  REV1 and 
polymerase zeta were also found to be necessary to either prevent formation of 
replication-associated DNA double strand breaks or repair DNA double strand breaks in 
response to ionizing radiation-induced DNA damage.  Polymerase eta, though, appeared 
to have no cellular role in protection against cytotoxicity induced by ionizing radiation.   
To address what biological pathways REV1 and polymerase zeta may participate 
in; RAD18 was down-regulated in HeLa cells to determine if disruption of PCNA 
monoubiquitination-dependent translesion synthesis resulted in similar phenotypes 
observed in REV1 or polymerase zeta-depleted HeLa cells following ionizing radiation.  
RAD18-depleted HeLa cells displayed similar phenotypes as Non-si transfected HeLa 
cells following exposure to ionizing radiation.  The results suggest translesion synthesis 
dependent upon PCNA monoubiquitination does not have a major role in protecting cells 
against ionizing radiation-induced cytotoxicity.  However, the phenotypes observed in 
RAD51 depleted HeLa cells were comparable to the phenotypes found in REV1 or 
polymerase zeta knockdown cells implying these translesion polymerase may play a role 
in repair of DNA double strand breaks.  REV1 and polymerase zeta depleted HeLa cells 
were also demonstrated to have a mild defect in homologous recombination as measured 
by a homologous recombination reporter assay. 
Multiple anti-cancer agents have a mechanism of action that results in DNA 
double stand break formation including ionizing radiation, bleomycin, the topoisomerase 
I poisons such as camptothecin and the topoisomerase II poisons including etoposide and 
doxorubicin.  Even though DNA double strand breaks are exceptionally lethal, cancer 
cells can become refractory to the damage 24.  The ability to repair DNA double strand 
breaks, thus lessening the cytotoxic effects, may contribute to resistance of double strand 
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break-inducing agents 25-27.  Evidence provided here suggests that the translesion 
polymerases REV1 and zeta have a cellular role in response to ionizing radiation, and 
that these polymerases may contribute to repair of ionizing radiation-induced DNA 
double strand breaks in HeLa cells.  Participation of REV1 and polymerase zeta in double 
strand break repair may allow for the discovery of new drug targets and treatments for 
cancers resistant to double strand break-inducing agents. 
 
Methods and Materials 
Cell lines and culture conditions.  HeLa cells obtained from ATCC were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine 
serum.  Construction of POLI, POLH, and REV3L -/- BL2 lines, cultured in RPMI-1640 
medium supplemented with 10% fetal bovine serum, have been described 28-29.   
RNA interference.  HeLa cells were seeded in 6 well plates at a density of 1x105 per 
well.  siRNA transfections were carried out with X-tremeGENE (Roche), using 50 nM 
siRNA plus 5µl X-tremeGENE per well.  Transfections were allowed to go overnight in 
the presence of serum followed by a change in medium the next morning.  When 
delivering siRNA into cells cultured in 12 well plates, the conditions for transfection was 
reduced by one half.  The non-specific (Non-si) siRNA as well as the siRNAs directed 
against RAD18, polymerase eta (Polη), REV1, polymerase zeta (REV3 and REV7), and 
RAD51 were obtained from Qiagen.  The gene-specific target sequences are as follows: 
RAD18-3 (GAG CAT GGA TTA TCT ATT CAA), Polη-1 (CTG GTT GTG AGC ATT 
CGT GTA), REV1-4 (ATC GGT GGA ATC GGT TTG GAA), REV3-2 (CCC ACT 
GGA ATT AAT GCA CAA), REV7-1 (GTG GAA GAG CGC GCT CAT AAA), 
RAD51 (AAG CTG AAG CTA TGT TCG CCA) and Non-si (AAT TCT CCG AAC 
GTG TCA CGT).  Refer to Figure 2.1 and supplemental data Figures S2.1 and S2.2 for 
further validation of siRNA sequences. 
Antibodies.  The rabbit polyclonal antibody anti-53BP1 (H-300) was purchased from 
Santa Cruz Biotechnology.  Mouse monoclonal anti-phospho-ATM (Ser 1981) antibody 
was obtained from Rockland.  The anti-phospho-histone H2A.X (Ser139, clone JBW301) 
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antibody was purchased from Millipore and the mouse anti-BrdU antibody was 
purchased from BD Pharmigen. 
Assessment of cell viability.  For clonogenic survival assays, HeLa cells were 
transfected overnight with siRNA as described above and allowed to recover the 
following day.  Forty-hours after the initiation of the siRNA transfections, cells were 
exposed to varying doses of ionizing radiation and then seeded at known cell densities for 
colony formation.  Twelve days later, colonies were stained and fixed in a solution 
containing 3:1 methanol and glacial acetic acid plus 1% trypan blue (Sigma).  Colonies of 
50 cells or greater were counted and the surviving fractions for each siRNA treatment 
group represent the plating efficiency for each treatment divided by the plating efficiency 
of the corresponding untreated control.  The BL2 lymphoma lines were exposed to 
ionizing radiation at varying doses.  Forty-eight hours following exposure to ionizing 
radiation, the cells were washed with PBS and assessed as to their ability to exclude  
trypan blue as a measure of viability.  
Cell proliferation.  HeLa cells with stable incorporation of the DR-GFP plasmid were 
down-regulated for RAD18, Polη, REV1, REV3, REV7 or RAD51 as described above.  
Twenty-four hours after initiation of siRNA transfections, the cells were infected with 
adenovirus containing I-Sce1 overnight. The next morning cells were washed once with 
PBS.  Forty-eight hours later the cells were incubated in media containing 33.3 µM BrdU 
(Fisher) for 17 minutes then collected and fixed in ice-cold 70% ethanol.  The cells were 
resuspended in PBS containing RNaseA (Roche) and incubated at 37°C for 30 minutes.  
After spinning down the cells, they were resuspended in 1 ml 0.1 N HCl containing 0.7% 
Triton X-100, and incubated on ice for 10 minutes.  One ml PBS was added to the cells, 
aspirated, and 1 ml sterile water was added followed by incubation at 97°C for 15 
minutes.  The samples were placed on ice for 15 minutes, spun down, and resuspended in 
100 µl blocking buffer (5% FBS, 1% goat serum, and 0.05% tween-20 in PBS).  Mouse 
anti-BrdU antibody (BD Pharmigen) was diluted 1:100 in the blocking solution and 100 
µl added to the samples for 30 minutes.  The cells were washed and 150 µl blocking 
solution containing a 1:20 dilution of anti-mouse IgG-FITC (Sigma) was added to the 
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cells for 30 minutes.  The cells were washed and resuspended in 500 µl PBS containing 
propidium iodide and acquired by flow cytometry.   
Homologous recombination plasmid reporter assay.  The puromycin resistant 
homologous recombination (HR) plasmid reporter (pDR-GFP) was a generous gift from 
Dr. Maria Jasin.  HeLa cells were plated at a density of 3 x105 cells per well of a six well 
plate and transfected with pDR-GFP utilizing 6 µl of Lipofectamine 2000 (Invitrogen) 
plus 2 µg of pDR-GFP per well for a total of 6 hours in serum free Opti-Mem (Gibco).  
HeLa cells with stable incorporation of the plasmid were selected for by plating the cells 
at a density of 1 cell per well in a 96 well plate and treating with 2 µg/ml puromycin.  
Puromycin resistant clones were characterized by introducing I-Sce1 into the cells and 
measuring GFP expression by flow cytometry.  Clones expressing GFP after introduction 
of I-Sce1 were deemed to have stable incorporation of pDR-GFP.  Twenty-four hours 
after the initiation of siRNA transfections, adenovirus containing I-Sce1 was added to the 
cells overnight. The next morning cells were washed once with PBS.  Forty-eight hours 
following adenovirus infection, the cells were collected and analyzed for GFP expression 
as detailed below.  The I-Sce1 adenovirus was a gift from the University of Michigan 
Vector Core. 
Flow cytometry.  For cell cycle analysis, cells were fixed with ice cold 70% methanol 
and then resuspended in PBS containing RNAse A and propidium iodide to determine 
DNA content.  For acquisition of GFP expression, HeLa cells were fixed with 3.7% para-
formaldehyde solution and on the day of analysis washed once with PBS before analysis.  
Cells were acquired on a BD FACSCaliber system using CellQuest software. 
Immunofluorescence.  For S1981P-ATM and 53BP1 immunofluorescence along with γ-
H2AX staining, cells were cultured and transfected on glass coverslips.  Before fixing in 
ice cold 100% methanol, the cells were washed in phosphate buffered saline (PBS) once. 
Samples were blocked with 5% fetal bovine serum, 0.05% Triton X-100, and 1% goat 
serum for 1 hour.  Following the block, cells were incubated with the appropriate primary 
antibody listed above for 45 minutes then washed three times with PBS and incubated 
with the appropriate secondary goat anti-rabbit or goat anti-mouse Alexa Fluor dye 
conjugated secondary antibody (Molecular Probes) for 45 minutes.  The cells were then 
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washed with PBS, counterstained with DAPI to visualize nuclear DNA, and then 
mounted onto slides with ProLong Gold antifade reagent (Invitrogen).  
Analysis of chromosomal aberrations.  HeLa cells were exposed to 4GY ionizing 
radiation, and 24 hrs later mitotic cells were enriched through the addition of 50 ng/mL 
colcemid (Gibco) for 45 minutes.  After colcemid exposure, the cells were treated for 18 
minute at 37°C with a hypotonic solution consisting of 0.075 M KCl and then fixed in 
Carnoy’s fixative (3:1 methanol:glacial acetic acid).  Cells were dropped onto microscope 
slides and allowed to dry.  Prior to analysis chromosomes were stained with Giemsa as 
described 30.  Fifty mitotic spreads were analyzed for each condition.  For comparisons of 
the average number of gaps and breaks per cell between control and ionizing radiation 




Differential roles for the translesion polymerases eta (Polη), REV1 and zeta (Polζ) in 
response to ionizing radiation-induced cytotoxicity. 
To investigate if the translesion polymerases eta, REV1 and zeta have a cellular 
role in response to ionizing radiation, HeLa cells depleted of these proteins were exposed 
to ionizing radiation or ultraviolet radiation for comparative purposes and analyzed for 
cell cycle distribution.  HeLa cells down-regulated for polymerase eta, REV1, or 
polymerase zeta (REV3 and REV7) were exposed to either 4 J/m2 ultraviolet radiation or 
4 GY ionizing radiation and collected 24 hours later.  Depletion of Polη, REV1, REV3 or 
REV7 individually in HeLa cells resulted in cell cycle arrest in S and G2 phases of the 
cell cycle following exposure to ultraviolet light (Fig. 4.1A).  The cell cycle distribution 
following exposure to UV radiation in Polη, REV1, REV3 or REV7-depleted HeLa cells 
is very similar to the cell cycle profile observed following cisplatin treatment (Fig. 2.2C).  
Over the course of 24 hours Polη, REV1, REV3 or REV7 knockdown cells arrested in the 
S and G2 phases of the cell cycle while the Non-si transfected cells are able to escape and 
progress through the cell cycle and proceed to G1.  The results are consistent with idea 
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that polymerase eta, REV1 and polymerase zeta are necessary for bypass of both cisplatin 
and ultraviolet radiation-induced DNA adducts as indicated by the inability of depleted 
cells to complete S phase. 
Figure 4.1  Differential roles of the translesion polymerases eta (Polη), REV1 and 
zeta (REV3 and REV7) in response to ultraviolet and ionizing radiation.  HeLa cells 
transfected with the indicated siRNAs were exposed to either 4 J/m2 ultraviolet (UV) 
radiation or 4GY ionizing radiation (IR).  Twenty-four hours later the cells were fixed, 
stained for DNA content with propidium iodide and analyzed by flow cytometry.  (A) 
Exposure of Polη, REV1, REV3 or REV7-depleted HeLa cells to 4 J/m2 ultraviolet (UV) 
radiation resulted in accumulation of cells in S and G2 phases of the cell cycle, a 
phenotype associated with replication stress due to stalled replication forks.  (B) REV1, 
REV3, or REV7 knockdown cells exhibit a prolonged G2 cell cycle checkpoint in 
response to IR.  HeLa cells deficient of Polη demonstrated a similar cell cycle 
distribution as Non-si transfected cells in response to IR implying Polη does not have a 
biological role in the response to ionizing radiation. 
 
HeLa cells deficient of REV1, REV3 or REV7, but not Polη, displayed a 
prolonged G2 cell cycle arrest 24 hours after ionizing radiation exposure, signifying Polη 
does not have a biological role in response to ionizing radiation (Fig. 4.1B).  
Approximately 8 to 16 hours after exposure to 4 GY ionizing radiation the Non-si, Polη, 
REV1, REV3 or REV7 siRNA transfected HeLa cells displayed a late S/G2 phase cell 
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cycle arrest (data not shown).  The cell cycle arrest is attributed to the activation of cell 
cycle checkpoints due to DNA damage induced by ionizing radiation.  By 24 hours Non-
si and Polη siRNA transfected cells escaped G2 cell cycle arrest and proceeded into the 
G1 phase of the cell cycle, implying that the ionizing radiation-induced damage was 
repaired.  The prolonged cell cycle arrest observed in the REV1, REV3 or REV7-
depleted cells suggest that DNA damage in not repaired, and is a similar phenotype 
observed in cells with a defect in non-homologous end-joining or homologous 
recombination 31.  Depletion of translesion synthesis proteins using several different 
siRNA sequences targeting Polη, REV1, REV3 or REV7 lead to similar cell cycle arrest 
profiles following ultraviolet or ionizing radiation exposure demonstrating that the effects 
observed here are gene-specific (supplemental data Fig. S4.1 and S4.2).   
The cell cycle distribution of REV1, REV3 or REV7-depleted HeLa cells was 
directly compared to HeLa cells with a nonfunctional homologous recombination repair 
pathway via RAD51 down-regulation (Fig. 3.4C).  The recombinase RAD51 forms a 
nucleoprotein filament on the 3΄ DNA overhang located at the site of a DNA double 
strand break, and actively searches the DNA for a homologous repair template.  In the 
absence of RAD51 the homologous recombination repair pathway is severely inhibited.  
RAD51-depleted HeLa cells were exposed to 4 GY ionizing radiation and collected 24 
hours later for cell cycle analysis (Fig 4.1B).  REV1, REV3 or REV7-depleted HeLa cells 
exhibited almost the same cell cycle redistribution as RAD51-depleted HeLa cells 
following ionizing radiation, suggesting REV1, REV3 or REV7 may have a role in repair 
of ionizing radiation-induced DNA double strand breaks possibly by participating in the 
homologous recombination repair pathway. 
Due to the observed differences in cell cycle distribution following ionizing 
radiation between REV1, REV3 or REV7-depleted HeLa cells and Polη knockdown 
cells, a hypothesis was formed that REV1, REV3 and REV7 are necessary to protect cells 
against ionizing radiation-induced cytotoxicity while polymerase eta would not be 
essential for protection against DNA damage caused by ionizing radiation.  To test this 
hypothesis, REV1 or polymerase zeta-depleted cells were subjected to a clonogenic 
survival assay to determine whether they are uniquely sensitive to ionizing radiation.  As 
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expected, HeLa cells deficient of polymerase eta are not any more sensitive to ionizing 
radiation than HeLa cells transfected with a non-specific (Non-si) siRNA (Fig. 4.2A).  
REV1, REV3, or REV7 siRNA-transfected HeLa cells, on the other hand, are 
significantly more sensitive to loss in clonogenic cell survival as compared to polymerase 
eta-depleted cells (Fig. 4.2A).  To confirm these results in a different model system, 
POLH or REV3L knockout Burkitt’s lymphoma BL2 cells were exposed to varying doses 
of ionizing radiation and viability measured 48 hrs later via trypan blue exclusion.  
Similar to the results obtain from the clonogenic survival assay, REV3L-/- BL2 cells were 
more sensitive to loss in viability after exposure to ionizing radiation when compared 
with POLH knockout cells (Fig.4.2B).  Based on the results obtained from the trypan 
blue exclusion assay, polymerase ίota is similar to polymerase eta in that this polymerase 
does not appear to have a biological role in protecting cells from ionizing radiation-
induced cell death. 
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Figure 4.2  REV1, REV3 or REV7, but not Polη, protects against ionizing radiation-
induced cytotoxicity.  (A) HeLa cells were transfected with non-specific siRNA (Non-si) 
or siRNA targeting Polη, REV1, REV3 or REV7.  Forty hours after the initiation of 
siRNA transfection, cells were exposed to varying doses of ionizing radiation, seeded at 
known densities, and then allowed to form colonies for approximately 12 days.  Data is 
expressed as the average surviving fraction ± S.E.M. of at least three independent 
experiments for each dose of ionizing radiation (IR).  (B) Wild type BL2 cells or BL2 
polymerase ίota (Polι), polymerase eta (Polη), or REV3 (clones 332 and 504) knockout 
cells were treated with various doses of IR.  Forty-eight hours later the cells were 
harvested and subjected to the trypan blue exclusion assay to assess viability.  Data is 
expressed as the average percentage of cells stained negative for trypan blue, normalized 
to untreated control.  At least three independent experiments were performed.  Error bars 
represent S.E.M. (C) siRNA transfected HeLa cells exposed to 4GY IR were assessed for 
chromosomal gaps and breaks 24 hours later as described in Materials and Methods.  
Data is expressed as the average gaps and breaks per metaphase ± S.E.M. (n=50).  REV1, 
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REV3, REV7 or RAD51-depleted cells displayed an increase of IR-induced 
chromosomal aberrations. 
 
In response to ionizing radiation-induced DNA damage, chromosomal aberrations 
may arise due to failed repair of DNA double strand breaks leading to gaps and breaks in 
the chromosome or improper rejoining of broken ends resulting in distorted 
chromosomes 32.  To determine if REV1, REV3 or REV7 protect against ionizing 
radiation-induced chromosomal aberrations, HeLa cells depleted of these proteins were 
exposed to 4 GY ionizing radiation and collected 24 hrs later for chromosomal aberration 
analysis.  Consistent with the loss in clonogenic survival, REV1, REV3, or REV7-
depleted HeLa cells displayed a greater number of ionizing radiation-induced 
chromosomal aberrations per metaphase as compared to polymerase eta-depleted cells 
(Fig. 4.2C).  RAD51-depleted HeLa cells exhibited similar numbers of chromosomal 
gaps and breaks as compared to REV1, REV3, or REV7-depleted cells (Fig. 4.2C).  
Similarities found between REV1, REV3 or REV7-depleted cells and RAD51-depleted 
cells suggest that chromosomal aberrations may arise due to defects in repair of DNA 
double strand breaks.  However, the enhancement of chromosomal aberrations in REV1, 
REV3 or REV7-depleted HeLa cells following ionizing radiation may also be due to the 
inability to bypass abasic sites along with other altered DNA bases caused by exposure to 
ionizing radiation.  
 
The REV1-polymerase zeta functional complex is necessary for efficient repair of 
DNA double strand breaks 
The prolonged G2 phase cell cycle arrest of REV1, REV3 or REV7 deficient cells 
along with the hypersensitivity observed following ionizing radiation is consistent with a 
defect in repair of ionizing radiation-induced DNA double strand breaks.  Moreover, 
REV1, REV3 or REV7-depleted cells displayed enhanced ionizing radiation-induced 
chromatid gaps and breaks, which may also be attributed to failure of efficient DNA 
double strand break repair.  To investigate if REV1, REV3 or REV7 is necessary for 
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repair of ionizing radiation-induced DNA double strand breaks, HeLa cells depleted of 
these proteins were exposed to 2 GY ionizing radiation, and probed for unrepaired DNA 
double strand breaks.  To quantitate unresolved double strand breaks, the cells were 
stained for phosphorylated ATM along with 53BP1 as surrogate markers of DNA double 
strand breaks.  ATM, which undergoes autophosphorylation on serine 1981(S1981P) in 
response to DNA double strand breaks, localizes to sites of breaks forming foci that mark 
the location of the DNA double strand breaks 33-34.  53BP1, a participant in DNA damage 
signaling and repair, also forms foci at sites of DNA double strand breaks 35-36.    
As shown in Figure 4.3A, 15 minutes after exposing HeLa cells to 2 GY ionizing 
radiation, approximately 100% of the cells displayed greater than ten S1981P ATM-
53BP1 containing foci per cell.  By 24 hours the S1981P ATM-53BP1 foci were resolved 
implying the DNA double strand breaks were either repaired or in the process of being 
repaired (Fig.4.3A).  The majority of the S1981 ATM-53BP1 containing foci were 
resolved by 24 hours in non-specific (Non-si) or polymerase eta siRNA transfected HeLa 
cells exposed to 2 GY ionizing radiation (Fig. 4.3B and C).  However, greater than 60% 
of the REV1, REV3 or REV7 down-regulated HeLa cells displayed greater than ten 
S1981P ATM-53BP1 containing foci per cell 24 hours after exposure to 2 GY ionizing 
radiation.  Approximately the same percentage of RAD51-depleted HeLa cells exhibited 
greater than ten S1981P ATM-53BP1 containing foci per cell as compared to REV1, 
REV3 or REV7 knockdown cells.  The persistence of S1981P ATM-53BP1 containing 
foci suggests ionizing radiation-induced DNA double strand breaks were not being 
repaired efficiently in the absence of REV1, REV3 or REV7 (Fig.4.3B and C).  However, 
the possibility cannot be ruled out that persistence of DNA double strand breaks is due to 
insufficient replicative bypass of ionizing radiation-induced base damage resulting in 
collapsed replication fork 
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Figure 4.3  The REV1/polymerase zeta functional complex is necessary for efficient 
resolution of DNA double strand breaks induced by ionizing radiation (IR).  HeLa 
cells were exposed to 2GY IR, then fixed in 100% methanol and stained for S1981P-
ATM (green) along with 53BP1 (red) as surrogate markers of DNA double strand breaks 
(DSBs).  Nuclear DNA was stained with DAPI (blue).  (A) HeLa cells were fixed 15 
minutes or 24 hours after exposure to IR.  Approximately 100% of the cells contained 
greater than ten pATM colocalizing with 53BP1 per cell 15 minutes following IR 
exposure.  (B) Polymerase eta (Polη), REV1, polymerase zeta (REV3 and REV7) or 
RAD51-depleted HeLa cells grown on coverslips were exposed to 2GY IR and allowed 
to recover for 24 hrs.  HeLa cells deficient of REV1, REV3, REV7 or RAD51 did not 
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resolve IR-induced DSBs in a timely manner.  (C) The graph represents the average 
percentage of cells exhibiting ten or more foci per cell containing both phospho-ATM 
and 53BP1.  Error bars represent S.E.M. (n=3).   
 
The REV1-polymerase zeta functional complex may contribute to homologous 
recombination repair but is not absolutely required  
Unresolved S1981P ATM-53BP1 containing foci in REV1, REV3 or REV7 
down-regulated HeLa cells following ionizing radiation may be explained by insufficient 
repair of double strand breaks induced by ionizing radiation.  Since the phenotypes 
observed in REV1, REV3 or REV7-depleted HeLa cells are comparable to RAD51 
deficient HeLa cells, REV1 and polymerase zeta may play role in homologous 
recombination.  To determine if REV1 and polymerase zeta have a cellular role in 
homologous recombination, a homologous recombination reporter plasmid obtained from 
Maria Jasin was utilized.  The homologous recombination reporter plasmid contains a full 
length GFP gene with premature stop codons flanking an I-Sce1 restriction enzyme site 
(Fig. 4.4A).  Downstream of the full length GFP gene is an incomplete GFP gene that is 
used as a homologous repair template.  I-Sce1 will cut at the restriction enzyme site in the 
full length GFP gene resulting in a DNA double strand break.  If correct homologous 
recombination occurs to repair the I-Sce1-induced DNA double strand break by 
employing the incomplete GFP repair template, then the premature stop codons will be 
removed and the I-Sce1 site will be abolished resulting in expression of GFP. 
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Figure 4.4  Depletion of the translesion polymerases REV1 and zeta results in a mild 
homologous recombination defect.  (A) A depiction of the homologous recombination 
plasmid reporter assay developed in Maria Jasin’s laboratory.  The plasmid contains a full 
length GFP gene with premature stop codons flanking an I-Sce1 restriction enzyme site 
and an incomplete GFP gene utilized as a repair template.  Introducing I-Sce1 into a cell 
containing the plasmid reporter results in the formation of a DNA double strand break at 
the restriction enzyme site.  If correct homologous recombination occurs to repair the I-
Sce1-induced DNA double strand break employing the incomplete GFP repair template, 
then the premature stop codons will be removed and the I-Sce1 site will be abolished 
resulting in the expression of GFP.  (B)   HeLa cells containing the homologous 
recombination reporter plasmid were depleted of polymerase eta (Polη), REV1, 
polymerase zeta (REV3 and REV7) or RAD51.  I-Sce1 was introduced into the cells via 
adenovirus 24 hours after initiation of siRNA transfection.  Forty-eight hours after 
adenovirus infection the cells were fixed with 3.7% para-formaldehyde and analyzed by 
flow cytometry for GFP positive cells.  Depletion of REV1 or REV3 resulted in 
approximately 30-40% reduction of GFP positive cells as compared to Non-si transfected 
HeLa cells, while depletion of RAD51 resulted in approximately 90% reduction of GFP 
positive cells. 
 
HeLa cells were transfected with the homologous recombination reporter plasmid 
(pDR-GFP) and selected for stable incorporation as described in Materials and Methods.  
HeLa cells containing the homologous recombination reporter plasmid were depleted of 
polymerase eta, REV1 and polymerase zeta (REV3 and REV7) and then infected with an 
adenovirus in order to deliver I-Sce1 into the cells at a high efficiency rate.  Forty-eight 
hours after introduction of the restriction enzyme I-Sce1, the cells were fixed and 
analyzed for GFP expression by flow cytometry.  RAD51 siRNA transfected HeLa cells 
were used a positive control for inhibition of homologous recombination.  Down-
regulation of RAD51 almost entirely abolished homologous recombination, as measured 
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by GFP expression.  Depletion of polymerase eta, though, had no effect on GFP 
expression, implying that in HeLa cells this polymerase does not have a role in 
homologous recombination (Fig 4.4B).  Knockdown of REV1 or REV3 did not 
completely inhibit GFP expression, but did result in approximately a 30-40% decrease of 
GFP positive cells.  No major differences were observed in cell proliferation (Fig. S4.3), 
thus a decrease in REV1, REV3 or RAD51-depleted cells replicating DNA cannot 
explain the diminished homologous recombination repair efficiency.  Therefore, 
depletion of REV1 or REV3 resulted in a mild homologous recombination defect.  
Surprisingly, depletion of REV7 did not appear to have as great of an effect upon 
homologous recombination as REV1 or REV3 knockdown.   
RAD18 does not regulate the REV1/polymerase zeta function complex in HeLa cells 
after ionizing radiation exposure 
 Following exposure to ionizing radiation, several different DNA lesions are 
formed including DNA adducts such as 7,8-dihydro-8-oxoguanine and abasic sites 15.  
REV1 and polymerase zeta may be necessary for bypass of DNA adducts and abasic sites 
induced by ionizing radiation.  As explained in Chapter 1, RAD18 is thought to be 
essential for initiation of translesion synthesis by monoubiquitinating PCNA at sites of 
stalled replication forks where helicase and polymerase uncoupling occurs.  To support 
this idea, inhibition of PCNA monoubiquitination results in diminished REV1 foci 
formation at sites of replication stress induced by cisplatin (Fig 2.6).  Abasic sites and 
DNA adducts caused by ionizing radiation would not be expected to inhibit helicase and 
polymerase uncoupling.  Therefore, if REV1 and polymerase zeta are necessary for 
replicating past DNA base damage induced by ionizing radiation, RAD18 would be 
expected to regulate this process by monoubiquitinating PCNA at sites of replication 
stress where helicase and polymerase uncoupling occurs.  
 To test whether RAD18 monoubiquitinates PCNA in response to ionizing 
radiation, HeLa cells were exposed to a relatively high dose of ionizing radiation and 
collected 24 hours later for immunoblot analysis.  Exposure to 10 GY ionizing radiation 
did not induce PCNA monoubiquitination (Fig 2.4).  Furthermore, PCNA does not 
localize to sites of DNA damage marked by H2AX phosphorylation following exposure 
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to ionizing radiation, suggesting a lack of replication fork stalling due to ionizing 
radiation-induced DNA damage (Fig. 2.4).  The most likely explanation for this 
observation is that the majority DNA adducts and abasic sites caused by ionizing 
radiation are corrected shortly after exposure.  It is possible, though, that the number of 
stalled replication forks where helicase and polymerase uncoupling occurs is significantly 
less in cells exposed to ionizing radiation when compared to cisplatin treated cells, thus 
rendering detection of monoubiquitinated PCNA difficult.   
If RAD18 regulates the REV1/polymerase zeta functional complex via PCNA 
monoubiquitination, then cell cycle distribution of RAD18-depleted HeLa cells should be 
similar to REV1, REV3 or REV7 knockdown cells following ionizing radiation.  
RAD18-depleted HeLa cells exposed to 4 J/m2 ultraviolet radiation were arrested in late 
S and G2 phase of the cell cycle 24 hours after exposure to ultraviolet light (Fig 4.5A).  
The cell cycle distribution following exposure to ultraviolet radiation was similar in 
RAD18, REV1, REV3 or REV7-depleted HeLa cells, suggesting RAD18 may have an 
important regulatory role in the cellular response of REV1and polymerase zeta to 
ultraviolet light (Fig. 4.1A and Fig 4.5A).  Twenty-four hours after exposure to 4 GY 
ionizing radiation, RAD18-depleted cells exhibited a similar cell cycle distribution as 
non-specific (Non-si) transfected cells (Fig 4.5B).  RAD18-depleted HeLa cells to do not 
display a similar prolonged G2 cell cycle arrest as observed in REV1, REV3 or REV7 
down-regulated HeLa cells.  The data suggest RAD18, via monoubiquitination of PCNA, 
does not regulate the REV1/polymerase zeta functional complex following ionizing 
radiation.  Depletion RAD18 of using several different siRNA sequences lead to similar 
cell cycle arrest profiles following ultraviolet or ionizing radiation exposure 
demonstrating that the effects observed here are gene-specific (supplemental data Fig. 
S4.1 and S4.2). 
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Figure 4.5  RAD18 does not regulate the REV1/polymerase (Polζ) zeta functional 
complex in response to ionizing radiation.  (A and B) RAD18-depleted HeLa cells 
were exposed to either 4 J/m2 ultraviolet (UV) radiation or 4 GY ionizing radiation (IR).  
Twenty-four hours later the cells were fixed, stained for DNA content with propidium 
iodide and analyzed by flow cytometry.  Down-regulation of RAD18 resulted in 
accumulation of cells in S and G2 phases of the cell cycle after UV exposure (A), but no 
cell cycle checkpoint was observed 24 hours following IR exposure (B).  (C) HeLa cells 
deficient of RAD18 were exposed to varying doses of ionizing radiation, seeded at 
known densities, and then allowed to form colonies for approximately 12 days.  Data is 
expressed as the average surviving fraction ± S.E.M. of at least three independent 
experiments for each dose of ionizing radiation (IR).   
 
A clonogenic survival assay was performed to determine if RAD18 deficient 
HeLa cells display a similar sensitivity to ionizing radiation as REV1, REV3 or REV7 
down-regulated cells.  RAD18 deficient cells did not display greater sensitivity to 
ionizing radiation than compared to Non-si transfected HeLa cells (Fig 4.5C).  A lack of 
radiosensitivity greater than that observed in the Non-si transfected HeLa cells strongly 
suggest RAD18 has no biological role in protecting cells from ionizing radiation-induced 
cytotoxicity.  Since RAD18-depleted cells do not show a similar sensitivity to ionizing 
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radiation as do REV1, REV3 or REV7 depleted cells, it is unlikely RAD18 regulates the 
REV1/polymerase zeta functional complex in response to ionizing radiation.   
To confirm RAD18 has no biological role in response to ionizing radiation in 
HeLa cells, RAD18-depleted cells were exposed to 2 GY ionizing radiation and 24 hours 
later probed for the presence of unresolved DNA double strand breaks.  RAD51-depleted 
cells, utilized as a positive control, did not resolve S1981 ATM-53BP1containing foci in 
a timely manner (Fig 4.6A).  RAD18 depleted cells, though, appeared to resolve S1981 
ATM-53BP1 containing foci within 24 hours of ionizing radiation exposure (Fig 4.6A 
and B).  In addition, RAD18 was determined not to have a role in homologous 
recombination in HeLa cells.  RAD18 was down-regulated in HeLa cells with the 
homologous recombination reporter plasmid stably integrated, and 24 hours later were 
infected with an adenovirus engineered to deliver the restriction enzyme I-Sce1 into the 
cells.  In contrast to REV1 or REV3 depleted cells, no difference in homologous 
recombination, as measured by GFP expression, was noted in RAD18 deficient cells.   
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Figure 4.6  RAD18 does not contribute to repair of ionizing radiation-induced DNA 
double strand breaks in HeLa cells.  (A) RAD18 or RAD51 deficient HeLa cells grown 
on coverslips were exposed to 2GY IR, then 24 hrs later fixed in 100% methanol and 
stained for S1981P-ATM (green) along with 53BP1 (red) as surrogate markers of DNA 
double strand breaks (DSBs).  Nuclear DNA was stained with DAPI (blue).  (B) The 
graph represents the average percentage of cells exhibiting 10 or more foci per cell 
containing both phospho-ATM and 53BP1.  Error bars represent S.E.M. (n=3).  (C) HeLa 
cells containing the homologous recombination reporter plasmid were depleted of 
RAD18 or RAD51.  Two different siRNA sequences targeting RAD18 mRNA were 
transfected into the cells independently of each other.  I-Sce1 was introduced into the 
cells via adenovirus 24 hours after initiation of siRNA transfection.  Forty-eight hours 
after adenovirus infection the cells were fixed with 3.7% para-formaldehyde and 
analyzed by flow cytometry for GFP positive cells.   
 
Based upon these results, the phenotypes observed in REV1, REV3 or REV7 
depleted cells following ionizing radiation is unlikely due to lack of translesion synthesis 
past DNA adducts, assuming RAD18-dependent monoubiquitination of PCNA promotes 
replicative bypass of ionizing radiation-induced base damage.  If the REV1/polymerase 
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zeta functional complex does have a role in bypass of ionizing radiation-induced base 
damage, the results obtained here are of great interest since no reports to date have 
suggested translesion polymerases replicate past DNA adducts in a monoubiquitinated 
PCNA-independent manner in intact human cells. 
 
Discussion 
 Here, evidence was provided to support a biological role for the translesion 
polymerases REV1 and zeta in protection against ionizing radiation-induced cytotoxicity.  
REV1 or polymerase zeta (REV3 and REV7)-depleted HeLa cells exposed to ionizing 
radiation displayed a prolonged G2 cell cycle arrest suggestive of a deficiency in repair of 
DNA damage.  In addition, REV1, REV3 or REV7-depleted cells were hypersensitive to 
ionizing radiation and exhibited an enhancement of chromosomal aberrations after 
exposure to ionizing radiation.  REV1, REV3 or REV7 down-regulated HeLa cells did 
not resolve DNA double strand breaks marked by S1981 ATM foci colocalizing with 
53BP1 foci in a timely manner after ionizing radiation exposure.  Even though previous 
studies have proposed that polymerase eta may a cellular role in repair of DNA double 
strand breaks, polymerase eta did not appear to be necessary for protection against 
cytotoxicity induced by ionizing radiation in HeLa cells 14.  Irradiated RAD51-depleted 
HeLa cells exhibited similar phenotypes as HeLa cells deficient in REV1, REV3 or 
REV7 suggesting that these polymerases may play a role in homologous recombination.  
Nevertheless, the phenotypes observed in REV1, REV3 or REV7-depleted HeLa cells 
following ionizing radiation could be explained by a lack of translesion synthesis across 
ionizing radiation-induced DNA adducts, or a defect in either non-homologous end-
joining or homologous recombination repair. 
  To address if REV1 or polymerase zeta have a cellular role in homologous 
recombination, a homologous recombination reporter plasmid was utilized.  Depletion of 
REV3 or REV1 resulted in a decrease of homologous recombination, as measured by 
GFP expression, by approximately 30-40% respectively.  The reason for the partial 
reduction of homologous recombination in REV1 or REV3-depleted cells is unclear.  The 
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Fanconi anemia pathway is thought to have an integral role in homologous 
recombination, but similar to REV1 or REV3-depleted HeLa cells, Fanconi anemia cells 
display mild homologous recombination defects 37-40.  Thus, depletion of proteins 
implicated in the homologous recombination pathway does not always completely 
eliminate homologous recombination as measured by the homologous recombination 
reporter assay utilized in this study.  One explanation may be that the type of double 
strand break formed by the I-Sce1 restriction enzyme may not represent the type of DNA 
double strand break translesion polymerases are needed to resolve.  If the homologous 
repair template contains abasic sites or other types of altered bases due to ionizing 
radiation damage, then translesion synthesis may be critical for extension of D-loops.  
Nevertheless, the reduction in homologous recombination observed in REV1 or REV3-
depleted HeLa cells suggest that REV1 and polymerase zeta may have a partial role in 
homologous recombination. 
Surprisingly, depletion of REV7 did not appear to have as great of an effect upon 
homologous recombination as REV1 or REV3 knockdown.  Since only one DNA double 
strand break is induced after introducing I-Sce1 into the cells, the level of protein 
depletion may of critical importance.  REV7 expression in HeLa cells is significantly 
greater than compared to REV1 or REV3 expression.  Even though immunoblot analysis 
suggest REV7 is depleted to a great extent in HeLa cells (Fig. 2.1 and S2.2) when 
compared to Non-si siRNA transfected HeLa cells, there may be enough REV7 protein 
present in the cells to participate in the repair of one DNA double strand break.  To 
support this idea, there appeared to be some inconsistency in percentage of GFP positive 
cells between the different siRNA sequences targeting REV7 mRNA.  Down-regulation 
of REV7 in HeLa cells containing the homologous recombination reporter plasmid via 
REV7-3 or REV7-4 siRNA sequences appeared to decrease homologous recombination, 
as measured by GFP expression, suggesting these two siRNA sequences may deplete 
REV7 to a greater extent.  REV7 does not have catalytic activity, but rather contributes to 
translesion synthesis by supporting the catalytic activity of REV3 and possibly directing 
REV3 to sites of DNA damage.  The possibility exists that for certain types of DNA 
damage REV7 is dispensable in terms of contributing to REV3’s catalytic activity. 
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Based upon the data obtained in this study, RAD18 does not appear to have a 
major role in protecting cells against ionizing radiation.  The results were somewhat 
surprising and bring up three intriguing points.  First, RAD18-dependent translesion 
synthesis across DNA adducts or abasic sites caused by ionizing radiation appears not to 
be a major contributor to protection against ionizing radiation-induced cytotoxicity.  
Chapter 2 provided several lines of evidence demonstrating RAD18 is essential for 
translesion synthesis across DNA adducts induced by both cisplatin and ultraviolet 
radiation.  RAD18 was also shown to be necessary for REV1 localization to sites of 
replication stress since U2OS cells depleted of RAD18 displayed diminished REV1 foci 
formation in response to cisplatin or ultraviolet radiation (data not presented) presumably 
due to lack of PCNA monoubiquitination (Fig 2.6).  However, exposure of RAD18-
depleted HeLa cells to ionizing radiation does not result in any phenotypes suggestive of 
a defect in translesion synthesis, and HeLa cells exposed to a relatively high dose of 
ionizing radiation do not exhibit monoubiquitinated PCNA as measured by immunoblot 
analysis (Fig. 2.4, 4.5 and 4.6).   
Second, the biological role of RAD18 in response to ionizing radiation is poorly 
understood.  Similar to the results presented here, RAD18 knockout mice have no 
observable phenotypes suggestive of a defect in homologous recombination or non-
homologous end-joining, and embryonic stem cells derived from these mice are not 
sensitive to ionizing radiation 41.  In contrast, Huang et al. recently proposed RAD18, via 
interactions with RAD51C and independently of it E3 ligase activity, is absolutely 
required for homologous recombination 42.  RAD18 has also been implicated in  double 
strand break repair in the G1 phase of the cell cycle, and is thought to contribute to repair 
by interacting with and monoubiquitinating 53BP1 43.  In addition, RAD18-/- mouse 
embryonic fibroblast have been shown to have no defect in homology-dependent repair, 
and in some cases even display an enhancement of sister chromatid exchanges 44-45.  
Lastly, RAD18 has been suggested to suppress non-homologous end-joining in order to 
facilitate homologous recombination-mediated repair 46.  Clearly, drastically different 
views of how RAD18 contributes, or does not contribute, to repair of DNA double strand 
breaks have been proposed in the literature.  Currently, it is poorly understood as to why 
results have varied so greatly.  One explanation is that different experimental methods or 
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endpoints could contribute to the discrepancies.  Also, the use of different cell lines 
between research groups could account for the diverse results, though many of the papers 
cited above utilized both RAD18-/- DT40 cells and RAD18-/- mouse embryonic fibroblast 
and still came to different conclusions.  Nonetheless, much work remains to be done in 
order to clarify the biological role of RAD18 in terms of DNA double strand break repair 
and what role, if any, RAD18 has in protection against ionizing radiation-induced DNA 
damage. 
Third, since depletion of RAD18 in HeLa cells has no obvious effect upon 
cellular phenotypes in response to ionizing radiation, it would be logical to assume 
RAD18, via its E3 ligase activity, has no regulatory control over the cellular roles of 
REV1 or polymerase zeta following ionizing radiation.  This leads to the question, how 
are REV1 and polymerase zeta regulated in terms of response to ionizing radiation-
induced DNA damage, or in other words what is signaling the REV1/polymerase zeta 
functional complex to sites of DNA damage caused by ionizing radiation.  Since the 
Fanconi anemia pathway is known to regulate translesion synthesis, via promotion of 
REV1 to sites of replication stress (Fig. 2.7) 47, the possibility exist for the Fanconi 
anemia pathway to have a role in localization of the REV1/polymerase zeta functional 
complex to sites of ionizing radiation-induced DNA damage.  In addition, the Fanconi 
anemia pathway may also promote the REV1/polymerase zeta functional complex to 
participate in the homologous recombination repair pathway.  Similar to HeLa cells 
depleted of REV1 or REV3, cells deficient of proteins composing the Fanconi Anemia 
core complex, such as FANCA or FANCC, are  known to have a mild defect in the 
homologous recombination repair pathway 38, 40, 48-49.  Besides the core complex, other 
Fanconi anemia proteins are involved in homologous recombination including 
FANCD1/BRAC2, FANCJ and FANCN/PALB2 40, 50-54.  For these reasons, there is 
potential that in response to ionizing radiation the REV1/polymerase zeta function 
complex may be regulated by the Fanconi anemia pathway. 
Taken as a whole, REV1 and polymerase zeta appear to have a biological role in 
the protection against ionizing radiation-induced cytotoxicity in a human cancer cell line, 
possibly by contributing to homologous recombination.  Further understanding of how 
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Rev1 and polymerase zeta contribute to protection against ionizing radiation-induced 
cytotoxicity may reveal new drug targets allowing for the treatment of radioresistant 
cancers.  In addition, RAD18 and polymerase eta appear to have no significant biological 

































Figure S4.1  Depletion of RAD18, Polη, REV1, REV3 or REV7 leads to cell cycle 
arrest in S and G2 phases of the cell cycle following ultraviolet radiation (UV-C) 
exposure.  HeLa cells were independently transfected with one of at least two different 
siRNA sequences targeting RAD18, Polη, REV1, REV3 or REV7 mRNA.  Forty hours 
after transfection the cells were exposed to 4 J/m2 UV-C.  Twenty-four hours later, cells 
were fixed, resuspended in PBS containing RNAse A and propidium iodide, and then 
acquired on a BD FACSCaliber system using CellQuest software.  The y-axis represents 
number of events.  The x-axis reflects DNA content.  Depletion of RAD18, Polη, REV1, 
REV3 or REV7 by each individual siRNA sequence resulted in similar cell cycle profiles 
following UV-C exposure.  Mock transfected or Non-si siRNA-transfected cells were 



















Figure S4.2  Depletion of REV1, REV3 or REV7 leads to cell cycle arrest in the G2 
phase of the cell cycle following ionizing radiation (IR) exposure.  HeLa cells were 
independently transfected with one of at least two different siRNA sequences targeting 
RAD18, Polη, REV1, REV3, or REV7 mRNA.  Forty hours after transfection the cells 
were exposed to 4 GY IR.  Twenty-four hours later, cells were fixed, resuspended in PBS 
containing RNAse A and propidium iodide, and then acquired on a BD FACSCaliber 
system using CellQuest software.  The y-axis represents number of events.  The x-axis 
reflects DNA content.  RAD18 or Polη siRNA transfected HeLa cells were able to escape 
G2 phase arrest and progress into G1.  REV1, REV3 or REV7 depletion by each 
individual siRNA sequence resulted in similar cell cycle profiles following IR exposure.  
A prolonged cell cycle arrest in G2 phase suggests an inability to repair ionizing radiation 
induced DNA damage. Mock transfected or Non-si siRNA-transfected cells were 









Figure S4.3  Depletion of RAD18, Polη, REV1, REV3 or REV7 does not alter cell 
proliferation.  HeLa cells with stable integration of the homologous recombination 
reporter plasmid (pDR-GFP) were depleted of RAD18, Polη, REV1, REV3, REV7 or 
RAD51.  Twenty-fours hours after the initiation of siRNA transfection, the cells were 
infected with an adenovirus containing the I-Sce1 gene.  Forty-eight hours later the cells 
were exposed to 2 mg/ml BrdU for 17 minutes.  The cells were collected and analyzed 













1. Friedberg, E.C., Walker, G.C., Siede, W., Wood, R.D., Schultz, R.A., Ellenberger, T., DNA 
Repair and Mutagenesis. 2nd ed. 2005, Washington DC: American Society for Microbiology. 
2. Friedberg, E.C., A.R. Lehmann, and R.P.P. Fuchs, Trading Places: How Do DNA Polymerases 
Switch during Translesion DNA Synthesis? Molecular Cell, 2005. 18(5): p. 499-505. 
3. Shachar, S., et al., Two-polymerase mechanisms dictate error-free and error-prone translesion 
DNA synthesis in mammals. EMBO J, 2009. 28(4): p. 383-393. 
4. Alt, A., et al., Bypass of DNA lesions generated during anticancer treatment with cisplatin by 
DNA polymerase eta. Science, 2007. 318(5852): p. 967-70. 
5. Vaisman, A., et al., Efficient Translesion Replication Past Oxaliplatin and Cisplatin GpG Adducts 
by Human DNA Polymerase η†. Biochemistry, 2000. 39(16): p. 4575-4580. 
6. Raschle, M., et al., Mechanism of replication-coupled DNA interstrand crosslink repair. Cell, 
2008. 134(6): p. 969-80. 
7. Zhang, N., et al., Double-strand breaks induce homologous recombinational repair of interstrand 
cross-links via cooperation of MSH2, ERCC1-XPF, REV3, and the Fanconi anemia pathway. 
DNA Repair, 2007. 6(11): p. 1670-1678. 
8. Niedzwiedz, W., et al., The Fanconi anaemia gene FANCC promotes homologous recombination 
and error-prone DNA repair. Mol Cell, 2004. 15(4): p. 607-20. 
9. Okada, T., et al., Multiple Roles of Vertebrate REV Genes in DNA Repair and Recombination. 
Mol. Cell. Biol., 2005. 25(14): p. 6103-6111. 
10. Simpson, L.J. and J.E. Sale, Rev1 is essential for DNA damage tolerance and non-templated 
immunoglobulin gene mutation in a vertebrate cell line. EMBO J, 2003. 22(7): p. 1654-1664. 
11. Sonoda, E., et al., Multiple roles of Rev3, the catalytic subunit of pol[zeta] in maintaining genome 
stability in vertebrates. EMBO J, 2003. 22(12): p. 3188-3197. 
12. Chen, C.C., et al., Genetic analysis of ionizing radiation-induced mutagenesis in Saccharomyces 
cerevisiae reveals TransLesion Synthesis (TLS) independent of PCNA K164 SUMOylation and 
ubiquitination. DNA Repair (Amst), 2006. 5(12): p. 1475-88. 
13. Cheung, H.W., et al., Inactivation of human MAD2B in nasopharyngeal carcinoma cells leads to 
chemosensitization to DNA-damaging agents. Cancer Res, 2006. 66(8): p. 4357-67. 
14. McIlwraith, M.J., et al., Human DNA Polymerase [eta] Promotes DNA Synthesis from Strand 
Invasion Intermediates of Homologous Recombination. Molecular Cell, 2005. 20(5): p. 783-792. 
15. Shikazono, N., et al., The Yield, Processing, and Biological Consequences of Clustered DNA 
Damage Induced by Ionizing Radiation. Journal of Radiation Research, 2009. 50(1): p. 27-36. 
16. Yuan, F., et al., Specificity of DNA lesion bypass by the yeast DNA polymerase eta. J Biol Chem, 
2000. 275(11): p. 8233-9. 
17. Haracska, L., et al., Efficient and accurate replication in the presence of 7,8-dihydro-8-
oxoguanine by DNA polymerase [eta]. Nat Genet, 2000. 25(4): p. 458-461. 
18. Haracska, L., et al., Roles of yeast DNA polymerases delta and zeta and of Rev1 in the bypass of 
abasic sites. Genes Dev, 2001. 15(8): p. 945-54. 
19. Avkin, S. and Z. Livneh, Efficiency, specificity and DNA polymerase-dependence of translesion 
replication across the oxidative DNA lesion 8-oxoguanine in human cells. Mutation 
Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2002. 510(1-2): p. 81-90. 
20. Gibbs, P.E. and C.W. Lawrence, Novel mutagenic properties of abasic sites in Saccharomyces 
cerevisiae. J Mol Biol, 1995. 251(2): p. 229-36. 
21. Covo, S., et al., Translesion DNA synthesis-assisted non-homologous end-joining of complex 
double-strand breaks prevents loss of DNA sequences in mammalian cells. Nucleic Acids Res, 
2009. 
22. Lee, J.W., et al., Implication of DNA polymerase lambda in alignment-based gap filling for 
nonhomologous DNA end joining in human nuclear extracts. J Biol Chem, 2004. 279(1): p. 805-
11. 
23. Andrade, P., et al., Limited terminal transferase in human DNA polymerase µ defines the required 
balance between accuracy and efficiency in NHEJ. Proceedings of the National Academy of 
Sciences, 2009. 106(38): p. 16203-16208. 
 165
24. Huerta, S., X. Gao, and D. Saha, Mechanisms of resistance to ionizing radiation in rectal cancer. 
Expert Review of Molecular Diagnostics, 2009. 9(5): p. 469-480. 
25. Kinsella, T.J., Coordination of DNA Mismatch Repair and Base Excision Repair Processing of 
Chemotherapy and Radiation Damage for Targeting Resistant Cancers. Clinical Cancer Research, 
2009. 15(6): p. 1853-1859. 
26. Belzile, J.P., et al., Targeting DNA repair proteins: a promising avenue for cancer gene therapy. 
Curr Gene Ther, 2006. 6(1): p. 111-23. 
27. Willers, H., J. Dahm-Daphi, and S.N. Powell, Repair of radiation damage to DNA. Br J Cancer, 
2004. 90(7): p. 1297-1301. 
28. Faili, A., et al., Induction of somatic hypermutation in immunoglobulin genes is dependent on 
DNA polymerase iota. Nature, 2002. 419(6910): p. 944-7. 
29. Gueranger, Q., et al., Role of DNA polymerases eta, iota and zeta in UV resistance and UV-
induced mutagenesis in a human cell line. DNA Repair (Amst), 2008. 7(9): p. 1551-62. 
30. Casper, A.M., et al., ATR regulates fragile site stability. Cell, 2002. 111(6): p. 779-89. 
31. Biard, D.S., Untangling the relationships between DNA repair pathways by silencing more than 
20 DNA repair genes in human stable clones. Nucleic Acids Res, 2007. 35(11): p. 3535-50. 
32. Giaccia, E.J.H.a.A.J., Radiobiology for the Radiologist. 6th ed. 2006, Philadelphia, PA: Lippincott 
Williams & Wilkins. 
33. Bakkenist, C.J. and M.B. Kastan, DNA damage activates ATM through intermolecular 
autophosphorylation and dimer dissociation. Nature, 2003. 421(6922): p. 499-506. 
34. Canman, C.E., et al., Activation of the ATM kinase by ionizing radiation and phosphorylation of 
p53. Science, 1998. 281(5383): p. 1677-9. 
35. Schultz, L.B., et al., p53 binding protein 1 (53BP1) is an early participant in the cellular response 
to DNA double-strand breaks. J Cell Biol, 2000. 151(7): p. 1381-90. 
36. J, O.W., et al., An essential role for REV3 in mammalian cell survival: absence of REV3 induces 
p53-independent embryonic death. Biochem Biophys Res Commun, 2002. 293(3): p. 1132-7. 
37. Kennedy, R.D. and A.D. D'Andrea, The Fanconi Anemia/BRCA pathway: new faces in the crowd. 
Genes & Development, 2005. 19(24): p. 2925-2940. 
38. Yamamoto, K., et al., Fanconi Anemia FANCG Protein in Mitigating Radiation- and Enzyme-
Induced DNA Double-Strand Breaks by Homologous Recombination in Vertebrate Cells. Mol. 
Cell. Biol., 2003. 23(15): p. 5421-5430. 
39. Niedzwiedz, W., et al., The Fanconi anaemia gene FANCC promotes homologous recombination 
and error-prone DNA repair. Molecular Cell, 2004. 15(4): p. 607-620. 
40. Nakanishi, K., et al., Human Fanconi anemia monoubiquitination pathway promotes homologous 
DNA repair. Proc Natl Acad Sci U S A, 2005. 102(4): p. 1110-5. 
41. Tateishi, S., et al., Enhanced genomic instability and defective postreplication repair in RAD18 
knockout mouse embryonic stem cells. Mol Cell Biol, 2003. 23(2): p. 474-81. 
42. Huang, J., et al., RAD18 transmits DNA damage signalling to elicit homologous recombination 
repair. Nat Cell Biol, 2009. 11(5): p. 592-603. 
43. Watanabe, K., et al., RAD18 promotes DNA double-strand break repair during G1 phase through 
chromatin retention of 53BP1. Nucleic Acids Res, 2009. 37(7): p. 2176-93. 
44. Adar, S., et al., Repair of gaps opposite lesions by homologous recombination in mammalian cells. 
Nucleic Acids Res, 2009. 37(17): p. 5737-48. 
45. Yamashita, Y.M., et al., RAD18 and RAD54 cooperatively contribute to maintenance of genomic 
stability in vertebrate cells. EMBO J, 2002. 21(20): p. 5558-66. 
46. Saberi, A., et al., RAD18 and poly(ADP-ribose) polymerase independently suppress the access of 
nonhomologous end joining to double-strand breaks and facilitate homologous recombination-
mediated repair. Mol Cell Biol, 2007. 27(7): p. 2562-71. 
47. Mirchandani, K.D., R.M. McCaffrey, and A.D. D'Andrea, The Fanconi anemia core complex is 
required for efficient point mutagenesis and Rev1 foci assembly. DNA Repair (Amst), 2008. 7(6): 
p. 902-11. 
48. Niedernhofer, L.J., The Fanconi anemia signalosome anchor. Mol Cell, 2007. 25(4): p. 487-90. 
49. Kennedy, R.D. and A.D. D'Andrea, The Fanconi Anemia/BRCA pathway: new faces in the crowd. 
Genes Dev, 2005. 19(24): p. 2925-40. 
50. Gupta, R., et al., Analysis of the DNA substrate specificity of the human BACH1 helicase 
associated with breast cancer. J Biol Chem, 2005. 280(27): p. 25450-60. 
 166
51. Wu, Y., A.N. Suhasini, and R.M. Brosh, Jr., Welcome the family of FANCJ-like helicases to the 
block of genome stability maintenance proteins. Cell Mol Life Sci, 2009. 66(7): p. 1209-22. 
52. Moldovan, G.L. and A.D. D'Andrea, How the Fanconi Anemia Pathway Guards the Genome. 
Annu Rev Genet, 2009. 
53. Sung, P. and H. Klein, Mechanism of homologous recombination: mediators and helicases take on 
regulatory functions. Nat Rev Mol Cell Biol, 2006. 7(10): p. 739-50. 
54. Xia, B., et al., Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol 









Based on the findings presented in this dissertation, the translesion DNA 
polymerases eta, REV1 and zeta appear to have differential cellular roles in response to 
DNA damage induced by chemotherapeutic agents.  The translesion polymerases eta, 
REV1 and zeta all appear to be necessary for replicating past cisplatin-induced 
intrastrand cross-links, thus preventing replication stress and eventual replication fork 
collapse.  REV1 and polymerase zeta, but not polymerase eta, may participate in repair of 
both interstrand cross-links induced by mitomycin C and DNA double strand breaks 
formed after exposure to ionizing radiation.  Whether bypassing or participating in the 
repair of damaged DNA, the translesion polymerases were found to protect against 
cytotoxicity induced by cisplatin, mitomycin C or ionizing radiation.  Therefore, 
developing inhibitors targeting translesion polymerases may allow for sensitization of 
cancer cells resistance to chemotherapeutic agents that induce DNA damage.  In addition 
to inhibiting translesion polymerases, chemotherapeutic agents may be designed that 
produce adducts to bulky to be replicated across. 
REV1 and polymerase zeta were found to be essential for bypassing cisplatin 
intrastrand cross-links along with repairing interstrand DNA cross-links induced by both 
cisplatin and mitomycin C.  Treatment of HeLa cells depleted of REV1, REV3 or REV7 
with cisplatin resulted in phenotypes suggestive of replication stress including cells 
accumulating in S and G2 phases of the cell cycle, pan-nuclear like pattern of γ-H2AX 
staining, and activation of ATR as measured by phosphorylation of CHK1.  REV1, REV3 
or REV7-depleted HeLa cells also displayed enhanced chromosomal aberrations and 
extreme sensitivity to cisplatin and mitomycin C, consist with the idea REV1 and 
polymerase zeta are necessary for repair of interstrand DNA cross-links.  In addition, 
DNA double strand breaks, most likely formed during recombination-dependent repair of 
 168
interstrand cross-links, were not resolved in a timely manner in REV1, REV3 or REV7 
knockdown cells.   The inability to repair double strand breaks induced by 
recombination-dependent repair of interstrand cross-links strongly implies REV1 and 
polymerase zeta are crucial for recombination-dependent interstrand cross-link repair.  
Furthermore, REV1 and polymerase zeta appeared to protect cells against 
ionizing radiation-induced cytotoxicity, as noted by a decrease in clonogenic survival and 
enhancement of chromosomal aberrations in HeLa cells depleted of REV1, REV3 or 
REV7.  Down-regulation of REV1 or REV3 in HeLa cells resulted in a mild defect in 
homologous recombination, as measured by a homologous recombination reporter 
plasmid, suggesting REV1 and polymerase zeta may participate in recombination-
dependent repair of DNA double strand breaks.  However, it is unclear if REV1 and 
polymerase zeta protect cells from ionizing radiation-induced cytotoxicity by repairing 
DNA double strand breaks via homologous recombination, or if these polymerases 
bypass damaged DNA bases preventing replication stress.  Also, the possibility cannot be 
ruled out that REV1 and polymerase zeta may participate in repair of DNA double strand 
breaks via the non-homologous end-joining pathway.  Taken together, the 
REV1/polymerase zeta functional complex appears to be necessary for protection against 
cytotoxicity induced by multiple chemotherapeutic agents including cisplatin, mitomycin 
C, and ionizing radiation   
Polymerase eta was found to have a more limited role in terms of protecting cells 
against chemotherapeutic-induced DNA damage.  Similar to REV1 and polymerase zeta, 
depletion of polymerase eta resulted in phenotypes suggestive of replicative stress 
following cisplatin treatment.  However, knockdown of polymerase eta did not lead to an 
enhancement of chromosomal aberrations in HeLa cells challenged with cisplatin, and 
did not result in as great of sensitivity to cisplatin as compared to REV1, REV3 or REV7 
knockdown.  Furthermore, polymerase eta siRNA transfected HeLa cells displayed 
similar phenotypes to Non-si siRNA transfected HeLa cells exposed to mitomycin C.  
These results suggest polymerase eta is essential for replicate bypass of cisplatin-induced 
intrastrand cross-links, but polymerase eta apparently has no cellular role in protecting 
cells against interstrand cross-links induced by both cisplatin and mitomycin C.  A 
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previously published report indicated that polymerase eta is essential for D-loop 
extension during homologous recombination 1.  Surprisingly, polymerase eta was not 
found to have a cellular role in response to ionizing radiation.  Thus, polymerase eta 
appears to be essential for bypass of cisplatin intrastrand cross-links, but unlike REV1 or 
polymerase zeta, does not protect cells against cytotoxicity induced by mitomycin C or 
ionizing radiation. 
RAD18 and the Fanconi anemia core complex were found to have a regulatory 
role over translesion synthesis in terms of bypassing adducted DNA bases.  RAD18, via 
monoubiquitination of PCNA, initiates translesion synthesis at sites of stalled replication 
forks where helicase and polymerase uncoupling occurs.  RAD18-depleted U2OS cells 
failed to show efficient polymerase eta or REV1 foci formation following cisplatin 
treatment.  In a parallel pathway, the Fanconi anemia core complex appeared to be 
essential for REV1 foci formation in response to cisplatin exposure.  Interestingly, 
RAD18 did not regulate the cellular functions of REV1 or polymerase zeta in response to 
agents that induce interstrand DNA cross-links or DNA double strand breaks.  The reason 
may be due to the fact interstrand cross-links and double strand breaks do not allow for 
uncoupling of the helicase and polymerase at sites of stalled replication forks.  The 
uncoupling of the helicase and polymerase, thus leading to single stranded DNA, is 
thought to be essential for localization of RAD18 to sites of replication stress.  If RAD18 
does not regulate the cellular functions of REV1 or polymerase zeta in response to 
mitomycin C and ionizing radiation, then the question arises as to what is regulating the 
REV1/ polymerase zeta functional complex following exposure to these agents.  One can 
speculate that the Fanconi anemia pathway may regulate the cellular roles of REV1 and 
polymerase zeta following exposure to mitomycin C and ionizing radiation. 
A summary of the major conclusions are as follows: 
1. The translesion polymerases eta, REV1 and zeta are all necessary for translesion 
synthesis past cisplatin intrastrand cross-links supporting an insertion and 
extension model in human cells.  Both RAD18 and the Fanconi anemia core 
complex have a regulatory role during replicative bypass of cisplatin adducts. 
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2. The REV1/polymerase zeta functional complex, but not polymerase eta, appears 
to have a cellular role in the repair of interstrand DNA cross-links, signifying that 
the translesion polymerases eta, REV1 and zeta have differential roles in response 
to the type of DNA damage present. 
3. The REV1/polymerase zeta functional complex, but not polymerase eta, protects 
from ionizing radiation-induced cytotoxicity possibly by participating in the 
repair of DNA double strand breaks via homologous recombination. 
4. RAD18 is necessary to initiate translesion synthesis at sites of DNA adducts by 
monoubiquitinating PCNA on lysine 164, but RAD18 does not regulate the 
cellular functions of REV1 or polymerase zeta in response to DNA damage 
caused by mitomycin C or ionizing radiation. 
5. The Fanconi anemia core complex influences translesion synthesis by promoting 
localization of REV1 to sites of cisplatin-induced replication stress.  Although 
unproven, the Fanconi anemia pathway may have an important role in regulating 
the REV1/polymerase zeta functional complex in response to mitomycin C and 
ionizing radiation-induced DNA damage. 
 
Although poorly understood, resistance to chemotherapeutic agents may be attributed 
to the ability of cells to bypass and/or repair damaged DNA, therefore lessening cytotoxic 
effects 2-9.  Inhibiting the ability to bypass or repair DNA damage may sensitize 
resistance cancers to chemotherapeutic agents.  Here, I investigated if the translesion 
polymerases eta, REV1 and zeta contribute to the bypass and repair of DNA damage 
induced by the chemotherapeutic agents cisplatin, mitomycin C and ionizing radiation.  
The depletion of polymerase eta, REV1 or polymerase zeta sensitized cells to cisplatin 
while down-regulation of REV1 or polymerase zeta resulted in hypersensitivity to both 
mitomycin C and ionizing radiation.  Based upon the data contained in this dissertation, 
the translesion polymerases eta, REV1 and zeta may be valid drug targets in order to 
sensitize cancer cells to chemotherapeutic agents.  Furthermore, developing drugs that 
inhibit the activities of the REV1/polymerase zeta functional complex may have the most 
significant impact upon treating resistant tumors since REV1 and polymerase zeta may 
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protect against cytotoxicity induced by multiple chemotherapeutic agents including 
cisplatin, mitomycin C and ionizing radiation. 
Translesion polymerases, due to there mutagenic properties, have been associated 
with cancer development 10-12.  It is speculated that secondary cancers can arise due to 
error prone translesion synthesis across chemotherapeutic-induced DNA damage.  
Inhibition of translesion polymerases may prevent mutagenic events from occurring 
during cancer treatment, thus reducing development of secondary tumors 13-14.  Targeting 
translesion polymerases in order to disrupt translesion synthesis holds the potential to not 
only sensitize resistance cancers to therapy, but prevent the development of resistance 
due to translesion synthesis associated mutagenesis 7, 9, 15-16.  Therefore, developing 
inhibitors targeting translesion polymerases may allow for prevention of cancer 
development, sensitization of cancer cells to chemotherapy, and inhibition of the 
emergence of resistance to anti-cancer agents. 
 It is unclear if disruption of translesion synthesis can be accomplished safely in 
humans.  Translesion polymerases, such as polymerase zeta, may be important for 
maintaining chromosomal stability and preventing tumor development 17-18.  However, 
cancer cells may be more dependent upon translesion polymerases allowing for 
selectivity between normal cells and cancer cells, thus reducing any potential cytotoxic 
effects to non-cancer cells.  Cancer cells lacking a functional G1 checkpoint could 
potentially be more dependent upon translesion polymerases since the cells cannot arrest 
in G1 allowing for repair of chemotherapeutic-induced DNA damage before progressing 
to S phase.  In this particular situation, the cells deficient in a G1 checkpoint may be 
dependent upon translesion polymerases to bypass or repair any DNA damage present 
during DNA synthesis.  Although poorly understood, p53 and p21 appear to regulate 
translesion synthesis, and in the absence of these proteins translesion synthesis is up-
regulated 19-20.  It is estimated that approximately 50% of tumors are p53 deficient.  
Therefore, 50% of tumors may have up-regulated translesion synthesis perhaps leading to 
dependence upon this pathway for coping with DNA damage.  If inhibitors targeting 
translesion polymerases cannot be developed, the possibility remains for designing 
chemotherapeutic agents that either produce DNA adducts too bulky to be bypassed or 
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cross-links that distort the DNA to such a degree translesion synthesis past the damage 
cannot occur. 
 In summary, I provided substantial evidence to support the hypothesis that 
polymerase eta, REV1 and polymerase zeta are all necessary for bypass of cisplatin 
intrastrand cross-links.  RAD18 initiates translesion synthesis via monoubiquitination of 
PCNA, and in a parallel pathway the Fanconi anemia core complex regulates REV1 focus 
formation in response to cisplatin exposure.  REV1 and polymerase zeta, but not 
polymerase eta, appear to be necessary for protection against cytotoxicity induced by 
mitomycin C and ionizing radiation.  Data were presented to support the idea REV1 and 
polymerase zeta are essential for repair of interstrand DNA cross-links.  The 
REV1/polymerase zeta functional complex may also be necessary for repair of DNA 
double strand breaks, and perhaps replicative bypass of ionizing radiation-induced base 
damage.  Based on the data presented in this dissertation, translesion polymerases may 
protect cancer cells from the cytotoxic effects of anti-cancer agents, validating the 
translesion synthesis pathway as a feasible drug target for sensitizing cancer cells to 
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